US20110045059A1 - Vaccine against varicella zoster virus - Google Patents

Vaccine against varicella zoster virus Download PDF

Info

Publication number
US20110045059A1
US20110045059A1 US12/784,296 US78429610A US2011045059A1 US 20110045059 A1 US20110045059 A1 US 20110045059A1 US 78429610 A US78429610 A US 78429610A US 2011045059 A1 US2011045059 A1 US 2011045059A1
Authority
US
United States
Prior art keywords
month
vzv
live attenuated
delivery
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/784,296
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110045059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to US12/784,296 priority Critical patent/US20110045059A1/en
Priority to US12/986,928 priority patent/US7939084B1/en
Publication of US20110045059A1 publication Critical patent/US20110045059A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • This invention relates to compositions capable of inducing an immune response against Varicella-Zoster Virus.
  • VZV Varicella-Zoster Virus
  • variants Humida-Zoster Virus
  • shingles zoster
  • VZV is a human herpes virus which is the etiological agent of chicken pox (varicella) and shingles (zoster).
  • Varicella results from an initial, or primary infection, usually contracted during childhood which is relatively benign. However, for adults who were not exposed to varicella during childhood, and occasionally to individuals who are immunocomprised, VZV can be life-threatening. Similarly, a VZV infection can be life-threatening to neonates, for the virus is capable of crossing the placenta. With direct contact, varicella is known to be a highly transmissible infectious disease.
  • VZV has a tendency to infect some cells in which its development is arrested. After a variable latent period, the Varicella-Zoster (VZ) virus can be released to initiate infection in other cells. This reactivation of the VZ virus causes an estimated 5 million cases of zoster annually (Plotkin et al., Postgrad Med J 61: 155-63 (1985)). Zoster is characterized by inflammation of the cerebral ganglia and peripheral nerves, and it is associated with acute pain.
  • the present invention provides in a first aspect an immunogenic composition
  • an immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • the invention further relates to a vaccine composition
  • a vaccine composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • the invention further relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia (PHN) comprising delivering to an individual an immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • PPN post herpetic neuralgia
  • the invention relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, the method comprising sequential or concomitant delivery to an individual of a VZV antigen or immunogenic derivative thereof and a live attenuated VZV or whole inactivated VZV.
  • the invention relates to a kit comprising a live attenuated VZV or whole inactivated VZV and, separately, a VZV antigen or immunogenic derivative thereof, the components suitable for concomitant or sequential delivery, or for mixing as a single composition prior to delivery.
  • the invention also relates to a method for the manufacture of an immunogenic composition, the method comprising combining a live attenuated VZV or whole inactivated VZV with a VZV antigen or immunogenic derivative thereof.
  • the invention further relates to use of a live attenuated VZV strain or whole inactivated VZV and a VZV antigen or immunogenic derivative thereof in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia.
  • the invention in a second aspect relates to an immunogenic composition and/or vaccine comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant.
  • the invention also relates to use of a composition comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant, in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia.
  • the invention also relates to a method for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia, the method comprising delivering to an individual in need thereof an immunogenic composition or vaccine comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant.
  • FIG. 1 discloses the sequence of a truncated VZV gE.
  • FIGS. 2-4 disclose humoral responses obtained in human clinical trials using compositions of the invention.
  • FIGS. 5 and 6 disclose cell mediated immunity obtained in human clinical trials using compositions of the invention.
  • the present invention relates to compositions and regimes as described herein for provoking an immune response to VZV.
  • the immune response generated by exposure to such compositions is suitably reproducibly higher and statistically significant when compared to that obtained in individuals who have received no exposure to the compositions of the invention.
  • the immune response may be assessed by analysis of any one or more aspects of CMI response and/or antibody responses using any of the techniques outlined below.
  • the invention relates to approaches for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia (PHN).
  • the invention relates in one aspect to use in the prevention of the incidence of zoster. Where zoster does occur then the severity of the reactivation of zoster is suitably reduced compared with an unvaccinated control (amelioration of zoster). In a further aspect, where zoster does occur, the invention relates to use in the prevention of the incidence of PHN. In a further aspect where PHN does occur then the severity of the PHN is suitably reduced compared with an unvaccinated control (amelioration of PHN).
  • Reduction in severity can suitably be assessed by a reduction in the pain caused by zoster or PHN, for example, using known measures of burden of pain (e.g. Coplan et al J Pain 2004; 5 (6) 344-56). Reduction in severity can also be assessed by other criteria such as duration of zoster or PHN, proportion of body area affected by zoster or PHN; or the site of zoster/PHN.
  • the live attenuated VZV strain is the OKA strain, a strain well known in the art, for example as disclosed in Arbeter et al. (Journal of Pediatrics, vol 100, No 6, p 886 ff), WO9402596, and references therein, such as U.S. Pat. No. 3,985,615, all incorporated herein by reference.
  • Any other suitable live attenuated strain may also be used in the invention.
  • the VarilrixTM and VarivaxTM strains are both appropriate and commercially available and could be employed in the invention.
  • inactivated VZV strains such as inactivated VZV OKA are also suitable for use in the present invention.
  • the VZV antigen for use in the invention may be any suitable VZV antigen or immunogenic derivative thereof, suitably being a purified VZV antigen.
  • the antigen or derivative is one that is able to elicit, when delivered in combination, concomitantly or sequentially with a live attenuated VZV strain or whole inactivated VZV, an immune response which is improved over that elicited by the live attenuated strain/whole inactivated strain alone or by the VZV antigen alone.
  • a response may be, for example, improved in terms of one or more of the magnitude of immune response, duration of immune response, the number or % or responders, or the breadth of response (e.g. the range of antibody or T cell responses detected), or may provide an improvement at the clinical level in terms of incidence, reduction of pain or symptoms. Improvements in the immune response can be assessed by, for example, antibody levels or cell mediated immunity (CMI) activity using standard techniques in the art; improvements at the clinical level can be also assessed using known clinical criteria.
  • CMI cell mediated immunity
  • the immune response elicited by the composition or vaccine of present invention shows one or more of:
  • a multivalent CMI response in comparison with pre-vaccination levels, when compared to VZV antigen or live attenuated strain/whole inactivated strain alone.
  • a multivalent CMI response considers a range of markers for CMI such as (but not limited to) IFN gamma, IL2, TNF alpha and CD40L and an improved multivalent response induces a CMI response across a wider range of such markers or a higher response in one or more of the markers when compared to a VZV antigen or live attenuated strain/whole inactivated strain alone;
  • persistence is measured over after 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months, 24 months, 36 months or 48 months.
  • improvements in the immune response are assessed in the elderly population, suitably the populations over 50 years of age, for whom the risk of zoster or PHN is increased with respect to the population under 50 years of age.
  • Improved immune responses can also be examined in immuno-compromised populations.
  • populations are target populations for any embodiment of the present invention.
  • the population is over 50 years, suitably over 60 years, over 70 years, or even over 80 years and above. In one aspect the population is 50-70 years old.
  • the invention relates to use of the compositions and approaches of the invention in preventing and/or decreasing the severity of zoster or PHN in humans over 50 years of age.
  • immunogenic derivative encompasses any molecule which retains the ability to induce an immune response to VZV following administration to man.
  • Immunogenic compounds herein are suitably capable of reacting detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with VZV. Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.
  • Suitable methods for the generation of derivatives are well known in the art and include standard molecular biology techniques as disclosed, for example, in Sambrook et al [Molecular Cloning: A Laboratory Manual, third edition, 2000, Cold Spring Harbor Laboratory Press], such as techniques for the addition, deletion, substitution or rearrangement of amino acids or chemical modifications thereof.
  • derivatives include, for example, truncations or other fragments.
  • derivatives in the context of this invention are amino acid sequences comprising epitopes, i.e., antigenic determinants substantially responsible for the immunogenic properties of a polypeptide and being capable of eliciting an immune response, in one aspect being T cell epitopes.
  • the level of immunogenic activity of the immunogenic derivative is at least about 50%, in one aspect at least about 70% and in one aspect at least or greater than about 90% of the immunogenicity for the polypeptide from which it is derived, suitably as assessed by immunoassay techniques described above.
  • immunogenic portions may be identified that have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, e.g., having greater than about 100% or 150% or more immunogenic activity.
  • the VZV antigen is a glycoprotein, in one aspect the gE antigen (also known as gp1), or immunogenic derivative thereof.
  • gE antigen, anchorless derivatives thereof (which are also immunogenic derivatives) and production thereof is described in EPO405867 and references therein [see also Vafai A. Antibody binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein Vaccine 1994 12:1265-9].
  • EP192902 also discloses gE and production thereof.
  • gE is a truncated gE having the sequence of FIG. 1 herein, and as disclosed in Virus research, vol 40, 1996 p 199 ff, herein incorporated fully by reference. Reference to gE hereinafter includes reference to truncated gE, unless otherwise apparent from the context.
  • Suitable antigens include, by way of example, gB, gH, gC, gI, IE63 (e.g. see, Huang et al. J. Virol. 1992, 66: 2664, Sharp et al. J. Inf. Dis. 1992, 165:852, Debrus, J. Virol. 1995 May; 69(5):3240-5 and references therein), IE62 (e.g. see Arvin et al. J. Immunol. 1991 146:257, Sabella J. Virol. 1993 December; 67(12):7673-6 and references therein) ORF4 or ORF 10 (Arvin et al. Viral Immunol. 2002 15: 507.)
  • the present invention herein also contemplates that antigen combinations may be used with the live attenuated or killed VZV, and in one aspect gE may be included in any such combination.
  • the invention relates to combinations of gE with IE63 and gE with IE62, for example.
  • VZV antigens and derivatives of VZV antigens can be tested for suitable immunogenic activity by use in the model systems as described in the Examples of the present application, or by clinical trials in humans.
  • One or more of the following indicators of activity are suitable for consideration in assessment of immunogenic activity:
  • cytokines such as interferon ⁇ or IL-2 or TNF ⁇ .
  • Increases or reductions are suitably statistically significant with respect to appropriate controls, such as an age-matched non-vaccinated group.
  • live attenuated VZV or killed VZV and the VZV antigen or antigen derivatives do not significantly interfere with one another, such that when used in combination the 2 components are still able to provide an immunogenic response to VZV.
  • the response is a protective immunogenic response, whether the 2 components are used as a composition or used in sequential administration or coadministration. It will be appreciated that some interference is tolerated, however, provided that the overall protective immune response is improved in some way (increased in magnitude, increased % responders or broadened antigenic responses, for example) over that of either of the original components used individually.
  • the invention relates to the combination of the gE antigen and the OKA strain, used for concomitant or sequential administration, in either order.
  • delivery is concomitant then the 2 components are delivered into different injection sites but during the same day, for example.
  • different delivery routes are used for the 2 components, in particular subcutaneous delivery for the virus strain such as OKA and intramuscular delivery for the antigen such as gE
  • the combined composition, or either or both of the individual components may additionally comprise an adjuvant or immunostimulant such as but not limited to detoxified lipid A from any source and non-toxic derivatives of lipid A, saponins and other reagents, suitably capable of stimulating a TH1 type response.
  • an adjuvant or immunostimulant such as but not limited to detoxified lipid A from any source and non-toxic derivatives of lipid A, saponins and other reagents, suitably capable of stimulating a TH1 type response.
  • composition comprises an adjuvant capable of stimulating a TH1 type response.
  • Th1-type cytokines tend to favour the induction of cell mediated immune responses to a given antigen, whilst high levels of Th2-type cytokines tend to favour the induction of humoral immune responses to the antigen.
  • Th1 and Th2-type immune response are not absolute. In reality an individual will support an immune response which is described as being predominantly Th1 or predominantly Th2.
  • Th1 and Th2-type immune response are often convenient to consider the families of cytokines in terms of that described in murine CD4+ ve T cell clones by Mosmann and Coffman (Mosmann, T. R. and Coffman, R. L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p 145-173).
  • Th1-type responses are associated with the production of the INF- ⁇ and IL-2 cytokines by T-lymphocytes.
  • Suitable adjuvant systems which promote a predominantly Th1 response include, Monophosphoryl lipid A or a derivative thereof, particularly 3-de-O-acylated monophosphoryl lipid A.
  • LPS enterobacterial lipopolysaccharide
  • MPL monophosphoryl lipid A
  • a further detoxified version of MPL results from the removal of the acyl chain from the 3-position of the disaccharide backbone, and is called 3-O-Deacylated monophosphoryl lipid A (3D-MPL). It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3-O-deacylated variants thereof.
  • 3D-MPL is in the form of an emulsion having a small particle size less than 0.2 ⁇ m in diameter, and its method of manufacture is disclosed in WO 94/21292.
  • Aqueous formulations comprising monophosphoryl lipid A and a surfactant have been described in WO9843670A2.
  • the bacterial lipopolysaccharide derived adjuvants to be formulated in the compositions of the present invention may be purified and processed from bacterial sources, or alternatively they may be synthetic.
  • purified monophosphoryl lipid A is described in Ribi et al 1986 (supra)
  • 3-O-Deacylated monophosphoryl or diphosphoryl lipid A derived from Salmonella sp. is described in GB 2220211 and U.S. Pat. No. 4,912,094.
  • Other purified and synthetic lipopolysaccharides have been described (Hilgers et al., 1986, Int. Arch. Allergy.
  • the bacterial lipopolysaccharide adjuvant is 3D-MPL.
  • the LPS derivatives that may be used in the present invention are those immuno stimulants that are similar in structure to that of LPS or MPL or 3D-MPL.
  • the LPS derivatives may be an acylated monosaccharide, which is a sub-portion to the above structure of MPL.
  • Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. Phytomedicine vol 2 pp 363-386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins.
  • Saponins are known as adjuvants in vaccines for systemic administration.
  • the adjuvant and haemolytic activity of individual saponins has been extensively studied in the art (Lacaille-Dubois and Wagner, supra).
  • Quil A derived from the bark of the South American tree Quillaja Saponaria Molina
  • fractions thereof are described in U.S. Pat. No. 5,057,540 and “Saponins as vaccine adjuvants”, Kensil, C. R., Crit. Rev Ther Drug Carrier Syst, 1996, 12 (1-2):1-55; and EP 0 362 279 B1.
  • IDS Immune Stimulating Complexes
  • Quil A fractions of Quil A are haemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 B1; WO 96/11711; WO 96/33739).
  • the haemolytic saponins QS21 and QS17 HPLC purified fractions of Quil A have been described as potent systemic adjuvants, and the method of their production is disclosed in U.S. Pat. No. 5,057,540 and EP 0 362 279 B1.
  • Other saponins which have been used in systemic vaccination studies include those derived from other plant species such as Gypsophila and Saponaria (Bomford et al., Vaccine, 10(9):572-577, 1992).
  • An enhanced system involves the combination of a non-toxic lipid A derivative and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.
  • the combination of QS21 with 3D MPL is used in the present invention.
  • the adjuvant for use in the invention comprises QS21 and a liposomal formulation comprising cholesterol and 3D MPL.
  • a particularly potent adjuvant formulation involving QS21 and 3D-MPL in an oil in water emulsion is described in WO 95/17210 and is also suitable for use in the present invention.
  • composition additionally comprises a saponin, which in one aspect is QS21, and in another aspect is QS21 quenched with cholesterol as disclosed in WO 96/33739.
  • the immunogenic composition of the invention optionally comprises an oil in water emulsion, which may be used in combination with other adjuvants such as QS21 and/or 3D MPL as disclosed above.
  • adjuvants such as QS21 and/or 3D MPL as disclosed above.
  • Adjuvant formulations comprising an oil in water emulsion are disclosed in WO9911241 and WO9912565, incorporated herein by reference.
  • CpG CpG dinucleotides
  • CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in nucleic acid.
  • CpG oligonucleotides are disclosed in WO 96/02555 and EP 468520.
  • a combination of any of the adjuvants of the invention described herein (QS21 or QS21 quenched with cholesterol+3DMPL, optionally with an oil in water emulsion) is used with gE, or immunogenic derivative thereof, used in concomitant or sequential administration with a live attenuated VZV or inactivated whole VZV.
  • the present invention also provides a method for producing a kit suitable for inducing an immune response against zoster, the method comprising mixing a VZV antigen preparation of the present invention together with an adjuvant or adjuvant combination, and combining in a kit with a live attenuated VZV.
  • the amount of VZV antigen is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, such as 2-100 ⁇ g, or 5-60 ⁇ g. Where gE is used then in one aspect 25-100 ⁇ g of gE may be used in humans, such as 40-100 ⁇ g of gE for human use, in one aspect about 25 ⁇ g, about 50 ⁇ g or about 100 ⁇ g of gE, suitably 25 ⁇ g, 50 ⁇ g or 100 ⁇ g gE.
  • a suitable dose is 500-50000 pfu/0.5 ml, such as 2000-6000 pfu/0.5 ml, with a suitable dose of the GSK Varilrix Oka strain for example being 6000-25,000 per dose, for example 10,000 pfu/dose.
  • Higher doses such as 30,000 pfu, 40000 pfu, 50,000 pfu 60,000 pfu, 70000 pfu, 80000 pfu, 90000 pfu or even 100000 pfu may be employed.
  • An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.
  • composition(s) of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, mucosal, intravenous, intradermal, intraperitoneal, subcutaneous and intramuscular administration. Delivery of the OKA strain is, in one aspect, by subcutaneous delivery.
  • the VZV antigen and attenuated VZV of the present invention may be used together in a composition to provoke an immune response to VZV, or separately—either concomitantly or sequentially in a prime boost regime.
  • the components of the vaccine may be used in either order.
  • delivery of a live attenuated VZV or whole inactivated VZV is followed by a VZV antigen or immunogenic derivative thereof.
  • delivery of a VZV antigen or immunogenic derivative thereof is followed by delivery of live attenuated VZV or whole inactivated VZV.
  • the invention further relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia comprising delivering to an individual at risk of zoster an immunogenic composition comprising a live attenuated VZV and a VZV antigen.
  • the invention relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia comprising sequential or concomitant delivery to an individual at risk of zoster of a live attenuated VZV and a VZV antigen.
  • the invention relates to a prime boost regime wherein a VZV antigen, in one aspect an adjuvanted antigen, is delivered first, after which the immune system is boosted with delivery of an attenuated VZV.
  • a prime boost regime in humans comprises, in one aspect, priming with 25-100 ⁇ g gE, in one aspect 40-100 ⁇ g gE, such as 50 or about 50 ⁇ g gE, or an immunogenic derivative thereof, adjuvanted with QS21 (for example QS21 quenched with cholesterol as described above) and 3D-MPL, and boosting with the OKA strain of VZV.
  • priming with 25-100 ⁇ g gE in one aspect 40-100 ⁇ g gE, such as 50 or about 50 ⁇ g gE, or an immunogenic derivative thereof, adjuvanted with QS21 (for example QS21 quenched with cholesterol as described above) and 3D-MPL, and boosting with the OKA strain of VZV.
  • prime boost regimes are used, or where multiple vaccination regimes are used, then 2, 3, 4 or more immunisations may be employed.
  • Suitable regimes for prime boost include 1, 2, 3, 4, 5 or 6 months between individual immunisations.
  • a prime boost schedule comprises, in one aspect, delivery of a VZV antigen or immunogenic derivative thereof, suitably an adjuvanted VZV antigen or derivative, at 0 months and boosting with a live attenuated VZV at 2M.
  • the invention relates to a kit comprising a live attenuated VZV or inactivated whole VZV and a VZV antigen.
  • the invention also relates to a method for the manufacture of an immunogenic composition, the method comprising combining a live attenuated VZV/whole inactivated and a VZV antigen.
  • the invention further relates to use of a live attenuated VZV strain in the preparation of a combination vaccine with a VZV antigen for the prevention of herpes zoster, and to use of a VZV antigen in the preparation of a combination vaccine with a live attenuated VZV strain for the prevention of herpes zoster.
  • a gE antigen, or immunogenic derivative or immunogenic fragment thereof may be used with an adjuvant to provide an immunogenic composition or vaccine. That is, the gE antigen or immunogenic derivative or immunogenic fragment thereof may be used in a vaccination schedule in the absence of a live attenuated strain or whole inactivated strain.
  • the second aspect of the invention relates to an immunogenic composition or vaccine comprising gE or immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant.
  • the invention also particularly relates to use of a composition comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH-1 adjuvant, in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia.
  • immunogenic derivative in respect of gE is as described above, along with methods to obtain such derivatives such as fragments of gE.
  • Immunogenic fragments as described herein are immunogenic derivatives which retain the ability to induce an immune response to VZV following administration to man.
  • a gE truncate is used in which gE has a C terminal truncation.
  • the truncation removes from 4 to 20 percent of the total amino acid residues at the carboxy terminal end.
  • the gE is lacking the carboxy terminal anchor region (suitably approximately amino acids 547-623 of the wild type sequence).
  • gE is a truncated gE having the sequence of FIG. 1 herein, and as disclosed in Virus research, (Haumont et al Vol 40, 1996 p 199-204), herein incorporated fully by reference.
  • gE hereinafter includes reference to truncated gE, or other fragments or derivative of gE, unless otherwise apparent from the context.
  • composition comprises full length gE.
  • the gE or derivative or fragment thereof is lyophilised. In another aspect the gE or derivative or fragment thereof is reconstituted in a solution containing an adjuvant (such as an adjuvant containing QS21, cholesterol and 3D MPL) before delivery.
  • an adjuvant such as an adjuvant containing QS21, cholesterol and 3D MPL
  • composition or vaccine comprises gE and a TH-1 adjuvant and does not comprise an IE63 antigen or portion thereof. In one embodiment the composition or vaccine comprises gE and a TH-1 adjuvant and does not comprise any other VZV antigen. In one embodiment the composition or vaccine comprises gE and a TH-1 adjuvant and does not comprise any other viral antigen.
  • the gE or immunogenic fragment thereof is not in the form of a fusion protein.
  • composition or vaccine consists essentially of QS21, a truncated VZV gE antigen and liposomes comprising cholesterol and 3D-MPL.
  • composition or vaccine consists of 3D-MPL, QS21, a truncated VZV gE antigen, liposomes comprising cholesterol and a pharmaceutically acceptable carrier.
  • composition may be used in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia.
  • composition or vaccine is suitably used in the population of people 50 or older than 50.
  • the population is the population of those older than 55, 60, 65, 70, 75, 80, or older than 80.
  • the population is 50-70 years.
  • the population of individuals are those who have had varicella or who have had a live varicella vaccine.
  • the invention relates to use of a composition as described above in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia in a population of people 50 or above.
  • the invention thus also relates to a method for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia, the method comprising delivering to an individual in need thereof a composition of the invention.
  • composition of the first and second aspects of the invention are used in those individuals in whom the varicella zoster virus has not reactivated.
  • the composition may be used at doses and delivery routes as outlined above for the first aspect of the invention.
  • the amount of gE antigen is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, such as 2-100 ⁇ g, or 5-60 ⁇ g. Where gE is used then suitably 25-100 ⁇ g gE is used, in one aspect 40-100 ⁇ g of gE, such as about 25 ⁇ g, 50 ⁇ g or about 100 ⁇ g of gE, suitably 25 ⁇ g, 50 ⁇ g or 100 ⁇ g gE.
  • An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.
  • the gE and adjuvant composition or vaccine is used in a one dose delivery regime. In one aspect the gE and adjuvant composition or vaccine is used in a two dose delivery regime.
  • composition or vaccine of the invention is used in a 2 dose regime with a 2 month spacing between doses.
  • the TH-1 adjuvant is any adjuvant identified above for the first aspect of the invention.
  • a combination of 3D MPL and QS21 may be used, for example as disclosed in WO94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739 and U.S. Pat. No. 6,846,489.
  • An alternative adjuvant comprises QS21 and 3D-MPL in an oil in water emulsion as described in WO 95/17210.
  • a formulation comprises a C terminal truncation of the VZV gE antigen, for example that given in FIG. 1 , in combination with 3D MPL and QS21.
  • the invention in another aspect relates to a kit comprising, as separate components, a TH-1 adjuvant and a gE antigen or immunogenic fragment thereof, as described above, suitable for extemporaneous preparation of a vaccine composition.
  • both components are liquids.
  • one component is lyophilised and is suitable for reconstitution with the other component.
  • the kit comprises a gE antigen having the sequence of FIG. 1 and an adjuvant comprising QS21 and liposomes comprising cholesterol and 3D MPL.
  • Vaccine preparation is generally described in New Trends and Developments in Vaccines, Voller et al. (eds), University Park Press, Baltimore, Md., 1978.
  • An immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • B A method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia (PHN) comprising delivering to an individual an immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • PPN post herpetic neuralgia
  • a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia comprising sequential or concomitant delivery to an individual of a VZV antigen or immunogenic derivative thereof and a live attenuated VZV or whole inactivated VZV.
  • D A method according to paragraph C wherein a VZV antigen is delivered before live attenuated VZV.
  • E A method according to paragraph C wherein a VZV antigen is delivered after live attenuated VZV.
  • G A kit comprising a live attenuated VZV or whole inactivated VZV and, separately, a VZV antigen or immunogenic derivative thereof, the components suitable for concomitant or sequential delivery, or for mixing as a single composition prior to delivery.
  • H A method for the manufacture of an immunogenic composition, the method comprising combining a live attenuated VZV or whole inactivated VZV with a VZV antigen or immunogenic derivative thereof.
  • I Use of a live attenuated VZV strain in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, wherein the live attenuated VZV strain is used in combination with a VZV antigen or immunogenic derivative thereof.
  • J Use of a whole inactivated VZV strain in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, wherein the whole inactivated VZV strain is used in combination with a VZV antigen or immunogenic derivative thereof.
  • VZV antigen or immunogenic derivative thereof in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, wherein the VZV antigen is used in combination with a live attenuated VZV strain or whole inactivated VZV strain.
  • L Use according to any of paragraphs I-K wherein the antigen or derivative thereof is delivered in a prime boost approach before the VZV strain.
  • M Use according to any of paragraphs I-K wherein the antigen or derivative thereof is delivered in a prime boost approach after the VZV strain.
  • N Use according to any of paragraphs I-K wherein the antigen or derivative thereof is delivered concomitantly with the VZV strain.
  • the present invention is illustrated by the following, non limiting Examples.
  • the gE used can be truncated gE, as disclosed in FIG. 1 .
  • VarilrixTM is a commercially available OKA strain.
  • Human volunteers for example, 50 per group—healthy, aged 50-70 years
  • results may be assessed by measuring both cell mediated immunity and antibody responses, for example by intracellular staining (ICS, Roederer et al. 2004 Clin. Immunol. 110: 199) or ELISA techniques respectively, these being well known in the art.
  • Specific cell-mediated immunity may be evaluated by, for example, in vitro incubation of patient PBMC with varicella-zoster virus extracts as well as specific VZV antigens or peptides gE, IE63 and IE62. Analysis may be made at the level of, for example:
  • Efficacy can be assessed by looking for a significant increase in the CMI and/or antibody response in comparison with pre-vaccination levels.
  • Efficacy of other antigens or approaches can be assessed using these or similar techniques, and comparing pre-vaccination levels with post vaccination levels.
  • Example 1 The experiment of Example 1 was carried out in human volunteers of different ages, as follows:
  • Group C Varilrix OKA strain alone in adults 50-70 years
  • the vaccination schedule was as follows:
  • the adjuvant AS1 comprises 3D MPL and QS21 in a quenched form with cholesterol, and was made as described in WO9633739, incorporated herein by reference.
  • AS1 adjuvant was prepared essentially as Example 1.1 of WO9633739.
  • the adjuvant comprises: liposomes, which in turn comprise dioleoyl phosphatidylcholine (DOPC), cholesterol and 3D MPL [in an amount of 1000 ⁇ g DOPC, 250 ⁇ g cholesterol and 50 ⁇ g 3D MPL, each value given approx per vaccine dose], QS21 [50 ⁇ g/dose], PBS and water to a volume of 0.5 ml.
  • DOPC dioleoyl phosphatidylcholine
  • 3D MPL in an amount of 1000 ⁇ g DOPC, 250 ⁇ g cholesterol and 50 ⁇ g 3D MPL, each value given approx per vaccine dose
  • QS21 50 ⁇ g/dose
  • PBS water to a volume of 0.5 ml.
  • the truncated gE of FIG. 1 was expressed in CHO K1 cells using standard techniques and purified using, in order, anion exchange chromatography, hydrophobic interaction chromatography, ion exchange chromatography, diafiltration, and nanofiltration followed by sterilisation through a 0.22 ⁇ m filter.
  • the culture supernatant containing the gE (approx. 30 mg/l) is purified, either directly after clarification of the cell suspension or after defrosting at 4° C. After transfer into a 20-litre carboy, the pH of the supernatant is adjusted to 6.
  • the capture stage takes place at ambient temperature on a chromatography column containing a Q Sepharose XL resin.
  • the column After sanitisation with sodium hydroxide, the column is conditioned in the capture buffer (piperazine 20 mM pH 6). The supernatant is then loaded on the column and the column is washed with equilibration buffer and a solution of piperazine 20 mM+NaCl 150 mM pH 6.
  • the fraction containing the gE is then eluted with a solution of piperazine 20 mM+NaCl 250 mM at pH 6.
  • This chromatography stage takes place at ambient temperature on a Toyopearl butyl-650 M resin (Tosoh Biosep).
  • the fraction eluted with 20 mM piperazine+250 mM NaCl in the Q Sepharose XL stage is made up to 1 M in ammonium sulphate and adjusted to pH 7.5.
  • the column After sanitisation with sodium hydroxide and before loading of this fraction, the column is conditioned in the capture buffer (50 mM KH 2 PO 4 +1 M ammonium sulphate pH 7.5). After loading, the column is washed with buffer 50 mM KH 2 PO 4 +100 mM (NH 4 ) 2 SO 4 pH 7.5. The gE is eluted with buffer 50 mM KH 2 PO 4 +25 mM (NH 4 ) 2 SO 4 pH 7.5.
  • This chromatography stage takes place at ambient temperature on a Chelating Sepharose Fast Flow resin.
  • This resin is saturated in metal ion (Ni) by application of a nickel sulphate solution (1%) and excess unbound ions (Ni), removed by washing.
  • the gE fraction eluted at 50 mM KH 2 PO 4 +25 mM (NH 4 ) 2 SO 4 pH 7.5 in the hydrophobic phase is made up to 0.5 M NaCl and adjusted to pH 7.5.
  • the column is equilibrated in the capture buffer (50 mM KH 2 PO 4 +0.5 M NaCl pH 7.5).
  • the gE solution is loaded on the column, which is then washed with a solution of 50 mM KH 2 PO 4 +0.5 M NaCl pH 5.6.
  • the gE is then eluted with a buffer of 50 mM sodium acetate+0.5 M NaCl pH 5, and neutralised with a Tris 1 M solution pH 9.5.
  • the buffer exchange and the elimination of salts from the gE fraction eluted at pH 5 in the previous stage are carried out by tangential ultrafiltration. This stage is carried out entirely at +4° C.
  • the ultrafiltration is run by the Millipore Proflux M12 system, fitted with a 10 kDa Pellicon2 Mini membrane of regenerated cellulose (cat: P2C010C01) of limit nominal molecular weight and a surface area of 0.1 m 2 placed in a Pellicon2 mini-cassette housing (cat.XX42PMINI).
  • modified PBS buffer 8 mM Na 2 HPO 4 2H 2 O, 1.47 mM KH 2 PO 4 , 137 mM NaCl, 2.68 mM KCL pH 7.2
  • the measurement of the permeability of the membrane is verified.
  • the integrity test on the membrane is carried out by putting the system under pressure up to 1 bar before and at the end of the diafiltration stage. If this membrane is used twice with an interval of one week, the integrity will be tested 3 times (once before each ultrafiltration and once after the second filtration). The membrane is considered to be intact if the loss of pressure recorded over 5 minutes is less than 0.1 bar.
  • the pressure conditions are set such that the diafiltration period is about 11 ⁇ 2-2 hours (permeate flow approx. 60 ml/min).
  • the diafiltration residue is then recovered and on the basis of the baseline OD 2 80 the membrane is rinsed with modified PBS to give an approximate final concentration of 0.4 mg/ml.
  • This next stage makes it possible to eliminate viruses with a diameter of more than 15 nm by retention.
  • the stage is carried out entirely at +4° C.
  • the nanofiltration is carried out on a PLANOVA 15N filter (mean pore size 15 nm; filtration surface area 0.12 m 2 (ASAHI cat: 15NZ-120)). Under a constant pressure of 0.45 bar, the gE solution is filtered on the membrane and recovered on the other side with viruses removed.
  • the pipes and housing (column XK50) are sanitised for 2 hours with a solution of NaOH 0.5M. The whole is then rinsed and neutralised with the modified PBS buffer (same buffer as for the diafiltration) until a pH value of 7.2 is achieved.
  • the filter is rinsed and equilibrated with a modified PBS solution.
  • the diafiltration residue containing the gE solution is first pre-filtered through 0.22 ⁇ m (mini kleenpak OU Acropak20, depending on the volume to be filtered) before being nano-filtered at a constant pressure of 0.45 bar on the PLANOVA 15N.
  • the filter is rinsed with a sufficient volume of modified PBS to give a final concentration of the bulk of approx. 0.3 mg/ml.
  • the membrane is washed with 50 ml modified PBS.
  • the solution is recovered through the residue outlet.
  • the first test consists of putting the membrane under pressure (1.0 kg/cm 2 ) and observing for formation of air bubbles. This test detects any large splits.
  • the gE component of the vaccine comprises 50 ⁇ g gE and the excipients sodium chloride, potassium chloride, monopotassium phosphate, disodium phosphate and water for injection as well as the AS1 adjuvant.
  • the function of the inorganic salts is to ensure isotonicity and physiological pH.
  • Quantitative Ingredients per dose: gE 50 ⁇ g Sodium chloride (NaCl) 1603 ⁇ g Disodium phosphate (NaH 2 PO 4 ) 288 ⁇ g Monopotassium phosphate (KH 2 PO 4 ) 40 ⁇ g Potassium chloride (KCl) 40 ⁇ g Water for injection q.s. ad 0.2 mL
  • the solution is mixed for 30 to 40 minutes.
  • the pH is checked and adjusted at 7.2+ ⁇ .0.1 with HCl or NaCl or appropriate and stir for an additional 10 minutes.
  • the final bulk was stored in polypropylene bottles at ⁇ 20° C. and transferred to GSK Bio for filling.
  • the vaccine is filled into 3 ml, sterile, siliconised glass vials (0.25 ml/vial) which are closed with grey chlorobutyl rubber stoppers and sealed with central tear-off aluminium cap.
  • the inspected, approved vials are then stored at ⁇ 20° C.
  • the gE-AS1 vaccine for administration was obtained by mixing the liquid antigen preparation with the liquid AS1 adjuvant immediately prior to injection (a maximum of one hour before injection).
  • the OKA (VarilrixTM) was a commercially available lot prepared according to the manufacturer's instructions.
  • Vaccine formulations were as follows:
  • Vaccine Varilrix with diluent Formulation Approximately 10 4.0 pfu/dose 0/5 ml volume Presentation Glass vial containing containing lyophilized vaccine for reconstitution Total Dose Volume* 0.5 ml
  • the gE AS1 component was administered by intramuscular injection.
  • the Varilrix component was administered by subcutaneous injection.
  • GM GM
  • % % of responders after stimulation by VZV lysate.
  • IFN gamma and/or IL2 TNF alpha, CD40L, CD4 and CD8 response by ICS (intracellular staining): GM,-fold increase in GM and % of responders after stimulation by VZV lysate and gE, IE62 and IE63 peptides.
  • Peripheral blood antigen-specific lymphocytes can be restimulated in vitro to proliferate if incubated with their corresponding antigen. Consequently, the amount of antigen specific lymphocytes can be estimated by counting tritiated thymidine incorporation assay.
  • VZV antigen or peptide derived from VZV proteins will be used as antigen to restimulate VZV-specific lymphocytes. Results will be expressed as a stimulation index (SI) which corresponds to the ratio between antigen-specific and background lymphoproliferation.
  • SI stimulation index
  • Peripheral blood antigen-specific CD4 and CD8 T cells can be restimulated in vitro to express CD40L, IL-2, TNF alpha and IFN gamma if incubated with their corresponding antigen. Consequently, antigen-specific CD4 and CD8 T cells can be enumerated by flow cytometry following conventional immunofluorescence labelling of cellular phenotype as well as intracellular cytokines production.
  • VZV antigen or peptide derived from VZV proteins will be used as antigen to restimulate VZV-specific T cells. Results will be expressed as a frequency of cytokine(s)-positive CD4 or CD8 T cell within the CD4 or CD8 T cell sub-population.
  • Anti-VZV and Anti-gE Specific Antibody
  • Antibody levels against VZV and gE will be measured using classical ELISA assays.
  • FIGS. 2-6 present results in a graphical form for antibody ( FIGS. 2-4 , see tables 1.1 a-c) and CMI responses (FIGS. 5 and 6 —see table C1/“CD4 all doubles” test with gE antigen or Varilirix, median values).
  • Table I.3b Vaccine response for gE antibody titer at each post- vaccination time point (ATP cohort for immunogenicity) . . .
  • Table I.3c Vaccine response for IFA antibody titer at each post- vaccination time point (ATP cohort for immunogenicity) . . .
  • Intracellular Cytokine Staining Descriptive Statistics on CD4 T cells at each time point (Total vaccinated Cohort) . . . Supplementary Table C.1
  • Intracellular Cytokine Staining ICS: Descriptive Statistics on CD8 T cells at each time point (Total vaccinated Cohort) . . . Table C.2
  • Intracellular Cytokine Staining ICS: Inferential statistics: P-values from Kruskal-Wallis Tests for CD4 T cells at each time point (Total Vaccinated Cohort) . . .
  • Intracellular Cytokine Staining Inferential statistics: P- values from Kruskal-Wallis Tests for CD8 T cells at each time point (Total Vaccinated Cohort) . . . Table C.3 Intracellular Cytokine Staining (ICS): Descriptive Statistics on CD4 T cells at POST-PRE (Total vaccinated Cohort) . . . Supplementary Table C.3 Intracellular Cytokine Staining (ICS): Descriptive Statistics on CD8 T cells at POST-PRE (Total vaccinated Cohort) . . .
  • Intracellular Cytokine Staining Inferential statistics: P- values from Kruskal-Wallis Tests for CD4 T cells at each time point (Total Vaccinated Cohort) Groups P_value at P_value at P_value at T cells compared Antigen Test day 0 Month 1 Month 2 Month 3 CD4 VAR ⁇ E and Pool gE ALL DOUBLES 0.5025 0.0000 0.0015 0.0000 gEVAR ⁇ E CD40L 0.4448 0.0000 0.0004 0.0000 IFN ⁇ 0.5900 0.0001 0.0956 0.0000 IL2 0.6415 0.0000 0.0001 0.0000 TNF ⁇ 0.2634 0.0000 0.0019 0.0000 Varilrix ALL DOUBLES 0.7118 0.1489 0.3148 0.0000 CD40L 0.6488 0.1664 0.2609 0.0000 IFN ⁇ 0.3602 0.2905 0.2277 0.0000 IL2 0.4880 0.1442 0.2406 0.0000 TNF ⁇ 0.8631 0.
  • ICS Intracellular Cytokine Staining: Inferential statistics: P-values from Kruskal-Wallis Tests for CD8 T cells at each time point (Total Vaccinated Cohort) Groups P_value at P_value at P_value at T cells compared Antigen Test day 0 Month 1 Month 2 Month 3 CD8 VAR ⁇ E and Pool gE ALL DOUBLES 0.1477 0.4418 0.8141 0.2762 gEVAR ⁇ E CD40L 0.2897 0.2513 0.0126 0.3511 IFN ⁇ 0.1695 0.4069 0.0478 0.0478 IL2 0.2705 0.1316 0.2008 0.5872 TNF ⁇ 0.2968 0.7017 0.6470 0.0947 Varilrix ALL DOUBLES 0.9267 0.7605 0.9651 0.1197 CD40L 0.6260 0.9111 0.6512 0.8826 IFN ⁇ 0.9846 0.9611 0.9225 0.1009 IL2 0.7027 0.6963 0.4626 0.1181 TNF ⁇
  • the gE AS1 vaccine and the concomitant delivery of gE AS1 with the OKA strain both provoke a good immune response in comparison to the response obtained by the OKA strain alone.

Abstract

Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed

Description

  • This application claims priority from co-pending U.S. application Ser. No. 11/817,175, filed Mar. 1, 2006, which claims priority to GB application 0504436.7, filed Mar. 3, 2005, each of which is hereby incorporated by reference in its entirety.
  • This invention relates to compositions capable of inducing an immune response against Varicella-Zoster Virus.
  • Varicella-Zoster Virus (VZV) is a human herpes virus which is the etiological agent of chicken pox (varicella) and shingles (zoster). Varicella results from an initial, or primary infection, usually contracted during childhood which is relatively benign. However, for adults who were not exposed to varicella during childhood, and occasionally to individuals who are immunocomprised, VZV can be life-threatening. Similarly, a VZV infection can be life-threatening to neonates, for the virus is capable of crossing the placenta. With direct contact, varicella is known to be a highly transmissible infectious disease.
  • Like most Herpes-Viruses, VZV has a tendency to infect some cells in which its development is arrested. After a variable latent period, the Varicella-Zoster (VZ) virus can be released to initiate infection in other cells. This reactivation of the VZ virus causes an estimated 5 million cases of zoster annually (Plotkin et al., Postgrad Med J 61: 155-63 (1985)). Zoster is characterized by inflammation of the cerebral ganglia and peripheral nerves, and it is associated with acute pain.
  • It has been shown that humans vaccinated with attenuated strains of VZV have received protective immunity from VZV infections (Arbeter et al., J. Pediatr 100 886-93 (1982) and Brunell et al., Lancet ii: 1069-72 (1982)). In particular the OKA strain of VZV has been used in trials for the prevention of herpes zoster and post herpetic neuralgia. The OKA strain has also been used in the preparation of vaccines for chickenpox for many years and is well characterised—for example see EP651789 and references therein.
  • A large clinical trial using the OKA strain for the zoster indication has been published in The New England Journal of Medicine 2005, number 22, Volume 352:2271-2284 (M. N. Oxman et al).
  • There is still a need for improved vaccines against herpes zoster and related disorders such as post herpetic neuralgia (PHN).
    • STATEMENT OF INVENTION First Aspect
  • The present invention provides in a first aspect an immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • The invention further relates to a vaccine composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • The invention further relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia (PHN) comprising delivering to an individual an immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
  • In a further embodiment the invention relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, the method comprising sequential or concomitant delivery to an individual of a VZV antigen or immunogenic derivative thereof and a live attenuated VZV or whole inactivated VZV.
  • In a still further embodiment the invention relates to a kit comprising a live attenuated VZV or whole inactivated VZV and, separately, a VZV antigen or immunogenic derivative thereof, the components suitable for concomitant or sequential delivery, or for mixing as a single composition prior to delivery.
  • The invention also relates to a method for the manufacture of an immunogenic composition, the method comprising combining a live attenuated VZV or whole inactivated VZV with a VZV antigen or immunogenic derivative thereof.
  • The invention further relates to use of a live attenuated VZV strain or whole inactivated VZV and a VZV antigen or immunogenic derivative thereof in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia.
    • Second Aspect
  • In a second aspect the invention relates to an immunogenic composition and/or vaccine comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant.
  • The invention also relates to use of a composition comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant, in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia.
  • The invention also relates to a method for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia, the method comprising delivering to an individual in need thereof an immunogenic composition or vaccine comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant.
    • FIGURES
  • FIG. 1 discloses the sequence of a truncated VZV gE.
  • FIGS. 2-4 disclose humoral responses obtained in human clinical trials using compositions of the invention.
  • FIGS. 5 and 6 disclose cell mediated immunity obtained in human clinical trials using compositions of the invention.
    •  DETAILED DESCRIPTION
  • In its broadest aspect the present invention relates to compositions and regimes as described herein for provoking an immune response to VZV. In one aspect the immune response generated by exposure to such compositions is suitably reproducibly higher and statistically significant when compared to that obtained in individuals who have received no exposure to the compositions of the invention. The immune response may be assessed by analysis of any one or more aspects of CMI response and/or antibody responses using any of the techniques outlined below.
  • In another aspect the invention relates to approaches for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia (PHN). For the avoidance of doubt, the invention relates in one aspect to use in the prevention of the incidence of zoster. Where zoster does occur then the severity of the reactivation of zoster is suitably reduced compared with an unvaccinated control (amelioration of zoster). In a further aspect, where zoster does occur, the invention relates to use in the prevention of the incidence of PHN. In a further aspect where PHN does occur then the severity of the PHN is suitably reduced compared with an unvaccinated control (amelioration of PHN). Reduction in severity can suitably be assessed by a reduction in the pain caused by zoster or PHN, for example, using known measures of burden of pain (e.g. Coplan et al J Pain 2004; 5 (6) 344-56). Reduction in severity can also be assessed by other criteria such as duration of zoster or PHN, proportion of body area affected by zoster or PHN; or the site of zoster/PHN.
  • The above statements relate to all aspects of the invention.
  • Where a live attenuated strain is used in the first aspect of the invention, then in one aspect the live attenuated VZV strain is the OKA strain, a strain well known in the art, for example as disclosed in Arbeter et al. (Journal of Pediatrics, vol 100, No 6, p 886 ff), WO9402596, and references therein, such as U.S. Pat. No. 3,985,615, all incorporated herein by reference. Any other suitable live attenuated strain may also be used in the invention. For example, the Varilrix™ and Varivax™ strains are both appropriate and commercially available and could be employed in the invention.
  • Whole inactivated VZV strains, such as inactivated VZV OKA are also suitable for use in the present invention.
  • The VZV antigen for use in the invention may be any suitable VZV antigen or immunogenic derivative thereof, suitably being a purified VZV antigen.
  • In one aspect the antigen or derivative is one that is able to elicit, when delivered in combination, concomitantly or sequentially with a live attenuated VZV strain or whole inactivated VZV, an immune response which is improved over that elicited by the live attenuated strain/whole inactivated strain alone or by the VZV antigen alone. Such a response may be, for example, improved in terms of one or more of the magnitude of immune response, duration of immune response, the number or % or responders, or the breadth of response (e.g. the range of antibody or T cell responses detected), or may provide an improvement at the clinical level in terms of incidence, reduction of pain or symptoms. Improvements in the immune response can be assessed by, for example, antibody levels or cell mediated immunity (CMI) activity using standard techniques in the art; improvements at the clinical level can be also assessed using known clinical criteria.
  • In particular, in one aspect the immune response elicited by the composition or vaccine of present invention shows one or more of:
  • a statistically significant increase in the CMI and/or antibody response, in comparison with pre-vaccination levels, when compared to VZV antigen or live attenuated strain/whole inactivated strain alone;
  • An improved multivalent CMI response, in comparison with pre-vaccination levels, when compared to VZV antigen or live attenuated strain/whole inactivated strain alone. A multivalent CMI response considers a range of markers for CMI such as (but not limited to) IFN gamma, IL2, TNF alpha and CD40L and an improved multivalent response induces a CMI response across a wider range of such markers or a higher response in one or more of the markers when compared to a VZV antigen or live attenuated strain/whole inactivated strain alone;
  • Better persistent CMI or antibody response, in comparison with pre-vaccination levels, when compared to VZV antigen or live attenuated strain/whole inactivated strain alone. In one aspect persistence is measured over after 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months, 24 months, 36 months or 48 months.
  • In one aspect improvements in the immune response are assessed in the elderly population, suitably the populations over 50 years of age, for whom the risk of zoster or PHN is increased with respect to the population under 50 years of age. Improved immune responses can also be examined in immuno-compromised populations. In one aspect such populations are target populations for any embodiment of the present invention.
  • In one aspect the population is over 50 years, suitably over 60 years, over 70 years, or even over 80 years and above. In one aspect the population is 50-70 years old.
  • Thus in one aspect the invention relates to use of the compositions and approaches of the invention in preventing and/or decreasing the severity of zoster or PHN in humans over 50 years of age.
  • In one aspect the invention relates to use of the compositions and approaches of the invention in preventing and/or decreasing the severity of zoster or PHN in immunocompromised individuals, such as transplant patients or those who are HIV positive.
  • The term ‘immunogenic derivative’ encompasses any molecule which retains the ability to induce an immune response to VZV following administration to man. Immunogenic compounds herein are suitably capable of reacting detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with VZV. Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.
  • Suitable methods for the generation of derivatives are well known in the art and include standard molecular biology techniques as disclosed, for example, in Sambrook et al [Molecular Cloning: A Laboratory Manual, third edition, 2000, Cold Spring Harbor Laboratory Press], such as techniques for the addition, deletion, substitution or rearrangement of amino acids or chemical modifications thereof. In one aspect derivatives include, for example, truncations or other fragments.
  • In one aspect derivatives in the context of this invention are amino acid sequences comprising epitopes, i.e., antigenic determinants substantially responsible for the immunogenic properties of a polypeptide and being capable of eliciting an immune response, in one aspect being T cell epitopes.
  • In one aspect, the level of immunogenic activity of the immunogenic derivative is at least about 50%, in one aspect at least about 70% and in one aspect at least or greater than about 90% of the immunogenicity for the polypeptide from which it is derived, suitably as assessed by immunoassay techniques described above. In some aspects of the invention immunogenic portions may be identified that have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, e.g., having greater than about 100% or 150% or more immunogenic activity.
  • In one aspect the VZV antigen is a glycoprotein, in one aspect the gE antigen (also known as gp1), or immunogenic derivative thereof.
  • The gE antigen, anchorless derivatives thereof (which are also immunogenic derivatives) and production thereof is described in EPO405867 and references therein [see also Vafai A. Antibody binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein Vaccine 1994 12:1265-9]. EP192902 also discloses gE and production thereof.
  • The disclosure of all cited documents is herein fully incorporated by reference.
  • In one aspect gE is a truncated gE having the sequence of FIG. 1 herein, and as disclosed in Virus research, vol 40, 1996 p 199 ff, herein incorporated fully by reference. Reference to gE hereinafter includes reference to truncated gE, unless otherwise apparent from the context.
  • Other suitable antigens include, by way of example, gB, gH, gC, gI, IE63 (e.g. see, Huang et al. J. Virol. 1992, 66: 2664, Sharp et al. J. Inf. Dis. 1992, 165:852, Debrus, J. Virol. 1995 May; 69(5):3240-5 and references therein), IE62 (e.g. see Arvin et al. J. Immunol. 1991 146:257, Sabella J. Virol. 1993 December; 67(12):7673-6 and references therein) ORF4 or ORF 10 (Arvin et al. Viral Immunol. 2002 15: 507.)
  • The present invention herein also contemplates that antigen combinations may be used with the live attenuated or killed VZV, and in one aspect gE may be included in any such combination. In one aspect the invention relates to combinations of gE with IE63 and gE with IE62, for example.
  • VZV antigens and derivatives of VZV antigens can be tested for suitable immunogenic activity by use in the model systems as described in the Examples of the present application, or by clinical trials in humans. One or more of the following indicators of activity are suitable for consideration in assessment of immunogenic activity:
  • Increased CD4 or CD8 T cell responses to VZV or antigen derivatives.
  • Elevation in VZV or antigens derivative specific antibodies.
  • Enhanced production of cytokines such as interferon γ or IL-2 or TNF α.
  • Enhanced expression of CD40L on CD4 and CD8 T cells.
  • Reduction in the incidence of zoster below the incidence found in the general population of similarly at risk individuals, and likewise reduced disease severity and/or associated pain below the incidence found in the general population of similarly at risk individuals.
  • Increases or reductions, as described above, are suitably statistically significant with respect to appropriate controls, such as an age-matched non-vaccinated group. In one aspect the live attenuated VZV or killed VZV and the VZV antigen or antigen derivatives do not significantly interfere with one another, such that when used in combination the 2 components are still able to provide an immunogenic response to VZV. In one aspect the response is a protective immunogenic response, whether the 2 components are used as a composition or used in sequential administration or coadministration. It will be appreciated that some interference is tolerated, however, provided that the overall protective immune response is improved in some way (increased in magnitude, increased % responders or broadened antigenic responses, for example) over that of either of the original components used individually.
  • In one aspect the invention relates to the combination of the gE antigen and the OKA strain, used for concomitant or sequential administration, in either order. Where delivery is concomitant then the 2 components are delivered into different injection sites but during the same day, for example. In one aspect different delivery routes are used for the 2 components, in particular subcutaneous delivery for the virus strain such as OKA and intramuscular delivery for the antigen such as gE
  • The present invention also extends to cover, in all embodiments described, the use of combinations of VZV antigens or derivatives with a live attenuated VZV strain or killed VZV. Suitable combinations of antigens include in one aspect gE or immunogenic derivative thereof.
  • The combined composition, or either or both of the individual components may additionally comprise an adjuvant or immunostimulant such as but not limited to detoxified lipid A from any source and non-toxic derivatives of lipid A, saponins and other reagents, suitably capable of stimulating a TH1 type response.
  • In one aspect the composition comprises an adjuvant capable of stimulating a TH1 type response.
  • High levels of Th1-type cytokines tend to favour the induction of cell mediated immune responses to a given antigen, whilst high levels of Th2-type cytokines tend to favour the induction of humoral immune responses to the antigen.
  • The distinction of Th1 and Th2-type immune response is not absolute. In reality an individual will support an immune response which is described as being predominantly Th1 or predominantly Th2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4+ ve T cell clones by Mosmann and Coffman (Mosmann, T. R. and Coffman, R. L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p 145-173). Traditionally, Th1-type responses are associated with the production of the INF-γ and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of Th1-type immune responses are not produced by T-cells, such as IL-12. In contrast, Th2-type responses are associated with the secretion of 11-4, IL-5, IL-6, IL-10.
  • Suitable adjuvant systems which promote a predominantly Th1 response include, Monophosphoryl lipid A or a derivative thereof, particularly 3-de-O-acylated monophosphoryl lipid A. It has long been known that enterobacterial lipopolysaccharide (LPS) is a potent stimulator of the immune system, although its use in adjuvants has been curtailed by its toxic effects. A non-toxic derivative of LPS, monophosphoryl lipid A (MPL), produced by removal of the core carbohydrate group and the phosphate from the reducing-end glucosamine, has been described by Ribi et al (1986, Immunology and Immunopharmacology of bacterial endotoxins, Plenum Publ. Corp., NY, p 407-419) and has the following structure:
  • Figure US20110045059A1-20110224-C00001
  • A further detoxified version of MPL results from the removal of the acyl chain from the 3-position of the disaccharide backbone, and is called 3-O-Deacylated monophosphoryl lipid A (3D-MPL). It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3-O-deacylated variants thereof.
  • In one aspect 3D-MPL is in the form of an emulsion having a small particle size less than 0.2 μm in diameter, and its method of manufacture is disclosed in WO 94/21292. Aqueous formulations comprising monophosphoryl lipid A and a surfactant have been described in WO9843670A2.
  • The bacterial lipopolysaccharide derived adjuvants to be formulated in the compositions of the present invention may be purified and processed from bacterial sources, or alternatively they may be synthetic. For example, purified monophosphoryl lipid A is described in Ribi et al 1986 (supra), and 3-O-Deacylated monophosphoryl or diphosphoryl lipid A derived from Salmonella sp. is described in GB 2220211 and U.S. Pat. No. 4,912,094. Other purified and synthetic lipopolysaccharides have been described (Hilgers et al., 1986, Int. Arch. Allergy. Immunol., 79(4):392-6; Hilgers et al., 1987, Immunology, 60(1):141-6; and EP 0 549 074 B1). In one aspect the bacterial lipopolysaccharide adjuvant is 3D-MPL.
  • Accordingly, the LPS derivatives that may be used in the present invention are those immuno stimulants that are similar in structure to that of LPS or MPL or 3D-MPL. In another embodiment of the present invention the LPS derivatives may be an acylated monosaccharide, which is a sub-portion to the above structure of MPL.
  • Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. Phytomedicine vol 2 pp 363-386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins.
  • Saponins are known as adjuvants in vaccines for systemic administration. The adjuvant and haemolytic activity of individual saponins has been extensively studied in the art (Lacaille-Dubois and Wagner, supra). For example, Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina), and fractions thereof, are described in U.S. Pat. No. 5,057,540 and “Saponins as vaccine adjuvants”, Kensil, C. R., Crit. Rev Ther Drug Carrier Syst, 1996, 12 (1-2):1-55; and EP 0 362 279 B1. Particulate structures, termed Immune Stimulating Complexes (ISCOMS), comprising fractions of Quil A are haemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 B1; WO 96/11711; WO 96/33739). The haemolytic saponins QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants, and the method of their production is disclosed in U.S. Pat. No. 5,057,540 and EP 0 362 279 B1. Other saponins which have been used in systemic vaccination studies include those derived from other plant species such as Gypsophila and Saponaria (Bomford et al., Vaccine, 10(9):572-577, 1992).
  • An enhanced system involves the combination of a non-toxic lipid A derivative and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739. In one aspect the combination of QS21 with 3D MPL is used in the present invention.
  • In one aspect the adjuvant for use in the invention comprises QS21 and a liposomal formulation comprising cholesterol and 3D MPL.
  • A particularly potent adjuvant formulation involving QS21 and 3D-MPL in an oil in water emulsion is described in WO 95/17210 and is also suitable for use in the present invention.
  • Accordingly in one embodiment of the present invention there is provided a composition comprising a VZV antigen or derivative of the present invention adjuvanted with detoxified lipid A or a non-toxic derivative of lipid A. In one aspect the composition is adjuvanted with a monophosphoryl lipid A or derivative thereof.
  • In one aspect the composition additionally comprises a saponin, which in one aspect is QS21, and in another aspect is QS21 quenched with cholesterol as disclosed in WO 96/33739.
  • The immunogenic composition of the invention optionally comprises an oil in water emulsion, which may be used in combination with other adjuvants such as QS21 and/or 3D MPL as disclosed above. Adjuvant formulations comprising an oil in water emulsion are disclosed in WO9911241 and WO9912565, incorporated herein by reference.
  • An alternative adjuvant choice is an unmethylated CpG dinucleotides (“CpG”). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in nucleic acid. CpG oligonucleotides are disclosed in WO 96/02555 and EP 468520.
  • In one aspect a combination of any of the adjuvants of the invention described herein (QS21 or QS21 quenched with cholesterol+3DMPL, optionally with an oil in water emulsion) is used with gE, or immunogenic derivative thereof, used in concomitant or sequential administration with a live attenuated VZV or inactivated whole VZV.
  • The present invention also provides a method for producing a kit suitable for inducing an immune response against zoster, the method comprising mixing a VZV antigen preparation of the present invention together with an adjuvant or adjuvant combination, and combining in a kit with a live attenuated VZV.
  • The amount of VZV antigen is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 μg of protein, such as 2-100 μg, or 5-60 μg. Where gE is used then in one aspect 25-100 μg of gE may be used in humans, such as 40-100 μg of gE for human use, in one aspect about 25 μg, about 50 μg or about 100 μg of gE, suitably 25 μg, 50 μg or 100 μg gE. For the OKA strain, for example, a suitable dose is 500-50000 pfu/0.5 ml, such as 2000-6000 pfu/0.5 ml, with a suitable dose of the GSK Varilrix Oka strain for example being 6000-25,000 per dose, for example 10,000 pfu/dose. Higher doses such as 30,000 pfu, 40000 pfu, 50,000 pfu 60,000 pfu, 70000 pfu, 80000 pfu, 90000 pfu or even 100000 pfu may be employed.
  • An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.
  • The composition(s) of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, mucosal, intravenous, intradermal, intraperitoneal, subcutaneous and intramuscular administration. Delivery of the OKA strain is, in one aspect, by subcutaneous delivery.
  • The immunogenic composition of the present invention may be used in a vaccine composition, optionally in combination with an adjuvant and/or (other) suitable carrier.
  • The VZV antigen and attenuated VZV of the present invention may be used together in a composition to provoke an immune response to VZV, or separately—either concomitantly or sequentially in a prime boost regime. For concomitant or sequential delivery the components of the vaccine may be used in either order. In one embodiment, delivery of a live attenuated VZV or whole inactivated VZV is followed by a VZV antigen or immunogenic derivative thereof. In another embodiment delivery of a VZV antigen or immunogenic derivative thereof is followed by delivery of live attenuated VZV or whole inactivated VZV.
  • The invention further relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia comprising delivering to an individual at risk of zoster an immunogenic composition comprising a live attenuated VZV and a VZV antigen.
  • In a further embodiment the invention relates to a method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia comprising sequential or concomitant delivery to an individual at risk of zoster of a live attenuated VZV and a VZV antigen.
  • In one aspect the invention relates to a prime boost regime wherein a VZV antigen, in one aspect an adjuvanted antigen, is delivered first, after which the immune system is boosted with delivery of an attenuated VZV.
  • A prime boost regime in humans comprises, in one aspect, priming with 25-100 μg gE, in one aspect 40-100 μg gE, such as 50 or about 50 μg gE, or an immunogenic derivative thereof, adjuvanted with QS21 (for example QS21 quenched with cholesterol as described above) and 3D-MPL, and boosting with the OKA strain of VZV.
  • Where prime boost regimes are used, or where multiple vaccination regimes are used, then 2, 3, 4 or more immunisations may be employed. Suitable regimes for prime boost include 1, 2, 3, 4, 5 or 6 months between individual immunisations.
  • A prime boost schedule comprises, in one aspect, delivery of a VZV antigen or immunogenic derivative thereof, suitably an adjuvanted VZV antigen or derivative, at 0 months and boosting with a live attenuated VZV at 2M.
  • In an alternative delivery schedule there is concomitant delivery of both of the two individual components (VZV antigen or derivative and live attenuated VZV) at both 0 and 2 months.
  • In a still further embodiment the invention relates to a kit comprising a live attenuated VZV or inactivated whole VZV and a VZV antigen.
  • The invention also relates to a method for the manufacture of an immunogenic composition, the method comprising combining a live attenuated VZV/whole inactivated and a VZV antigen.
  • The invention further relates to use of a live attenuated VZV strain in the preparation of a combination vaccine with a VZV antigen for the prevention of herpes zoster, and to use of a VZV antigen in the preparation of a combination vaccine with a live attenuated VZV strain for the prevention of herpes zoster.
  • In a second, aspect of the invention a gE antigen, or immunogenic derivative or immunogenic fragment thereof, may be used with an adjuvant to provide an immunogenic composition or vaccine. That is, the gE antigen or immunogenic derivative or immunogenic fragment thereof may be used in a vaccination schedule in the absence of a live attenuated strain or whole inactivated strain.
  • Thus the second aspect of the invention relates to an immunogenic composition or vaccine comprising gE or immunogenic derivative or immunogenic fragment thereof in combination with a TH1-adjuvant.
  • The invention also particularly relates to use of a composition comprising gE or an immunogenic derivative or immunogenic fragment thereof in combination with a TH-1 adjuvant, in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia.
  • The term “immunogenic derivative” in respect of gE is as described above, along with methods to obtain such derivatives such as fragments of gE. Immunogenic fragments as described herein are immunogenic derivatives which retain the ability to induce an immune response to VZV following administration to man.
  • In one aspect of the invention a gE truncate is used in which gE has a C terminal truncation.
  • In one aspect the truncation removes from 4 to 20 percent of the total amino acid residues at the carboxy terminal end.
  • In one aspect the gE is lacking the carboxy terminal anchor region (suitably approximately amino acids 547-623 of the wild type sequence).
  • In one aspect gE is a truncated gE having the sequence of FIG. 1 herein, and as disclosed in Virus research, (Haumont et al Vol 40, 1996 p 199-204), herein incorporated fully by reference.
  • Reference to gE hereinafter includes reference to truncated gE, or other fragments or derivative of gE, unless otherwise apparent from the context.
  • In another aspect of the invention the composition comprises full length gE.
  • In another aspect the gE or derivative or fragment thereof is lyophilised. In another aspect the gE or derivative or fragment thereof is reconstituted in a solution containing an adjuvant (such as an adjuvant containing QS21, cholesterol and 3D MPL) before delivery.
  • In one embodiment the composition or vaccine comprises gE and a TH-1 adjuvant and does not comprise an IE63 antigen or portion thereof. In one embodiment the composition or vaccine comprises gE and a TH-1 adjuvant and does not comprise any other VZV antigen. In one embodiment the composition or vaccine comprises gE and a TH-1 adjuvant and does not comprise any other viral antigen.
  • In one aspect the gE or immunogenic fragment thereof is not in the form of a fusion protein.
  • In one aspect the composition or vaccine consists essentially of QS21, a truncated VZV gE antigen and liposomes comprising cholesterol and 3D-MPL.
  • In one aspect the composition or vaccine consists of 3D-MPL, QS21, a truncated VZV gE antigen, liposomes comprising cholesterol and a pharmaceutically acceptable carrier.
  • The composition may be used in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia.
  • The composition or vaccine is suitably used in the population of people 50 or older than 50. Suitably the population is the population of those older than 55, 60, 65, 70, 75, 80, or older than 80. Suitably the population is 50-70 years.
  • In one aspect the population of individuals are those who have had varicella or who have had a live varicella vaccine.
  • Thus the invention relates to use of a composition as described above in the preparation of a medicament for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia in a population of people 50 or above.
  • The invention thus also relates to a method for the prevention or amelioration of herpes zoster reactivation and/or post herpetic neuralgia, the method comprising delivering to an individual in need thereof a composition of the invention.
  • In one aspect the composition of the first and second aspects of the invention are used in those individuals in whom the varicella zoster virus has not reactivated.
  • The composition may be used at doses and delivery routes as outlined above for the first aspect of the invention. Specifically the amount of gE antigen is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 μg of protein, such as 2-100 μg, or 5-60 μg. Where gE is used then suitably 25-100 μg gE is used, in one aspect 40-100 μg of gE, such as about 25 μg, 50 μg or about 100 μg of gE, suitably 25 μg, 50 μg or 100 μg gE. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.
  • In one aspect the gE and adjuvant composition or vaccine is used in a one dose delivery regime. In one aspect the gE and adjuvant composition or vaccine is used in a two dose delivery regime.
  • In one aspect the composition or vaccine of the invention is used in a 2 dose regime with a 2 month spacing between doses.
  • In one aspect the TH-1 adjuvant is any adjuvant identified above for the first aspect of the invention. In particular, a combination of 3D MPL and QS21 may be used, for example as disclosed in WO94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739 and U.S. Pat. No. 6,846,489. An alternative adjuvant comprises QS21 and 3D-MPL in an oil in water emulsion as described in WO 95/17210.
  • In one aspect a formulation comprises a C terminal truncation of the VZV gE antigen, for example that given in FIG. 1, in combination with 3D MPL and QS21.
  • In another aspect the invention relates to a kit comprising, as separate components, a TH-1 adjuvant and a gE antigen or immunogenic fragment thereof, as described above, suitable for extemporaneous preparation of a vaccine composition. In one aspect both components are liquids. In one aspect one component is lyophilised and is suitable for reconstitution with the other component. In one aspect the kit comprises a gE antigen having the sequence of FIG. 1 and an adjuvant comprising QS21 and liposomes comprising cholesterol and 3D MPL.
  • Vaccine preparation is generally described in New Trends and Developments in Vaccines, Voller et al. (eds), University Park Press, Baltimore, Md., 1978.
  • Aspects of the present invention include:
  • A An immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
    B A method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia (PHN) comprising delivering to an individual an immunogenic composition comprising a VZV antigen or immunogenic derivative thereof in combination with a live attenuated VZV or whole inactivated VZV.
    C A method of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, the method comprising sequential or concomitant delivery to an individual of a VZV antigen or immunogenic derivative thereof and a live attenuated VZV or whole inactivated VZV.
    D A method according to paragraph C wherein a VZV antigen is delivered before live attenuated VZV.
    E A method according to paragraph C wherein a VZV antigen is delivered after live attenuated VZV.
    F A method according to paragraph C wherein a VZV antigen is delivered concomitantly with live attenuated VZV, preferably with each component in a different arm of a patient.
    G A kit comprising a live attenuated VZV or whole inactivated VZV and, separately, a VZV antigen or immunogenic derivative thereof, the components suitable for concomitant or sequential delivery, or for mixing as a single composition prior to delivery.
    H A method for the manufacture of an immunogenic composition, the method comprising combining a live attenuated VZV or whole inactivated VZV with a VZV antigen or immunogenic derivative thereof.
    I Use of a live attenuated VZV strain in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, wherein the live attenuated VZV strain is used in combination with a VZV antigen or immunogenic derivative thereof.
    J Use of a whole inactivated VZV strain in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, wherein the whole inactivated VZV strain is used in combination with a VZV antigen or immunogenic derivative thereof.
    K Use of a VZV antigen or immunogenic derivative thereof in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, wherein the VZV antigen is used in combination with a live attenuated VZV strain or whole inactivated VZV strain.
    L Use according to any of paragraphs I-K wherein the antigen or derivative thereof is delivered in a prime boost approach before the VZV strain.
    M Use according to any of paragraphs I-K wherein the antigen or derivative thereof is delivered in a prime boost approach after the VZV strain.
    N Use according to any of paragraphs I-K wherein the antigen or derivative thereof is delivered concomitantly with the VZV strain.
    O Use according to any of paragraphs I-K wherein the antigen or derivative thereof is delivered in admixture with the VZV strain.
    P A use, method, kit, or composition according to any preceding paragraph wherein the live attenuated VZV strain is the OKA strain.
    Q A use method, kit, composition according to any preceding paragraph wherein the VZV antigen the gE antigen or immunogenic derivative thereof.
    R A use, method, kit, composition or vaccine according to any preceding claim wherein the VZV antigen is delivered with an adjuvant capable of stimulating a TH1 type response.
  • The present invention is illustrated by the following, non limiting Examples.
    • Example 1
  • Three experimental groups may be set up to study both aspects of the invention:
  • Regime
    1 50 μg gE + adjuvant AS1 (MPL ®/QS21) 0, 2 months
    2 OKA strain (Varilrix ™) ~10,000 pfu/ dose 0, 2 months
    3 Concomitant administration of 50 μg gE + AS1 group 0, 2 months
    (as in 1) with Varilrix ™ (as in 2)
    MPL ® = 3D-MPL
  • The gE used can be truncated gE, as disclosed in FIG. 1.
  • Varilrix™ is a commercially available OKA strain.
  • Human volunteers (for example, 50 per group—healthy, aged 50-70 years) can be selected to be vaccinated according to the above protocol, and results may be assessed by measuring both cell mediated immunity and antibody responses, for example by intracellular staining (ICS, Roederer et al. 2004 Clin. Immunol. 110: 199) or ELISA techniques respectively, these being well known in the art.
  • Specific cell-mediated immunity may be evaluated by, for example, in vitro incubation of patient PBMC with varicella-zoster virus extracts as well as specific VZV antigens or peptides gE, IE63 and IE62. Analysis may be made at the level of, for example:
  • a Lymphoproliferation (data expressed as Stimulation Index [SI]): GM, GM fold increase and % of responders
  • b Analysis of IFNγ or IL2 or TNFα, or CD 40L expression by CD4 and CD8 cells by ICS (intracellular cytokine staining): GM, GM fold increase and % of responders
  • Efficacy can be assessed by looking for a significant increase in the CMI and/or antibody response in comparison with pre-vaccination levels.
  • Efficacy of other antigens or approaches can be assessed using these or similar techniques, and comparing pre-vaccination levels with post vaccination levels.
    • Example 2
  • The experiment of Example 1 was carried out in human volunteers of different ages, as follows:
  •
    Group A gE AS1 in adults 18-30 years
    Group B gE delivered concomitantly with the Varilrix OKA strain
    18-30 years
    Group C Varilrix OKA strain alone in adults 50-70 years
    Group D gE AS1 in adults 50-70 years
    Group E gE delivered concomitantly with the Varilrix OKA strain
    50-70 years
  • The vaccination schedule was as follows:
  • Group Age (Y) N Vacc 1 (Month 0) Vacc 2 (Month 2)
    A 18-30 10 gE-AS1 gE-AS1
    B 18-30 10 gE-AS1 + Varilrix ™ gE AS1 + Varilrix ™
    C 50-70 45 Varilrix ™ Varilrix ™
    D 50-70 45 gE-AS1 gE-AS1
    E 50-70 45 gE-AS1 + Varilrix ™ gE-AS1 + Varilrix ™
  • The adjuvant AS1 comprises 3D MPL and QS21 in a quenched form with cholesterol, and was made as described in WO9633739, incorporated herein by reference. In particular the AS1 adjuvant was prepared essentially as Example 1.1 of WO9633739.
  • The adjuvant comprises: liposomes, which in turn comprise dioleoyl phosphatidylcholine (DOPC), cholesterol and 3D MPL [in an amount of 1000 μg DOPC, 250 μg cholesterol and 50 μg 3D MPL, each value given approx per vaccine dose], QS21 [50 μg/dose], PBS and water to a volume of 0.5 ml.
  • In the process of production of liposomes containing MPL the DOPC (Dioleyl phosphatidylcholine), cholesterol and MPL are dissolved in ethanol. A lipid film is formed by solvent evaporation under vacuum. Phosphate Buffer Saline or PBS (9 mM Na2HPO4, 41 mM KH2PO4, 100 mM NaCl) at pH 6.1 is added and the mixture is submitted to prehomogenization followed by microfluidization at 15,000 psi (20 cycles). This leads to the production of liposomes which are sterile filtered through a 0.22 μm membrane in an aseptic (class 100) area. The sterile product is then distributed in sterile glass containers and stored in a cold room (+2 to +8° C.). In this way the liposomes produced contain MPL in the membrane (the “MPL in” embodiment of WO9633739).
  • The truncated gE of FIG. 1 was expressed in CHO K1 cells using standard techniques and purified using, in order, anion exchange chromatography, hydrophobic interaction chromatography, ion exchange chromatography, diafiltration, and nanofiltration followed by sterilisation through a 0.22 μm filter.
  • In particular, the following steps were used in the purification of gE
    • First Stage: Anion Exchange Chromatography
  • The culture supernatant containing the gE (approx. 30 mg/l) is purified, either directly after clarification of the cell suspension or after defrosting at 4° C. After transfer into a 20-litre carboy, the pH of the supernatant is adjusted to 6.
  • The capture stage takes place at ambient temperature on a chromatography column containing a Q Sepharose XL resin.
  • After sanitisation with sodium hydroxide, the column is conditioned in the capture buffer (piperazine 20 mM pH 6). The supernatant is then loaded on the column and the column is washed with equilibration buffer and a solution of piperazine 20 mM+NaCl 150 mM pH 6.
  • The fraction containing the gE is then eluted with a solution of piperazine 20 mM+NaCl 250 mM at pH 6.
    • Second Stage: Hydrophobic Interaction Chromatography
  • This chromatography stage takes place at ambient temperature on a Toyopearl butyl-650 M resin (Tosoh Biosep).
  • The fraction eluted with 20 mM piperazine+250 mM NaCl in the Q Sepharose XL stage is made up to 1 M in ammonium sulphate and adjusted to pH 7.5.
  • After sanitisation with sodium hydroxide and before loading of this fraction, the column is conditioned in the capture buffer (50 mM KH2PO4+1 M ammonium sulphate pH 7.5). After loading, the column is washed with buffer 50 mM KH2PO4+100 mM (NH4)2SO4 pH 7.5. The gE is eluted with buffer 50 mM KH2PO4+25 mM (NH4)2SO4 pH 7.5.
    • Third Stage: Affinity Chromatography on Immobilised Metal Ion
  • This chromatography stage takes place at ambient temperature on a Chelating Sepharose Fast Flow resin. This resin is saturated in metal ion (Ni) by application of a nickel sulphate solution (1%) and excess unbound ions (Ni), removed by washing. The gE fraction eluted at 50 mM KH2PO4+25 mM (NH4)2SO4 pH 7.5 in the hydrophobic phase is made up to 0.5 M NaCl and adjusted to pH 7.5.
  • After sanitisation, the column is equilibrated in the capture buffer (50 mM KH2PO4+0.5 M NaCl pH 7.5). The gE solution is loaded on the column, which is then washed with a solution of 50 mM KH2PO4+0.5 M NaCl pH 5.6. The gE is then eluted with a buffer of 50 mM sodium acetate+0.5 M NaCl pH 5, and neutralised with a Tris 1 M solution pH 9.5.
    • Fourth Stage: Diafiltration
  • The buffer exchange and the elimination of salts from the gE fraction eluted at pH 5 in the previous stage are carried out by tangential ultrafiltration. This stage is carried out entirely at +4° C.
  • The ultrafiltration is run by the Millipore Proflux M12 system, fitted with a 10 kDa Pellicon2 Mini membrane of regenerated cellulose (cat: P2C010C01) of limit nominal molecular weight and a surface area of 0.1 m2 placed in a Pellicon2 mini-cassette housing (cat.XX42PMINI).
  • After rinsing with water and sanitisation with sodium hydroxide, the whole system with membrane is rinsed with 2 litres of modified PBS buffer (=8.1 mM Na2HPO42H2O, 1.47 mM KH2PO4, 137 mM NaCl, 2.68 mM KCL pH 7.2) and then equilibrated with 2 litres of the same buffer until a pH value of 7.2 is reached in the permeate.
  • The measurement of the permeability of the membrane is verified. The integrity test on the membrane is carried out by putting the system under pressure up to 1 bar before and at the end of the diafiltration stage. If this membrane is used twice with an interval of one week, the integrity will be tested 3 times (once before each ultrafiltration and once after the second filtration). The membrane is considered to be intact if the loss of pressure recorded over 5 minutes is less than 0.1 bar. The concentration of the gE fraction eluted at pH 5 in the affinity stage is evaluated by measuring the optical density at 280 nm. The correlation between the absorbance at 280 nm and the protein concentration of the gE by microBCA is fixed at 1 OD280=1.75 mg/ml.
  • The solution containing the gE is dia-filtered against 10 volumes of modified PBS buffer (=8.1 mM Na2HPO42H2O, 1.47 mM KH2PO4, 137 mM NaCl, 2.68 mM KCL pH 7.2). The pressure conditions are set such that the diafiltration period is about 1½-2 hours (permeate flow approx. 60 ml/min). The diafiltration residue is then recovered and on the basis of the baseline OD280 the membrane is rinsed with modified PBS to give an approximate final concentration of 0.4 mg/ml.
    • Fifth Stage: Nanofiltration
  • This next stage makes it possible to eliminate viruses with a diameter of more than 15 nm by retention. The stage is carried out entirely at +4° C.
  • The nanofiltration is carried out on a PLANOVA 15N filter (mean pore size 15 nm; filtration surface area 0.12 m2 (ASAHI cat: 15NZ-120)). Under a constant pressure of 0.45 bar, the gE solution is filtered on the membrane and recovered on the other side with viruses removed.
  • The pipes and housing (column XK50) are sanitised for 2 hours with a solution of NaOH 0.5M. The whole is then rinsed and neutralised with the modified PBS buffer (same buffer as for the diafiltration) until a pH value of 7.2 is achieved.
  • After fixing the nanofilter PLANOVA 15N (feed side) under the casing, the filter is rinsed and equilibrated with a modified PBS solution.
  • The diafiltration residue containing the gE solution is first pre-filtered through 0.22 μm (mini kleenpak OU Acropak20, depending on the volume to be filtered) before being nano-filtered at a constant pressure of 0.45 bar on the PLANOVA 15N.
  • At the end of nanofiltration, the filter is rinsed with a sufficient volume of modified PBS to give a final concentration of the bulk of approx. 0.3 mg/ml.
  • To end, the membrane is washed with 50 ml modified PBS. The solution is recovered through the residue outlet.
  • The integrity tests on the PLANOVA 15N membrane are then carried out as follows:
  • the first test consists of putting the membrane under pressure (1.0 kg/cm2) and observing for formation of air bubbles. This test detects any large splits.
  • the second test: elimination of particles of gold (PARTICORPLANOVA-QCVAL4) verifies the structure of the membrane (good distribution of large pores and capillaries).
    • Vaccine Composition
  • The gE component of the vaccine comprises 50 μg gE and the excipients sodium chloride, potassium chloride, monopotassium phosphate, disodium phosphate and water for injection as well as the AS1 adjuvant. The function of the inorganic salts is to ensure isotonicity and physiological pH.
  • In a sterile glass container, water for injection, concentrated phosphate buffered saline and gE antigen were mixed in order to reach the ingredient concentration as below:
  • Quantitative
    Ingredients (per dose)
    gE 50 μg
    Sodium chloride (NaCl) 1603 μg
    Disodium phosphate (NaH2PO4) 288 μg
    Monopotassium phosphate (KH2PO4) 40 μg
    Potassium chloride (KCl) 40 μg
    Water for injection q.s. ad 0.2 mL
  • The solution is mixed for 30 to 40 minutes. The pH is checked and adjusted at 7.2+−.0.1 with HCl or NaCl or appropriate and stir for an additional 10 minutes.
  • The final bulk was stored in polypropylene bottles at −20° C. and transferred to GSK Bio for filling. The vaccine is filled into 3 ml, sterile, siliconised glass vials (0.25 ml/vial) which are closed with grey chlorobutyl rubber stoppers and sealed with central tear-off aluminium cap. The inspected, approved vials are then stored at −20° C.
    • Vaccine Delivery
  • The gE-AS1 vaccine for administration was obtained by mixing the liquid antigen preparation with the liquid AS1 adjuvant immediately prior to injection (a maximum of one hour before injection). The OKA (Varilrix™) was a commercially available lot prepared according to the manufacturer's instructions.
  • Vaccine formulations were as follows:
  • Vaccine gE
    Formulation 50 μg VZV (gE) antigen in 0.2 ml volume
    AS1 in 0.5 ml volume
    Presentation Glass vial containing liquid gE
    Total Dose Volume* 0.7 ml (after reconstitution)
  • Vaccine Varilrix with diluent
    Formulation Approximately 104.0 pfu/dose
    0/5 ml volume
    Presentation Glass vial containing containing lyophilized
    vaccine for reconstitution
    Total Dose Volume* 0.5 ml
  • The gE AS1 component was administered by intramuscular injection.
  • The Varilrix component was administered by subcutaneous injection.
    • Analysis of Results
  • The clinical trial protocol, filed in preparation for the clinical trial, outlined the types of studies that were to be carried out in the trial, as follows:
  • a Lymphoproliferation (data expressed as Stimulation Index [SI]): GM, fold increase in GM and % of responders after stimulation by VZV lysate.
  • b IFN gamma and/or IL2, TNF alpha, CD40L, CD4 and CD8 response by ICS (intracellular staining): GM,-fold increase in GM and % of responders after stimulation by VZV lysate and gE, IE62 and IE63 peptides.
    • Lymphoproliferation
  • Peripheral blood antigen-specific lymphocytes can be restimulated in vitro to proliferate if incubated with their corresponding antigen. Consequently, the amount of antigen specific lymphocytes can be estimated by counting tritiated thymidine incorporation assay. In the present study, VZV antigen or peptide derived from VZV proteins will be used as antigen to restimulate VZV-specific lymphocytes. Results will be expressed as a stimulation index (SI) which corresponds to the ratio between antigen-specific and background lymphoproliferation.
    • Cytokine Flow Cytometry (CFC)
  • Peripheral blood antigen-specific CD4 and CD8 T cells can be restimulated in vitro to express CD40L, IL-2, TNF alpha and IFN gamma if incubated with their corresponding antigen. Consequently, antigen-specific CD4 and CD8 T cells can be enumerated by flow cytometry following conventional immunofluorescence labelling of cellular phenotype as well as intracellular cytokines production. In the present study, VZV antigen or peptide derived from VZV proteins will be used as antigen to restimulate VZV-specific T cells. Results will be expressed as a frequency of cytokine(s)-positive CD4 or CD8 T cell within the CD4 or CD8 T cell sub-population.
    • Specific Antibody (Anti-VZV and Anti-gE)
  • Antibody levels against VZV and gE will be measured using classical ELISA assays.
  • Results of the experiment are shown in tabular form. FIGS. 2-6 present results in a graphical form for antibody (FIGS. 2-4, see tables 1.1 a-c) and CMI responses (FIGS. 5 and 6—see table C1/“CD4 all doubles” test with gE antigen or Varilirix, median values).
  • HUMORAL IMMUNE RESPONSE
    Table I.1a Seropositivity rates and GMTs for VZV IGG antibodies
    (ATP cohort for immunogenicity) . . .
    Table I.1b Seropositivity rates and GMTs for VZV.GE antibodies
    (ATP cohort for immunogenicity) . . .
    Table I.1c Seropositivity rates and GMTs for IFA antibodies (ATP
    cohort for immunogenicity) . . .
    Table I.2b Seroconversion rates for gE antibody titer at each post-
    vaccination time point (ATP cohort for
    immunogenicity) . . .
    Table I.3a Vaccine response for VZV antibody titer at each post-
    vaccination time point (ATP cohort for
    immunogenicity) . . .
    Table I.3b Vaccine response for gE antibody titer at each post-
    vaccination time point (ATP cohort for
    immunogenicity) . . .
    Table I.3c Vaccine response for IFA antibody titer at each post-
    vaccination time point (ATP cohort for
    immunogenicity) . . .
  • TABLE I.1a
    Seropositivity rates and GMTs for VZV IGG antibodies (ATP
    cohort for immunogenicity)
    >=50 MIU/ML GMT
    95% CI 95% CI
    Antibody Group Timing N n % LL UL value LL UL Min Max
    VZV IGG gE/Y PRE 10 10 100 69.2 100 1875.9 1077.2 3266.8 455.0 4634.0
    PI(M1) 10 10 100 69.2 100 14843.0 8457.7 26049.0 6051.0 65242.0
    PI(M2) 10 10 100 69.2 100 10697.6 6768.2 16908.4 3167.0 29622.0
    PII(M3) 10 10 100 69.2 100 14330.6 10492.9 19571.9 7173.0 30894.0
    gEVAR/Y PRE 10 10 100 69.2 100 1047.4 519.3 2112.6 300.0 5754.0
    PI(M1) 10 10 100 69.2 100 12859.4 7063.0 23412.8 3346.0 49163.0
    PI(M2) 10 10 100 69.2 100 10072.2 5631.4 18014.7 3678.0 36289.0
    PII(M3) 10 10 100 69.2 100 15245.7 9930.9 23404.8 6381.0 36534.0
    VAR/E PRE 45 45 100 92.1 100 856.9 647.5 1134.1 100.0 5377.0
    PI(M1) 45 45 100 92.1 100 2538.8 2072.3 3110.3 288.0 8034.0
    PI(M2) 45 45 100 92.1 100 2292.2 1880.6 2793.9 374.0 7549.0
    PII(M3) 45 45 100 92.1 100 2338.3 1933.6 2827.7 523.0 16994.0
    gE/E PRE 45 45 100 92.1 100 940.1 744.2 1187.6 208.0 4221.0
    PI(M1) 45 45 100 92.1 100 5897.4 4594.7 7569.5 659.0 27042.0
    PI(M2) 45 45 100 92.1 100 4523.0 3570.6 5729.4 598.0 19268.0
    PII(M3) 45 45 100 92.1 100 9083.9 7437.6 11094.5 2493.0 42073.0
    gEVAR/E PRE 44 44 100 92.0 100 1165.1 954.6 1422.1 209.0 5558.0
    PI(M1) 44 44 100 92.0 100 8371.7 6637.2 10559.5 2509.0 56066.0
    PI(M2) 44 44 100 92.0 100 6849.1 5422.6 8650.8 1753.0 55958.0
    PII(M3) 44 44 100 92.0 100 9849.1 8201.7 11827.3 3528.0 38664.0
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    GMC = geometric mean antibody concentration calculated on all subjects
    N = number of subjects with available results
    n/% = number/percentage of subjects with concentration within the specified range
    95% CI = 95% confidence interval;
    LL = Lower Limit,
    UL = Upper Limit
    MIN/MAX = Minimum/Maximum
    PRE = Pre-vaccination dose 1
    PI(M1) = Post-vacciantion dose 1 (Month 1)
    PI(M2) = Post-vaccination dose 1 (Month 2)
    PII(M3) = Post-vaccination dose 2 (Month 3)
  • TABLE I.1b
    Seropositivity rates and GMTs for VZV.GE antibodies (ATP
    cohort for immunogenicity)
    >=109 ELU/ML GMT
    95% CI 95% CI
    Antibody Group Timing N n % LL UL value LL UL Min Max
    VZV.GE gE/Y PRE 10 8 80.0 44.4 97.5 302.6 120.5 759.9 <109.0 2169.0
    PI(M1) 10 10 100 69.2 100 18365.0 9610.6 35094.1 5697.0 106829.0
    PI(M2) 10 10 100 69.2 100 11076.6 7037.4 17433.9 3528.0 30190.0
    PII(M3) 10 10 100 69.2 100 15842.6 11543.4 21743.1 7502.0 30487.0
    gEVAR/Y PRE 10 7 70.0 34.8 93.3 190.3 96.4 375.6 <109.0 661.0
    PI(M1) 10 10 100 69.2 100 16225.7 8657.3 30410.6 3613.0 58950.0
    PI(M2) 10 10 100 69.2 100 11554.7 6312.5 21150.4 3656.0 47423.0
    PII(M3) 10 10 100 69.2 100 18101.2 11384.7 28780.0 7649.0 44539.0
    VAR/E PRE 44 35 79.5 64.7 90.2 266.9 189.6 375.8 <109.0 5866.0
    PI(M1) 45 45 100 92.1 100 1011.3 770.0 1328.2 177.0 6386.0
    PI(M2) 45 45 100 92.1 100 948.1 701.6 1281.2 127.0 6759.0
    PII(M3) 45 45 100 92.1 100 1146.9 841.5 1563.0 164.0 16249.0
    gE/E PRE 45 37 82.2 67.9 92.0 231.1 178.8 298.7 <109.0 899.0
    PI(M1) 45 45 100 92.1 100 6099.1 4401.9 8450.8 367.0 40101.0
    PI(M2) 45 45 100 92.1 100 4844.2 3406.5 6888.8 288.0 42488.0
    PII(M3) 45 45 100 92.1 100 14816.8 12122.2 18110.2 3047.0 58792.0
    gEVAR/E PRE 44 42 95.5 84.5 99.4 336.1 268.0 421.5 <109.0 1531.0
    PI(M1) 44 44 100 92.0 100 8272.6 6071.1 11272.4 363.0 54878.0
    PI(M2) 44 44 100 92.0 100 7870.4 5937.0 10433.4 1512.0 84465.0
    PII(M3) 44 44 100 92.0 100 16616.0 13972.3 19760.0 4774.0 61558.0
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    GMC = geometric mean antibody concentration calculated on all subjects
    N = number of subjects with available results
    n/% = number/percentage of subjects with concentration within the specified range
    95% CI = 95% confidence interval;
    LL = Lower Limit,
    UL = Upper Limit
    MIN/MAX = Minimum/Maximum
    PRE = Pre-vaccination dose 1
    PI(M1) = Post-vacciantion dose 1 (Month 1)
    PI(M2) = Post-vaccination dose 1 (Month 2)
    PII(M3) = Post-vaccination dose 2 (Month 3)
  • TABLE I.1c
    Seropositivity rates and GMTs for IFA antibodies (ATP cohort for
    immunogenicity)
    >=4 1/DIL GMT
    95% CI 95% CI
    Antibody Group Timing N n % LL UL value LL UL Min Max
    IFA gE/Y PRE 10 10 100 69.2 100 1351.2 691.9 2638.8 256.0 4096.0
    PI(M1) 10 10 100 69.2 100 10809.4 6040.0 19345.1 4096.0 65536.0
    PI(M2) 10 10 100 69.2 100 12416.8 6631.6 23248.7 2048.0 32768.0
    PII(M3) 10 10 100 69.2 100 14263.1 10423.6 19516.8 8192.0 32768.0
    gEVAR/Y PRE 10 10 100 69.2 100 776.0 321.6 1872.5 256.0 16384.0
    PI(M1) 10 10 100 69.2 100 9410.1 5638.8 15703.7 4096.0 32768.0
    PI(M2) 10 10 100 69.2 100 14263.1 8546.9 23802.4 8192.0 65536.0
    PII(M3) 10 10 100 69.2 100 12416.8 8173.6 18862.6 8192.0 32768.0
    VAR/E PRE 45 45 100 92.1 100 686.1 508.5 925.6 128.0 8192.0
    PI(M1) 45 45 100 92.1 100 2702.4 2115.6 3451.9 512.0 32768.0
    PI(M2) 45 45 100 92.1 100 1838.7 1454.0 2325.2 256.0 16384.0
    PII(M3) 45 45 100 92.1 100 2144.9 1707.4 2694.4 256.0 8192.0
    gE/E PRE 45 45 100 92.1 100 597.3 452.8 787.8 128.0 8192.0
    PI(M1) 45 45 100 92.1 100 6402.6 4799.2 8541.8 512.0 32768.0
    PI(M2) 45 45 100 92.1 100 4356.3 3247.0 5844.7 256.0 32768.0
    PII(M3) 45 45 100 92.1 100 10163.5 8426.4 12258.7 1024.0 32768.0
    gEVAR/E PRE 44 44 100 92.0 100 783.4 620.8 988.7 128.0 4096.0
    PI(M1) 44 44 100 92.0 100 9004.1 6946.4 11671.3 2048.0 65536.0
    PI(M2) 44 44 100 92.0 100 6169.4 4908.2 7754.6 2048.0 32768.0
    PII(M3) 44 44 100 92.0 100 11225.9 9284.5 13573.3 4096.0 32768.0
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    GMT = geometric mean antibody titre calculated on all subjects
    N = number of subjects with available results
    n/% = number/percentage of subjects with titre within the specified range
    95% CI = 95% confidence interval;
    LL = Lower Limit,
    UL = Upper Limit
    MIN/MAX = Minimum/Maximum
    PRE = Pre-vaccination dose 1
    PI(M1) = Post-vacciantion dose 1 (Month 1)
    PI(M2) = Post-vaccination dose 1 (Month 2)
    PII(M3) = Post-vaccination dose 2 (Month 3)
  • TABLE I.2b
    Seroconversion rates for gE antibody titer at each post-
    vaccination time point (ATP cohort for immunogenicity)
    Seroconversion
    95% CI
    Group Timing N n % LL UL
    gE/Y Month 1 2 2 100.0 15.8 100.0
    Month 2 2 2 100.0 15.8 100.0
    Month 3 2 2 100.0 15.8 100.0
    gEVAR/Y Month 1 3 3 100.0 29.2 100.0
    Month 2 3 3 100.0 29.2 100.0
    Month 3 3 3 100.0 29.2 100.0
    VAR/E Month 1 9 9 100.0 66.4 100.0
    Month 2 9 9 100.0 66.4 100.0
    Month 3 9 9 100.0 66.4 100.0
    gE/E Month 1 8 8 100.0 63.1 100.0
    Month 2 8 8 100.0 63.1 100.0
    Month 3 8 8 100.0 63.1 100.0
    gEVAR/E Month 1 2 2 100.0 15.8 100.0
    Month 2 2 2 100.0 15.8 100.0
    Month 3 2 2 100.0 15.8 100.0
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of seronegative subjects at day 0
    n/% = number/percentage of initially seronegative subjects who became seropositive at the specified post-vaccination time point
    95% CI = 95% confidence interval;
    LL = Lower Limit,
    UL = Upper Limit
  • TABLE I.3a
    Vaccine response for VZV antibody titer at each post-
    vaccination time point (ATP cohort for immunogenicity)
    Vaccine response
    95% CI
    Group Timing N n % LL UL
    gE/Y Month 1 10 7 70.0 34.8 93.3
    Month 2 10 6 60.0 26.2 87.8
    Month 3 10 9 90.0 55.5 99.7
    gEVAR/Y Month 1 10 10 100.0 69.2 100.0
    Month 2 10 10 100.0 69.2 100.0
    Month 3 10 10 100.0 69.2 100.0
    VAR/E Month 1 45 11 24.4 12.9 39.5
    Month 2 45 10 22.2 11.2 37.1
    Month 3 45 11 24.4 12.9 39.5
    gE/E Month 1 45 29 64.4 48.8 78.1
    Month 2 45 24 53.3 37.9 68.3
    Month 3 45 39 86.7 73.2 94.9
    gEVAR/E Month 1 44 33 75.0 59.7 86.8
    Month 2 44 27 61.4 45.5 75.6
    Month 3 44 38 86.4 72.6 94.8
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of seropositive subjects at day 0
    n/% = number/percentage of initially seropositive subjects with a four-fold increase at the specified post-vaccination time point
    95% CI = 95% confidence interval;
    LL = Lower Limit,
    UL = Upper Limit
  • Analysis of CMI responses is given below
  • LIST OF TABLES
    Table C.1 Intracellular Cytokine Staining (ICS): Descriptive Statistics on CD4 T
    cells at each time point (Total vaccinated Cohort) . . .
    Supplementary Table C.1 Intracellular Cytokine Staining (ICS): Descriptive Statistics on
    CD8 T cells at each time point (Total vaccinated Cohort) . . .
    Table C.2 Intracellular Cytokine Staining (ICS): Inferential statistics: P-values from
    Kruskal-Wallis Tests for CD4 T cells at each time point (Total Vaccinated
    Cohort) . . .
    Supplementary Table C.2 Intracellular Cytokine Staining (ICS): Inferential statistics: P-
    values from Kruskal-Wallis Tests for CD8 T cells at each time point
    (Total Vaccinated Cohort) . . .
    Table C.3 Intracellular Cytokine Staining (ICS): Descriptive Statistics on CD4 T
    cells at POST-PRE (Total vaccinated Cohort) . . .
    Supplementary Table C.3 Intracellular Cytokine Staining (ICS): Descriptive Statistics on
    CD8 T cells at POST-PRE (Total vaccinated Cohort) . . .
    Table C.4 Intracellular Cytokine Staining (ICS): Inferential statistics: P-values from
    Kruskal-Wallis Tests for CD4 T cells at POST-PRE (Total Vaccinated
    Cohort) . . .
    Supplementary Table C.4 Intracellular Cytokine Staining (ICS): Inferential statistics: P-
    values from Kruskal-Wallis Tests for CD8 T cells at POST-PRE (Total
    Vaccinated Cohort) . . .
  • TABLE C.1
    Intracellular Cytokine Staining (ICS): Descriptive Statistics on
    CD4 T cells at each time point (Total vaccinated Cohort)
    Test Antigen Group Timing N N miss. Mean SD Min Q1 Median Q3 Max
    CD4-ALL Pool gE gE/Y Day 0 9 1 213.44 202.59 1.00 1.00 139.00 385.00 490.00
    DOUBLES Month 1 9 1 1383.78 1629.94 256.00 342.00 807.00 1333.00 5207.00
    Month 2 9 1 1787.56 1818.51 497.00 677.00 919.00 1775.00 5539.00
    Month 3 9 1 2739.89 1856.98 581.00 1770.00 2234.00 2909.00 6963.00
    gEVAR/Y Day 0 10 0 253.20 246.76 1.00 1.00 246.00 391.00 783.00
    Month 1 10 0 1179.70 991.68 1.00 567.00 979.00 1364.00 3535.00
    Month 2 9 1 1546.44 886.57 116.00 846.00 1996.00 2092.00 2538.00
    Month 3 10 0 3298.50 1477.17 1699.00 1970.00 2944.00 4924.00 5840.00
    VAR/E Day 0 44 1 299.98 922.48 1.00 1.00 126.00 238.00 6152.00
    Month 1 43 2 458.28 1256.04 1.00 89.00 194.00 294.00 8000.00
    Month 2 44 1 246.09 243.71 1.00 87.50 177.00 339.00 1252.00
    Month 3 45 0 476.40 1149.12 1.00 1.00 151.00 365.00 6264.00
    gE/E Day 0 44 1 166.27 180.38 1.00 1.00 104.50 291.50 657.00
    Month 1 42 3 849.10 1090.91 1.00 226.00 540.00 949.00 4487.00
    Month 2 43 2 522.12 577.93 1.00 115.00 402.00 627.00 2372.00
    Month 3 43 2 3221.91 2534.70 1.00 1184.00 2323.00 4767.00 11480.00
    gEVAR/E Day 0 45 0 206.02 265.71 1.00 36.00 158.00 249.00 1552.00
    Month 1 44 1 826.70 614.40 1.00 322.50 770.00 1158.50 2927.00
    Month 2 45 0 509.16 411.89 1.00 166.00 447.00 737.00 1553.00
    Month 3 45 0 2918.04 2522.39 8.00 1081.00 1902.00 4251.00 10468.00
    Varilrix gE/Y Day 0 9 1 1045.78 770.48 369.00 544.00 761.00 1067.00 2590.00
    Month 1 9 1 1302.67 1378.05 1.00 314.00 597.00 1877.00 4109.00
    Month 2 9 1 1656.00 1224.33 561.00 890.00 1238.00 2019.00 4494.00
    Month 3 9 1 1816.33 994.51 590.00 1241.00 1368.00 2540.00 3755.00
    gEVAR/Y Day 0 10 0 1188.40 580.19 412.00 783.00 1058.50 1535.00 2332.00
    Month 1 10 0 1090.00 1168.31 1.00 610.00 770.00 1123.00 4267.00
    Month 2 9 1 2659.78 1316.29 873.00 1868.00 2282.00 4171.00 4246.00
    Month 3 10 0 3369.70 2127.99 1147.00 1738.00 2854.50 4494.00 7745.00
    VAR/E Day 0 44 1 581.02 635.92 1.00 129.50 415.00 753.50 3327.00
    Month 1 43 2 992.35 1093.91 1.00 268.00 661.00 1447.00 5359.00
    Month 2 44 1 815.75 928.07 1.00 222.50 517.00 1065.00 4575.00
    Month 3 45 0 984.67 832.16 1.00 364.00 774.00 1278.00 3287.00
    gE/E Day 0 44 1 758.18 982.52 1.00 81.50 395.00 929.50 4479.00
    Month 1 42 3 1216.60 1674.07 1.00 307.00 591.00 1410.00 7779.00
    Month 2 43 2 869.35 1017.90 1.00 217.00 543.00 1072.00 4556.00
    Month 3 43 2 2192.42 1977.14 56.00 840.00 1862.00 2557.00 9167.00
    gEVAR/E Day 0 45 0 510.73 512.13 1.00 219.00 376.00 675.00 2218.00
    Month 1 44 1 1179.50 1005.41 1.00 434.50 982.00 1529.00 4478.00
    Month 2 45 0 961.78 915.99 1.00 292.00 704.00 1078.00 3975.00
    Month 3 45 0 2484.47 1713.46 109.00 1270.00 2008.00 3429.00 6585.00
    CD4- Pool gE gE/Y Day 0 9 1 204.67 193.66 1.00 1.00 139.00 356.00 490.00
    CD40L Month 1 9 1 1347.33 1570.63 244.00 400.00 768.00 1273.00 5021.00
    Month 2 9 1 1724.44 1737.50 466.00 660.00 869.00 1859.00 5252.00
    Month 3 9 1 2567.89 1723.12 514.00 1744.00 1905.00 2813.00 6414.00
    gEVAR/Y Day 0 10 0 253.80 240.23 1.00 41.00 265.50 361.00 752.00
    Month 1 10 0 1122.30 999.38 1.00 480.00 948.00 1266.00 3534.00
    Month 2 9 1 1520.33 898.50 116.00 732.00 2045.00 2068.00 2633.00
    Month 3 10 0 3169.30 1452.28 1555.00 1857.00 2910.50 4539.00 5840.00
    VAR/E Day 0 44 1 292.50 872.61 1.00 1.00 119.50 238.50 5812.00
    Month 1 43 2 444.93 1175.20 1.00 70.00 214.00 316.00 7453.00
    Month 2 44 1 242.66 242.66 1.00 95.00 178.00 333.00 1252.00
    Month 3 45 0 465.67 1124.33 1.00 18.00 154.00 365.00 6072.00
    gE/E Day 0 44 1 158.55 173.14 1.00 5.50 98.50 290.50 564.00
    Month 1 42 3 840.79 1061.43 1.00 237.00 530.00 910.00 4428.00
    Month 2 43 2 529.58 558.23 1.00 147.00 365.00 645.00 2251.00
    Month 3 43 2 3133.65 2453.67 1.00 1172.00 2294.00 4703.00 10561.00
    gEVAR/E Day 0 45 0 206.16 257.80 1.00 35.00 167.00 278.00 1525.00
    Month 1 44 1 814.57 606.93 1.00 314.00 773.00 1153.00 2762.00
    Month 2 45 0 515.11 400.69 1.00 204.00 459.00 737.00 1523.00
    Month 3 45 0 2898.40 2512.50 97.00 1073.00 1915.00 4200.00 10418.00
    Varilrix gE/Y Day 0 9 1 1027.78 746.06 373.00 544.00 761.00 1033.00 2507.00
    Month 1 9 1 1264.11 1345.95 1.00 277.00 554.00 1854.00 3992.00
    Month 2 9 1 1609.67 1112.38 561.00 978.00 1238.00 1992.00 4094.00
    Month 3 9 1 1750.67 987.16 573.00 1039.00 1329.00 2556.00 3598.00
    gEVAR/Y Day 0 10 0 1174.60 581.33 379.00 747.00 1061.50 1535.00 2327.00
    Month 1 10 0 1051.70 1159.05 1.00 610.00 706.50 1019.00 4211.00
    Month 2 9 1 2623.56 1344.14 873.00 1726.00 2281.00 4168.00 4273.00
    Month 3 10 0 3229.20 2099.64 1089.00 1624.00 2797.00 4400.00 7592.00
    VAR/E Day 0 44 1 574.57 617.51 1.00 129.50 410.00 785.50 3268.00
    Month 1 43 2 976.98 1068.41 1.00 282.00 661.00 1386.00 5305.00
    Month 2 44 1 801.14 922.73 1.00 230.50 519.50 1044.00 4601.00
    Month 3 45 0 965.73 817.64 1.00 409.00 733.00 1255.00 3264.00
    gE/E Day 0 44 1 742.41 978.83 1.00 85.00 367.50 906.00 4506.00
    Month 1 42 3 1184.31 1577.03 1.00 307.00 608.00 1410.00 7748.00
    Month 2 43 2 868.70 1000.52 2.00 195.00 521.00 1020.00 4435.00
    Month 3 43 2 2143.84 1963.92 64.00 840.00 1849.00 2508.00 9008.00
    gEVAR/E Day 0 45 0 506.91 508.06 1.00 177.00 367.00 586.00 2191.00
    Month 1 44 1 1172.11 1005.52 19.00 452.00 949.50 1507.50 4478.00
    Month 2 45 0 963.98 907.43 7.00 325.00 680.00 1091.00 3975.00
    Month 3 45 0 2438.44 1675.69 73.00 1239.00 2008.00 3372.00 6538.00
    CD4-IFNγ Pool gE gE/Y Day 0 9 1 111.00 101.80 1.00 1.00 104.00 154.00 295.00
    Month 1 9 1 966.89 1288.87 1.00 212.00 499.00 824.00 3972.00
    Month 2 9 1 1263.67 1422.73 193.00 498.00 665.00 1298.00 4705.00
    Month 3 9 1 1952.44 1798.75 358.00 1189.00 1302.00 2103.00 6292.00
    gEVAR/Y Day 0 10 0 177.30 118.58 24.00 112.00 138.00 242.00 437.00
    Month 1 10 0 823.50 948.60 1.00 272.00 591.00 851.00 3334.00
    Month 2 9 1 1087.22 751.60 39.00 503.00 1290.00 1626.00 2226.00
    Month 3 10 0 2285.60 1272.75 1146.00 1243.00 1967.00 2691.00 5437.00
    VAR/E Day 0 44 1 174.95 478.34 1.00 29.50 54.50 154.00 3179.00
    Month 1 43 2 290.14 764.08 1.00 47.00 92.00 220.00 4988.00
    Month 2 44 1 172.70 201.53 1.00 40.50 117.00 216.00 1105.00
    Month 3 45 0 279.49 586.44 1.00 1.00 100.00 193.00 3226.00
    gE/E Day 0 44 1 128.91 150.94 1.00 10.50 75.50 197.00 586.00
    Month 1 42 3 513.38 768.05 1.00 55.00 250.00 520.00 3471.00
    Month 2 43 2 293.86 414.90 1.00 48.00 144.00 333.00 1894.00
    Month 3 43 2 1672.33 1602.24 1.00 596.00 1307.00 2104.00 6309.00
    gEVAR/E Day 0 45 0 123.78 173.17 1.00 36.00 76.00 159.00 1078.00
    Month 1 44 1 474.86 405.90 1.00 161.00 326.00 746.50 1536.00
    Month 2 45 0 295.87 316.87 1.00 68.00 190.00 425.00 1132.00
    Month 3 45 0 1516.18 1303.21 67.00 620.00 1024.00 2188.00 5829.00
    Varilrix gE/Y Day 0 9 1 855.44 722.82 310.00 391.00 577.00 839.00 2466.00
    Month 1 9 1 1051.89 1228.06 1.00 247.00 384.00 1462.00 3637.00
    Month 2 9 1 1283.67 1065.12 410.00 475.00 966.00 1482.00 3808.00
    Month 3 9 1 1362.44 910.53 448.00 833.00 1045.00 1873.00 3297.00
    gEVAR/Y Day 0 10 0 946.70 536.60 438.00 548.00 822.50 1097.00 2162.00
    Month 1 10 0 921.30 1143.99 1.00 365.00 586.00 1047.00 4042.00
    Month 2 9 1 2176.56 1249.74 838.00 1181.00 1711.00 3439.00 3885.00
    Month 3 10 0 2715.60 1892.41 716.00 1327.00 2380.50 3836.00 6992.00
    VAR/E Day 0 44 1 481.73 550.51 1.00 95.50 367.50 600.00 2960.00
    Month 1 43 2 827.30 941.73 1.00 253.00 529.00 1287.00 4765.00
    Month 2 44 1 641.86 757.75 3.00 160.00 444.50 797.50 3922.00
    Month 3 45 0 772.67 690.72 1.00 244.00 580.00 1003.00 2797.00
    gE/E Day 0 44 1 629.98 847.28 1.00 72.50 228.00 819.00 3920.00
    Month 1 42 3 972.52 1380.48 1.00 186.00 419.00 1154.00 6695.00
    Month 2 43 2 673.05 857.44 1.00 137.00 371.00 730.00 4126.00
    Month 3 43 2 1581.98 1625.99 58.00 618.00 1381.00 1735.00 7796.00
    gEVAR/E Day 0 45 0 386.82 395.99 1.00 92.00 263.00 483.00 1579.00
    Month 1 44 1 937.20 879.65 1.00 338.50 656.50 1132.50 3637.00
    Month 2 45 0 786.73 775.90 1.00 343.00 566.00 901.00 3205.00
    Month 3 45 0 1769.78 1236.32 1.00 884.00 1439.00 2289.00 4992.00
    CD4-IL2 Pool gE gE/Y Day 0 9 1 166.44 178.37 1.00 1.00 66.00 337.00 420.00
    Month 1 9 1 1259.44 1464.99 240.00 371.00 768.00 1119.00 4701.00
    Month 2 9 1 1662.11 1698.78 402.00 593.00 892.00 1721.00 5076.00
    Month 3 9 1 2317.67 1497.67 410.00 1423.00 2011.00 2595.00 5534.00
    gEVAR/Y Day 0 10 0 237.20 233.77 1.00 50.00 231.00 349.00 751.00
    Month 1 10 0 987.90 796.31 1.00 509.00 751.50 1361.00 2799.00
    Month 2 9 1 1404.67 723.26 270.00 802.00 1905.00 1975.00 2029.00
    Month 3 10 0 2747.80 1210.11 1436.00 1563.00 2367.50 4296.00 4451.00
    VAR/E Day 0 44 1 269.98 833.31 1.00 33.00 119.00 212.00 5582.00
    Month 1 43 2 388.26 995.89 1.00 58.00 164.00 293.00 6248.00
    Month 2 44 1 211.18 231.64 1.00 53.50 158.00 286.50 1182.00
    Month 3 45 0 397.51 916.41 1.00 2.00 146.00 329.00 4728.00
    gE/E Day 0 44 1 149.86 153.06 1.00 1.00 95.50 252.00 550.00
    Month 1 42 3 761.98 992.38 5.00 157.00 451.50 800.00 4039.00
    Month 2 43 2 467.58 523.51 1.00 103.00 329.00 541.00 2094.00
    Month 3 43 2 2809.07 2307.31 1.00 1037.00 2177.00 4347.00 10316.00
    gEVAR/E Day 0 45 0 165.16 246.51 1.00 35.00 116.00 203.00 1551.00
    Month 1 44 1 712.59 540.93 1.00 228.00 728.50 1048.00 2381.00
    Month 2 45 0 465.58 354.74 1.00 184.00 385.00 667.00 1239.00
    Month 3 45 0 2550.27 2304.36 1.00 945.00 1713.00 3910.00 9561.00
    Varilrix gE/Y Day 0 9 1 941.44 645.88 446.00 492.00 617.00 967.00 2217.00
    Month 1 9 1 1092.22 1164.69 1.00 249.00 469.00 1576.00 3480.00
    Month 2 9 1 1482.00 1067.28 393.00 906.00 1148.00 1715.00 3938.00
    Month 3 9 1 1551.22 851.75 484.00 869.00 1275.00 2083.00 3112.00
    gEVAR/Y Day 0 10 0 1074.70 505.73 414.00 748.00 988.00 1265.00 2094.00
    Month 1 10 0 903.00 887.48 1.00 486.00 650.50 880.00 3256.00
    Month 2 9 1 2403.33 1122.05 989.00 1679.00 2086.00 3309.00 4127.00
    Month 3 10 0 2791.90 1716.41 1043.00 1472.00 2186.50 3978.00 6004.00
    VAR/E Day 0 44 1 536.80 592.24 1.00 135.50 403.50 710.00 3190.00
    Month 1 43 2 866.63 984.53 1.00 220.00 608.00 1154.00 4813.00
    Month 2 44 1 711.09 830.59 1.00 204.50 452.50 907.50 4261.00
    Month 3 45 0 828.55 733.60 1.00 331.00 632.00 1076.00 2948.00
    gE/E Day 0 44 1 701.02 866.81 1.00 97.50 280.00 885.50 3493.00
    Month 1 42 3 1076.55 1440.99 1.00 233.00 548.00 1316.00 6726.00
    Month 2 43 2 785.88 884.51 1.00 167.00 515.00 971.00 3707.00
    Month 3 43 2 1866.37 1721.01 1.00 670.00 1569.00 2295.00 7835.00
    gEVAR/E Day 0 45 0 465.67 489.70 1.00 142.00 334.00 557.00 2107.00
    Month 1 44 1 1056.59 942.76 18.00 441.50 802.00 1408.50 4071.00
    Month 2 45 0 885.89 853.16 1.00 328.00 628.00 1013.00 3815.00
    Month 3 45 0 2114.20 1524.74 72.00 993.00 1660.00 3199.00 5671.00
    CD4-TNFα Pool gE gE/Y Day 0 9 1 99.33 94.45 1.00 32.00 68.00 189.00 245.00
    Month 1 9 1 659.56 926.82 114.00 155.00 201.00 757.00 2960.00
    Month 2 9 1 891.11 1360.20 71.00 261.00 347.00 868.00 4435.00
    Month 3 9 1 1423.33 1570.82 238.00 494.00 914.00 1350.00 5269.00
    gEVAR/Y Day 0 10 0 117.00 157.25 1.00 1.00 28.00 265.00 380.00
    Month 1 10 0 649.30 523.37 34.00 352.00 551.00 805.00 1952.00
    Month 2 9 1 804.67 520.96 39.00 504.00 717.00 1191.00 1578.00
    Month 3 10 0 1770.00 890.04 470.00 1223.00 1865.00 2258.00 3054.00
    VAR/E Day 0 44 1 211.11 697.05 1.00 1.00 73.00 158.00 4652.00
    Month 1 43 2 271.98 755.07 1.00 43.00 109.00 217.00 4812.00
    Month 2 44 1 149.80 172.34 1.00 38.50 109.00 233.00 1007.00
    Month 3 45 0 291.98 713.57 1.00 1.00 108.00 198.00 4213.00
    gE/E Day 0 44 1 125.23 143.92 1.00 1.00 54.00 213.00 531.00
    Month 1 42 3 444.05 585.76 1.00 64.00 283.50 473.00 2574.00
    Month 2 43 2 319.30 371.77 1.00 103.00 225.00 425.00 1808.00
    Month 3 43 2 1902.56 1602.67 1.00 779.00 1414.00 2860.00 7655.00
    gEVAR/E Day 0 45 0 153.76 193.78 1.00 33.00 129.00 190.00 1025.00
    Month 1 44 1 432.39 326.71 1.00 135.50 410.50 694.50 1479.00
    Month 2 45 0 318.69 273.85 1.00 96.00 265.00 438.00 1097.00
    Month 3 45 0 1662.40 1570.03 1.00 671.00 1091.00 2194.00 6609.00
    Varilrix gE/Y Day 0 9 1 754.44 694.51 260.00 286.00 315.00 902.00 2217.00
    Month 1 9 1 812.11 925.84 1.00 131.00 370.00 1275.00 2851.00
    Month 2 9 1 1204.56 980.05 420.00 690.00 738.00 1436.00 3581.00
    Month 3 9 1 1129.33 872.35 286.00 592.00 719.00 1539.00 2972.00
    gEVAR/Y Day 0 10 0 816.50 449.18 239.00 597.00 733.00 1024.00 1577.00
    Month 1 10 0 660.20 520.39 217.00 342.00 482.50 895.00 1965.00
    Month 2 9 1 1789.67 952.77 418.00 1084.00 1396.00 2627.00 3273.00
    Month 3 10 0 2016.50 1220.42 437.00 1321.00 1774.00 3179.00 4156.00
    VAR/E Day 0 44 1 467.02 590.33 1.00 86.50 303.00 607.50 3075.00
    Month 1 43 2 751.72 934.46 1.00 223.00 405.00 1079.00 4794.00
    Month 2 44 1 638.30 813.04 1.00 215.50 340.00 812.00 3974.00
    Month 3 45 0 711.04 662.11 1.00 268.00 535.00 865.00 2893.00
    gE/E Day 0 44 1 623.09 800.32 1.00 96.50 257.50 833.50 3426.0
    Month 1 42 3 862.48 1203.33 1.00 197.00 389.00 1091.00 5641.0
    Month 2 43 2 664.63 820.99 22.00 142.00 334.00 845.00 3582.0
    Month 3 43 2 1508.67 1419.81 1.00 537.00 1353.00 1836.00 6451.0
    gEVAR/E Day 0 45 0 405.42 379.35 1.00 168.00 260.00 558.00 1616.0
    Month 1 44 1 814.70 780.82 1.00 274.50 574.50 989.00 3311.0
    Month 2 45 0 699.20 628.49 1.00 232.00 549.00 898.00 2501.0
    Month 3 45 0 1634.80 1160.30 73.00 854.00 1450.00 2097.00 4405.0
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of subjects with available results
    N miss. = number of subjects with missing results
    SD = Standard Deviation
    Min, Max = Minimum, Maximum
    Q1, Q3 = First, Third quartile
  • SUPPLEMENTARY TABLE C.1
    Intracellular Cytokine Staining (ICS): Descriptive
    Statistics on CD8 T cells at each time point (Total vaccinated Cohort)
    Test Antigen Group Timing N N miss. Mean SD Min Q1 Median Q3 Max
    CD8-ALL Pool gE gE/Y Day 0 9 1 37.78 48.76 1.00 1.00 1.00 68.00 137.00
    DOUBLES Month 1 9 1 61.78 111.15 1.00 1.00 1.00 68.00 345.00
    Month 2 9 1 587.67 1585.68 1.00 1.00 1.00 137.00 4811.00
    Month 3 9 1 38.67 50.04 1.00 1.00 1.00 67.00 141.00
    gEVAR/Y Day 0 10 0 151.00 246.45 1.00 1.00 35.00 206.00 742.00
    Month 1 10 0 34.30 65.70 1.00 1.00 1.00 64.00 205.00
    Month 2 9 1 39.00 114.00 1.00 1.00 1.00 1.00 343.00
    Month 3 10 0 177.80 313.49 1.00 1.00 36.00 272.00 1013.00
    VAR/E Day 0 44 1 40.32 79.95 1.00 1.00 1.00 68.00 348.00
    Month 1 43 2 33.16 59.81 1.00 1.00 1.00 72.00 216.00
    Month 2 43 2 41.14 75.20 1.00 1.00 1.00 70.00 284.00
    Month 3 45 0 29.20 62.99 1.00 1.00 1.00 1.00 286.00
    gE/E Day 0 44 1 23.64 50.66 1.00 1.00 1.00 1.00 221.00
    Month 1 42 3 35.17 82.74 1.00 1.00 1.00 28.00 422.00
    Month 2 43 2 45.02 72.29 1.00 1.00 1.00 73.00 368.00
    Month 3 43 2 34.74 86.80 1.00 1.00 1.00 1.00 461.00
    gEVAR/E Day 0 43 2 15.58 39.75 1.00 1.00 1.00 1.00 220.00
    Month 1 44 1 40.25 63.63 1.00 1.00 1.00 70.50 296.00
    Month 2 45 0 30.38 55.59 1.00 1.00 1.00 68.00 267.00
    Month 3 45 0 77.04 205.13 1.00 1.00 1.00 71.00 1135.00
    Varilrix gE/Y Day 0 9 1 506.11 1386.23 1.00 1.00 2.00 69.00 4198.00
    Month 1 9 1 594.89 1659.25 1.00 1.00 1.00 120.00 5015.00
    Month 2 9 1 990.22 2761.19 1.00 1.00 68.00 136.00 8351.00
    Month 3 9 1 419.33 1152.89 1.00 1.00 1.00 71.00 3491.00
    gEVAR/Y Day 0 10 0 42.30 68.03 1.00 1.00 1.00 67.00 214.00
    Month 1 10 0 21.50 45.55 1.00 1.00 1.00 1.00 134.00
    Month 2 9 1 77.33 105.58 1.00 1.00 1.00 142.00 274.00
    Month 3 10 0 98.40 149.12 1.00 1.00 37.00 141.00 481.00
    VAR/E Day 0 44 1 228.18 753.26 1.00 1.00 1.00 138.00 4822.00
    Month 1 43 2 205.77 502.36 1.00 1.00 70.00 149.00 3021.00
    Month 2 44 1 191.41 509.66 1.00 1.00 34.00 136.00 3158.00
    Month 3 45 0 356.69 1417.74 1.00 1.00 70.00 170.00 9496.00
    gE/E Day 0 44 1 244.86 491.44 1.00 1.00 71.50 224.50 2300.00
    Month 1 42 3 279.14 611.61 1.00 1.00 68.00 225.00 2909.00
    Month 2 43 2 236.79 551.54 1.00 1.00 66.00 225.00 2663.00
    Month 3 43 2 245.67 489.68 1.00 1.00 71.00 201.00 2491.00
    gEVAR/E Day 0 43 2 159.93 381.14 1.00 1.00 1.00 130.00 2072.00
    Month 1 44 1 188.82 311.58 1.00 1.00 69.50 217.00 1398.00
    Month 2 45 0 223.47 517.02 1.00 1.00 1.00 212.00 2491.00
    Month 3 45 0 304.16 520.03 1.00 1.00 143.00 290.00 2487.00
    CD8- Pool gE gE/Y Day 0 9 1 30.11 34.57 1.00 1.00 1.00 68.00 68.00
    CD40L Month 1 9 1 54.22 112.89 1.00 1.00 1.00 67.00 345.00
    Month 2 9 1 565.11 1593.60 1.00 1.00 1.00 68.00 4811.00
    Month 3 9 1 16.22 30.21 1.00 1.00 1.00 1.00 70.00
    gEVAR/Y Day 0 10 0 130.10 235.43 1.00 1.00 1.00 206.00 674.00
    Month 1 10 0 34.30 65.70 1.00 1.00 1.00 64.00 205.00
    Month 2 9 1 31.33 91.00 1.00 1.00 1.00 1.00 274.00
    Month 3 10 0 164.20 315.17 1.00 1.00 2.00 204.00 1013.00
    VAR/E Day 0 44 1 13.66 31.15 1.00 1.00 1.00 1.00 142.00
    Month 1 43 2 9.65 29.29 1.00 1.00 1.00 1.00 153.00
    Month 2 43 2 5.19 19.42 1.00 1.00 1.00 1.00 105.00
    Month 3 45 0 12.62 31.58 1.00 1.00 1.00 1.00 142.00
    gE/E Day 0 44 1 12.32 26.28 1.00 1.00 1.00 1.00 76.00
    Month 1 42 3 14.31 27.82 1.00 1.00 1.00 1.00 78.00
    Month 2 43 2 17.26 33.86 1.00 1.00 1.00 1.00 146.00
    Month 3 43 2 14.16 32.29 1.00 1.00 1.00 1.00 150.00
    gEVAR/E Day 0 43 2 7.16 19.48 1.00 1.00 1.00 1.00 71.00
    Month 1 44 1 18.95 46.55 1.00 1.00 1.00 1.00 221.00
    Month 2 45 0 22.71 43.70 1.00 1.00 1.00 1.00 200.00
    Month 3 45 0 45.80 146.31 1.00 1.00 1.00 1.00 780.00
    Varilrix gE/Y Day 0 9 1 260.56 651.12 1.00 1.00 68.00 69.00 1992.00
    Month 1 9 1 235.78 609.46 1.00 1.00 1.00 120.00 1854.00
    Month 2 9 1 291.22 741.43 1.00 1.00 68.00 71.00 2264.00
    Month 3 9 1 240.78 644.21 1.00 1.00 1.00 70.00 1954.00
    gEVAR/Y Day 0 10 0 21.00 32.21 1.00 1.00 1.00 67.00 69.00
    Month 1 10 0 1.00 0.00 1.00 1.00 1.00 1.00 1.00
    Month 2 9 1 24.00 49.34 1.00 1.00 1.00 1.00 142.00
    Month 3 10 0 62.60 153.10 1.00 1.00 1.00 1.00 481.00
    VAR/E Day 0 44 1 15.89 33.39 1.00 1.00 1.00 1.00 152.00
    Month 1 43 2 31.95 58.90 1.00 1.00 1.00 68.00 261.00
    Month 2 44 1 17.93 45.21 1.00 1.00 1.00 1.00 156.00
    Month 3 45 0 17.84 39.12 1.00 1.00 1.00 1.00 152.00
    gE/E Day 0 44 1 23.45 53.70 1.00 1.00 1.00 1.50 227.00
    Month 1 42 3 25.02 65.40 1.00 1.00 1.00 1.00 363.00
    Month 2 43 2 11.16 30.54 1.00 1.00 1.00 1.00 154.00
    Month 3 43 2 20.49 44.84 1.00 1.00 1.00 1.00 218.00
    gEVAR/E Day 0 43 2 25.58 48.47 1.00 1.00 1.00 1.00 147.00
    Month 1 44 1 27.93 55.29 1.00 1.00 1.00 68.00 304.00
    Month 2 45 0 12.18 38.15 1.00 1.00 1.00 1.00 225.00
    Month 3 45 0 19.80 43.49 1.00 1.00 1.00 1.00 209.00
    CD8-IFNγ Pool gE gE/Y Day 0 9 1 15.22 28.26 1.00 1.00 1.00 1.00 68.00
    Month 1 9 1 38.44 35.55 1.00 1.00 67.00 68.00 72.00
    Month 2 9 1 215.78 472.21 1.00 1.00 68.00 135.00 1464.00
    Month 3 9 1 31.11 50.03 1.00 1.00 1.00 66.00 141.00
    gEVAR/Y Day 0 10 0 89.40 110.49 1.00 1.00 68.00 143.00 336.00
    Month 1 10 0 13.90 27.20 1.00 1.00 1.00 1.00 67.00
    Month 2 9 1 31.11 68.87 1.00 1.00 1.00 1.00 205.00
    Month 3 10 0 62.40 66.91 1.00 1.00 68.00 76.00 202.00
    VAR/E Day 0 44 1 30.77 74.58 1.00 1.00 1.00 1.00 348.00
    Month 1 43 2 21.30 50.45 1.00 1.00 1.00 1.00 216.00
    Month 2 43 2 38.81 69.55 1.00 1.00 1.00 70.00 284.00
    Month 3 45 0 15.13 38.77 1.00 1.00 1.00 1.00 146.00
    gE/E Day 0 44 1 12.91 28.23 1.00 1.00 1.00 1.00 110.00
    Month 1 42 3 30.40 71.67 1.00 1.00 1.00 1.00 351.00
    Month 2 43 2 36.77 73.76 1.00 1.00 1.00 66.00 368.00
    Month 3 43 2 31.33 85.07 1.00 1.00 1.00 1.00 461.00
    gEVAR/E Day 0 43 2 12.63 38.39 1.00 1.00 1.00 1.00 220.00
    Month 1 44 1 25.36 49.38 1.00 1.00 1.00 35.00 230.00
    Month 2 45 0 11.67 25.17 1.00 1.00 1.00 1.00 75.00
    Month 3 45 0 58.51 147.37 1.00 1.00 1.00 70.00 851.00
    Varilrix gE/Y Day 0 9 1 475.11 1319.18 1.00 1.00 1.00 1.00 3984.00
    Month 1 9 1 561.78 1644.43 1.00 1.00 1.00 1.00 4946.00
    Month 2 9 1 935.22 2701.84 1.00 1.00 1.00 70.00 8139.00
    Month 3 9 1 403.89 1183.38 1.00 1.00 1.00 1.00 3559.00
    gEVAR/Y Day 0 10 0 49.30 87.98 1.00 1.00 1.00 68.00 283.00
    Month 1 10 0 28.60 58.23 1.00 1.00 1.00 1.00 144.00
    Month 2 9 1 61.44 86.91 1.00 1.00 1.00 68.00 208.00
    Month 3 10 0 78.20 100.95 1.00 1.00 34.50 147.00 274.00
    VAR/E Day 0 44 1 223.32 719.34 1.00 1.00 1.00 134.00 4534.00
    Month 1 43 2 208.47 507.58 1.00 1.00 70.00 213.00 3021.00
    Month 2 44 1 185.43 499.14 1.00 1.00 1.50 145.50 3085.00
    Month 3 45 0 342.33 1408.21 1.00 1.00 31.00 147.00 9423.00
    gE/E Day 0 44 1 227.52 482.15 1.00 1.00 1.00 204.50 2216.00
    Month 1 42 3 273.88 613.11 1.00 1.00 66.00 225.00 2909.00
    Month 2 43 2 228.79 542.44 1.00 1.00 70.00 206.00 2591.00
    Month 3 43 2 235.33 490.73 1.00 1.00 69.00 189.00 2491.00
    gEVAR/E Day 0 43 2 156.53 390.28 1.00 1.00 1.00 76.00 2000.00
    Month 1 44 1 177.48 309.13 1.00 1.00 67.00 217.00 1398.00
    Month 2 45 0 220.84 518.38 1.00 1.00 1.00 147.00 2491.00
    Month 3 45 0 291.38 515.67 1.00 1.00 92.00 290.00 2418.00
    CD8-IL2 Pool gE gE/Y Day 0 9 1 22.67 32.55 1.00 1.00 1.00 62.00 68.00
    Month 1 9 1 61.78 111.15 1.00 1.00 1.00 68.00 345.00
    Month 2 9 1 557.67 1595.67 1.00 1.00 1.00 68.00 4811.00
    Month 3 9 1 31.33 50.21 1.00 1.00 1.00 66.00 141.00
    gEVAR/Y Day 0 10 0 136.90 232.25 1.00 1.00 1.00 206.00 674.00
    Month 1 10 0 34.30 65.70 1.00 1.00 1.00 64.00 205.00
    Month 2 9 1 39.00 114.00 1.00 1.00 1.00 1.00 343.00
    Month 3 10 0 170.70 315.26 1.00 1.00 35.50 272.00 1013.00
    VAR/E Day 0 44 1 20.30 46.60 1.00 1.00 1.00 1.00 223.00
    Month 1 43 2 13.14 36.17 1.00 1.00 1.00 1.00 153.00
    Month 2 43 2 16.26 43.32 1.00 1.00 1.00 1.00 212.00
    Month 3 45 0 17.49 38.46 1.00 1.00 1.00 1.00 152.00
    gE/E Day 0 44 1 16.55 43.92 1.00 1.00 1.00 1.00 212.00
    Month 1 42 3 19.29 36.16 1.00 1.00 1.00 1.00 140.00
    Month 2 43 2 28.53 54.26 1.00 1.00 1.00 66.00 221.00
    Month 3 43 2 16.28 44.66 1.00 1.00 1.00 1.00 229.00
    gEVAR/E Day 0 43 2 7.21 19.47 1.00 1.00 1.00 1.00 71.00
    Month 1 44 1 25.84 51.64 1.00 1.00 1.00 6.50 221.00
    Month 2 45 0 24.18 44.41 1.00 1.00 1.00 3.00 149.00
    Month 3 45 0 45.76 148.50 1.00 1.00 1.00 1.00 851.00
    Varilrix gE/Y Day 0 9 1 102.78 207.48 1.00 1.00 1.00 69.00 640.00
    Month 1 9 1 151.78 359.31 1.00 1.00 1.00 120.00 1098.00
    Month 2 9 1 227.78 503.56 1.00 1.00 68.00 136.00 1556.00
    Month 3 9 1 93.56 181.12 1.00 1.00 1.00 71.00 559.00
    gEVAR/Y Day 0 10 0 14.40 28.25 1.00 1.00 1.00 1.00 69.00
    Month 1 10 0 7.60 20.87 1.00 1.00 1.00 1.00 67.00
    Month 2 9 1 39.11 60.89 1.00 1.00 1.00 67.00 142.00
    Month 3 10 0 62.60 153.10 1.00 1.00 1.00 1.00 481.00
    VAR/E Day 0 44 1 99.27 241.07 1.00 1.00 1.00 73.00 1223.00
    Month 1 43 2 78.49 122.70 1.00 1.00 66.00 109.00 575.00
    Month 2 44 1 97.00 226.12 1.00 1.00 1.00 75.50 1028.00
    Month 3 45 0 144.38 452.96 1.00 1.00 1.00 137.00 2994.00
    gE/E Day 0 44 1 140.34 240.41 1.00 1.00 33.50 153.00 1271.00
    Month 1 42 3 124.21 246.93 1.00 1.00 1.00 145.00 1017.00
    Month 2 43 2 99.79 166.75 1.00 1.00 1.00 144.00 863.00
    Month 3 43 2 148.19 264.30 1.00 1.00 14.00 145.00 1173.00
    gEVAR/E Day 0 43 2 68.81 116.27 1.00 1.00 1.00 77.00 573.00
    Month 1 44 1 87.89 122.66 1.00 1.00 68.00 141.00 521.00
    Month 2 45 0 113.91 231.46 1.00 1.00 1.00 138.00 1127.00
    Month 3 45 0 163.44 232.53 1.00 1.00 71.00 215.00 967.00
    CD8-TNFα Pool gE gE/Y Day 0 9 1 23.33 33.50 1.00 1.00 1.00 68.00 68.00
    Month 1 9 1 1.00 0.00 1.00 1.00 1.00 1.00 1.00
    Month 2 9 1 15.89 44.67 1.00 1.00 1.00 1.00 135.00
    Month 3 9 1 23.89 49.04 1.00 1.00 1.00 1.00 141.00
    gEVAR/Y Day 0 10 0 35.00 65.20 1.00 1.00 1.00 68.00 201.00
    Month 1 10 0 1.00 0.00 1.00 1.00 1.00 1.00 1.00
    Month 2 9 1 8.56 22.67 1.00 1.00 1.00 1.00 69.00
    Month 3 10 0 8.00 21.10 1.00 1.00 1.00 1.00 68.00
    VAR/E Day 0 44 1 32.20 75.14 1.00 1.00 1.00 1.50 348.00
    Month 1 43 2 33.05 63.48 1.00 1.00 1.00 72.00 288.00
    Month 2 43 2 31.40 67.10 1.00 1.00 1.00 12.00 284.00
    Month 3 45 0 19.80 48.19 1.00 1.00 1.00 1.00 207.00
    gE/E Day 0 44 1 18.80 44.11 1.00 1.00 1.00 1.00 221.00
    Month 1 42 3 32.60 77.37 1.00 1.00 1.00 37.00 422.00
    Month 2 43 2 30.02 47.35 1.00 1.00 1.00 66.00 221.00
    Month 3 43 2 24.53 67.55 1.00 1.00 1.00 1.00 306.00
    gEVAR/E Day 0 43 2 15.79 40.14 1.00 1.00 1.00 1.00 220.00
    Month 1 44 1 28.91 57.44 1.00 1.00 1.00 33.50 230.00
    Month 2 45 0 21.13 41.06 1.00 1.00 1.00 1.00 149.00
    Month 3 45 0 52.49 124.92 1.00 1.00 1.00 69.00 709.00
    Varilrix gE/Y Day 0 9 1 459.33 1297.02 1.00 1.00 1.00 2.00 3913.00
    Month 1 9 1 535.67 1526.03 1.00 1.00 1.00 70.00 4603.00
    Month 2 9 1 928.11 2730.86 1.00 1.00 1.00 67.00 8210.00
    Month 3 9 1 373.22 1090.66 1.00 1.00 1.00 1.00 3281.00
    gEVAR/Y Day 0 10 0 35.60 68.51 1.00 1.00 1.00 67.00 214.00
    Month 1 10 0 21.50 45.55 1.00 1.00 1.00 1.00 134.00
    Month 2 9 1 69.33 102.76 1.00 1.00 1.00 70.00 274.00
    Month 3 10 0 44.20 77.20 1.00 1.00 1.00 73.00 215.00
    VAR/E Day 0 44 1 200.27 729.98 1.00 1.00 1.00 75.00 4678.00
    Month 1 43 2 168.60 469.56 1.00 1.00 34.00 141.00 2805.00
    Month 2 44 1 159.45 432.79 1.00 1.00 1.00 129.50 2717.00
    Month 3 45 0 309.73 1310.43 1.00 1.00 1.00 133.00 8765.00
    gE/E Day 0 44 1 201.23 441.88 1.00 1.00 1.00 150.50 2057.00
    Month 1 42 3 230.05 531.94 1.00 1.00 47.50 225.00 2545.00
    Month 2 43 2 221.44 535.05 1.00 1.00 66.00 225.00 2591.00
    Month 3 43 2 189.44 402.52 1.00 1.00 61.00 189.00 2125.00
    gEVAR/E Day 0 43 2 133.88 332.42 1.00 1.00 1.00 72.00 1712.00
    Month 1 44 1 172.50 306.32 1.00 1.00 67.00 212.50 1398.00
    Month 2 45 0 190.29 470.52 1.00 1.00 1.00 147.00 2340.00
    Month 3 45 0 255.16 490.59 1.00 1.00 71.00 215.00 2279.00
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of subjects with available results
    N miss. = number of subjects with missing results
    SD = Standard Deviation
    Min, Max = Minimum, Maximum
    Q1, Q3 = First, Third quartile
  • TABLE C.2
    Intracellular Cytokine Staining (ICS): Inferential statistics: P-
    values from Kruskal-Wallis Tests for CD4 T cells at each time
    point (Total Vaccinated Cohort)
    Groups P_value at P_value at P_value at P_value at
    T cells compared Antigen Test day 0 Month 1 Month 2 Month 3
    CD4 VAR\E and Pool gE ALL DOUBLES 0.5025 0.0000 0.0015 0.0000
    gEVAR\E CD40L 0.4448 0.0000 0.0004 0.0000
    IFNγ 0.5900 0.0001 0.0956 0.0000
    IL2 0.6415 0.0000 0.0001 0.0000
    TNFα 0.2634 0.0000 0.0019 0.0000
    Varilrix ALL DOUBLES 0.7118 0.1489 0.3148 0.0000
    CD40L 0.6488 0.1664 0.2609 0.0000
    IFNγ 0.3602 0.2905 0.2277 0.0000
    IL2 0.4880 0.1442 0.2406 0.0000
    TNFα 0.8631 0.2624 0.2455 0.0000
    VAR\E and Pool gE ALL DOUBLES 0.9764 0.0004 0.0100 0.0000
    gE\E CD40L 0.9765 0.0003 0.0026 0.0000
    IFNγ 0.9665 0.0228 0.2961 0.0000
    IL2 0.7183 0.0001 0.0035 0.0000
    TNFα 0.9026 0.0069 0.0053 0.0000
    Varilrix ALL DOUBLES 0.9069 0.9965 0.8552 0.0002
    CD40L 0.8904 0.9790 0.9155 0.0002
    IFNγ 0.8806 0.5797 0.6868 0.0010
    IL2 0.9601 0.9860 0.9054 0.0003
    TNFα 0.6073 0.9719 0.8154 0.0016
    gE\E and Pool gE ALL DOUBLES 0.4951 0.1777 0.5702 0.4832
    gEVAR\E CD40L 0.3731 0.2215 0.5312 0.5368
    IFNγ 0.7732 0.2331 0.5958 0.8576
    IL2 0.9406 0.3059 0.4181 0.5069
    TNFα 0.3949 0.2039 0.5613 0.3287
    Varilrix ALL DOUBLES 0.8469 0.1876 0.2409 0.2687
    CD40L 0.9803 0.1980 0.2060 0.2277
    IFNγ 0.7520 0.2103 0.1205 0.2182
    IL2 0.7211 0.2135 0.2375 0.3045
    TNFα 0.8118 0.2134 0.1817 0.2778
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
  • SUPPLEMENTARY TABLE C.2
    Intracellular Cytokine Staining (ICS): Inferential
    statistics: P-values from Kruskal-Wallis Tests for CD8 T cells at
    each time point (Total Vaccinated Cohort)
    Groups P_value at P_value at P_value at P_value at
    T cells compared Antigen Test day 0 Month 1 Month 2 Month 3
    CD8 VAR\E and Pool gE ALL DOUBLES 0.1477 0.4418 0.8141 0.2762
    gEVAR\E CD40L 0.2897 0.2513 0.0126 0.3511
    IFNγ 0.1695 0.4069 0.0478 0.0478
    IL2 0.2705 0.1316 0.2008 0.5872
    TNFα 0.2968 0.7017 0.6470 0.0947
    Varilrix ALL DOUBLES 0.9267 0.7605 0.9651 0.1197
    CD40L 0.6260 0.9111 0.6512 0.8826
    IFNγ 0.9846 0.9611 0.9225 0.1009
    IL2 0.7027 0.6963 0.4626 0.1181
    TNFα 0.9047 0.4655 0.9929 0.1639
    VAR\E and Pool gE ALL DOUBLES 0.4117 0.9608 0.4570 0.9320
    gE\E CD40L 0.7891 0.2636 0.0315 0.7302
    IFNγ 0.4922 0.5672 0.7960 0.3690
    IL2 0.6092 0.2137 0.1416 0.6416
    TNFα 0.5891 0.8828 0.4633 0.9530
    Varilrix ALL DOUBLES 0.2336 0.9168 0.4792 0.6436
    CD40L 0.5969 0.3443 0.6968 0.8133
    IFNγ 0.3606 0.9342 0.3019 0.5406
    IL2 0.1743 0.6509 0.2577 0.4652
    TNFα 0.3405 0.7627 0.3869 0.5577
    gE\E and Pool gE ALL DOUBLES 0.4942 0.3322 0.2975 0.3120
    gEVAR\E CD40L 0.1831 0.9898 0.6047 0.5555
    IFNγ 0.4515 0.8129 0.0948 0.2325
    IL2 0.6171 0.7224 0.8439 0.3147
    TNFα 0.6064 0.7472 0.2571 0.1078
    Varilrix ALL DOUBLES 0.2524 0.8479 0.4410 0.2783
    CD40L 0.9594 0.3385 0.9095 0.9433
    IFNγ 0.3465 0.9277 0.3691 0.2849
    IL2 0.2333 0.5263 0.7101 0.4173
    TNFα 0.4678 0.7167 0.3198 0.4684
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
  • TABLE C.3
    Intracellular Cytokine Staining (ICS): Descriptive Statistics on
    CD4 T cells at POST-PRE (Total vaccinated Cohort)
    Test Antigen Group Timing N N miss. Mean SD Min Q1 Median Q3 Max
    CD4-ALL Pool gE gE/Y Month 1 9 1 1170.33 1640.79 −80.00 230.00 434.00 1332.00 5096.00
    DOUBLES Month 2 9 1 1574.11 1884.90 256.00 496.00 723.00 1285.00 5428.00
    Month 3 9 1 2526.44 1927.96 442.00 1329.00 2233.00 2647.00 6852.00
    gEVAR/Y Month 1 10 0 926.50 846.70 −348.00 393.00 865.50 1363.00 2752.00
    Month 2 9 1 1308.56 846.35 −233.00 845.00 1681.00 1995.00 2178.00
    Month 3 10 0 3045.30 1361.87 1288.00 1969.00 2830.50 4533.00 5057.00
    VAR/E Month 1 42 3 147.90 460.77 −436.00 −49.00 25.50 155.00 1898.00
    Month 2 43 2 −84.23 947.38 −5979.00 −60.00 35.00 179.00 658.00
    Month 3 44 1 173.16 1441.28 −5191.00 −128.00 0.00 146.00 6263.00
    gE/E Month 1 42 3 691.74 1008.97 −163.00 135.00 310.00 826.00 4210.00
    Month 2 43 2 352.00 515.95 −337.00 39.00 206.00 485.00 1974.00
    Month 3 42 3 3118.48 2537.47 −112.00 1324.00 2344.50 4620.00 11479.00
    gEVAR/E Month 1 44 1 616.02 505.69 −184.00 165.00 597.50 902.00 2377.00
    Month 2 45 0 303.13 389.20 −549.00 52.00 266.00 515.00 1234.00
    Month 3 45 0 2712.02 2508.85 −542.00 925.00 1601.00 4223.00 10467.00
    Varilrix gE/Y Month 1 9 1 256.89 842.23 −811.00 −214.00 −87.00 712.00 1612.00
    Month 2 9 1 610.22 651.41 −72.00 129.00 361.00 831.00 1904.00
    Month 3 9 1 770.56 891.01 −787.00 548.00 718.00 1165.00 2343.00
    gEVAR/Y Month 1 10 0 −98.40 1180.58 −1610.00 −647.00 −31.50 75.00 2732.00
    Month 2 9 1 1547.67 993.79 225.00 797.00 1286.00 2179.00 3188.00
    Month 3 10 0 2181.30 1781.51 151.00 698.00 1867.00 2861.00 6210.00
    VAR/E Month 1 42 3 366.95 798.30 −663.00 0.00 173.00 536.00 4145.00
    Month 2 43 2 169.07 569.41 −2100.00 −39.00 197.00 325.00 1608.00
    Month 3 44 1 362.93 662.91 −2100.00 54.00 267.50 633.50 1906.00
    gE/E Month 1 42 3 524.74 946.86 −660.00 0.00 229.00 734.00 4178.00
    Month 2 43 2 95.30 633.65 −1405.00 −205.00 18.00 254.00 1961.00
    Month 3 42 3 1533.69 1557.01 −600.00 528.00 1090.00 2181.00 7044.00
    gEVAR/E Month 1 44 1 664.14 765.08 −555.00 184.50 575.00 1109.00 3364.00
    Month 2 45 0 451.04 652.53 −397.00 34.00 244.00 639.00 2601.00
    Month 3 45 0 1973.73 1577.30 70.00 918.00 1480.00 2659.00 6575.00
    CD4-CD40L Pool gE gE/Y Month 1 9 1 1142.67 1567.96 −77.00 290.00 434.00 1272.00 4889.00
    Month 2 9 1 1519.78 1786.74 336.00 465.00 680.00 1369.00 5120.00
    Month 3 9 1 2363.22 1772.92 375.00 1303.00 1870.00 2323.00 6282.00
    gEVAR/Y Month 1 10 0 868.50 852.69 −348.00 381.00 813.00 1265.00 2782.00
    Month 2 9 1 1278.44 841.17 −233.00 691.00 1620.00 2027.00 2048.00
    Month 3 10 0 2915.50 1350.46 1150.00 1816.00 2785.50 4273.00 5088.00
    VAR/E Month 1 42 3 141.24 434.95 −487.00 −22.00 44.00 161.00 1837.00
    Month 2 43 2 −80.09 893.99 −5627.00 −74.00 26.00 195.00 601.00
    Month 3 44 1 169.66 1401.60 −4969.00 −100.00 6.50 136.00 6071.00
    gE/E Month 1 42 3 691.05 975.64 −183.00 154.00 323.00 814.00 4153.00
    Month 2 43 2 367.37 493.31 −306.00 64.00 222.00 546.00 1976.00
    Month 3 42 3 3036.88 2447.00 −189.00 1342.00 2320.00 4568.00 10509.00
    gEVAR/E Month 1 44 1 603.75 496.38 −112.00 183.00 583.50 878.50 2268.00
    Month 2 45 0 308.96 364.06 −493.00 115.00 266.00 515.00 1185.00
    Month 3 45 0 2692.24 2497.48 −397.00 918.00 1652.00 4189.00 10417.00
    Varilrix gE/Y Month 1 9 1 236.33 828.70 −790.00 −212.00 −62.00 634.00 1594.00
    Month 2 9 1 581.89 584.04 −74.00 217.00 361.00 781.00 1587.00
    Month 3 9 1 722.89 892.40 −737.00 210.00 747.00 1091.00 2284.00
    gEVAR/Y Month 1 10 0 −122.90 1156.16 −1604.00 −613.00 −114.50 75.00 2676.00
    Month 2 9 1 1519.67 1018.54 259.00 684.00 1228.00 2137.00 3210.00
    Month 3 10 0 2054.60 1759.67 36.00 554.00 1840.50 2421.00 6057.00
    VAR/E Month 1 42 3 355.62 780.99 −623.00 25.00 150.50 529.00 4128.00
    Month 2 43 2 160.72 567.36 −2024.00 −32.00 158.00 349.00 1631.00
    Month 3 44 1 351.45 663.33 −2024.00 4.00 199.00 616.50 1972.00
    gE/E Month 1 42 3 509.52 852.27 −679.00 −5.00 213.50 747.00 3242.00
    Month 2 43 2 109.05 630.36 −1378.00 −181.00 27.00 257.00 2004.00
    Month 3 42 3 1501.02 1546.41 −881.00 562.00 1036.50 2095.00 7128.00
    gEVAR/E Month 1 44 1 661.55 758.32 −487.00 155.50 593.50 1066.50 3519.00
    Month 2 45 0 457.07 652.72 −411.00 33.00 290.00 580.00 2646.00
    Month 3 45 0 1931.53 1542.71 71.00 916.00 1427.00 2686.00 6529.00
    CD4-IFNγ Pool gE gE/Y Month 1 9 1 855.89 1270.64 −83.00 56.00 498.00 823.00 3836.00
    Month 2 9 1 1152.67 1414.76 192.00 402.00 511.00 1087.00 4569.00
    Month 3 9 1 1841.44 1805.38 254.00 894.00 1227.00 1892.00 6156.00
    gEVAR/Y Month 1 10 0 646.20 866.49 −241.00 194.00 402.00 739.00 2897.00
    Month 2 9 1 898.89 743.23 −203.00 367.00 1064.00 1602.00 1789.00
    Month 3 10 0 2108.30 1216.76 920.00 1089.00 1854.50 2667.00 5000.00
    VAR/E Month 1 42 3 104.52 323.14 −231.00 −17.00 29.50 84.00 1809.00
    Month 2 43 2 −25.56 505.62 −3122.00 −24.00 33.00 117.00 561.00
    Month 3 44 1 99.75 731.24 −2787.00 −32.00 11.00 88.50 3037.00
    gE/E Month 1 42 3 395.14 676.51 −72.00 45.00 174.50 333.00 3116.00
    Month 2 43 2 161.98 330.61 −305.00 5.00 54.00 219.00 1539.00
    Month 3 42 3 1583.48 1568.34 −47.00 491.00 1224.00 2077.00 6308.00
    gEVAR/E Month 1 44 1 350.95 333.21 −34.00 91.00 270.50 554.00 1349.00
    Month 2 45 0 172.09 273.80 −186.00 8.00 82.00 274.00 1062.00
    Month 3 45 0 1392.40 1301.10 −29.00 484.00 875.00 1961.00 5786.00
    Varilrix gE/Y Month 1 9 1 196.44 699.90 −663.00 −156.00 −144.00 431.00 1472.00
    Month 2 9 1 428.22 503.10 −132.00 84.00 332.00 743.00 1342.00
    Month 3 9 1 507.00 696.10 −781.00 196.00 471.00 831.00 1563.00
    gEVAR/Y Month 1 10 0 −25.40 1073.83 −1588.00 −456.00 −20.00 106.00 2599.00
    Month 2 9 1 1246.56 985.49 88.00 467.00 945.00 1661.00 3056.00
    Month 3 10 0 1768.90 1593.80 168.00 634.00 1485.50 2136.00 5549.00
    VAR/E Month 1 42 3 309.07 689.54 −701.00 16.00 187.50 396.00 3829.00
    Month 2 43 2 116.07 496.80 −1934.00 −74.00 134.00 283.00 1515.00
    Month 3 44 1 254.25 539.74 −1750.00 23.00 161.50 445.00 1861.00
    gE/E Month 1 42 3 405.48 723.30 −631.00 −25.00 204.00 515.00 2775.00
    Month 2 43 2 33.23 464.33 −1258.00 −102.00 42.00 204.00 1236.00
    Month 3 42 3 1042.86 1155.33 −529.00 402.00 805.00 1590.00 6357.00
    gEVAR/E Month 1 44 1 548.59 714.90 −621.00 111.00 374.50 757.50 3276.00
    Month 2 45 0 399.91 618.77 −454.00 47.00 231.00 474.00 2730.00
    Month 3 45 0 1382.96 1099.42 −1.00 652.00 1088.00 1679.00 4831.00
    CD4-IL2 Pool gE gE/Y Month 1 9 1 1093.00 1486.37 −40.00 228.00 465.00 1118.00 4669.00
    Month 2 9 1 1495.67 1762.08 316.00 524.00 623.00 1301.00 5044.00
    Month 3 9 1 2151.22 1569.05 344.00 1086.00 2010.00 2510.00 5502.00
    gEVAR/Y Month 1 10 0 750.70 647.88 −348.00 466.00 613.00 1063.00 2048.00
    Month 2 9 1 1167.22 708.40 −79.00 801.00 1192.00 1802.00 1974.00
    Month 3 10 0 2510.60 1142.73 1026.00 1562.00 2307.50 3545.00 4153.00
    VAR/E Month 1 42 3 106.40 368.83 −361.00 −83.00 54.00 126.00 1897.00
    Month 2 43 2 −85.70 860.78 −5429.00 −81.00 0.00 159.00 634.00
    Month 3 44 1 125.25 1203.10 −4856.00 −80.50 0.00 137.00 4576.00
    gE/E Month 1 42 3 617.10 907.63 −49.00 128.00 312.50 692.00 3736.00
    Month 2 43 2 314.26 460.49 −271.00 25.00 189.00 389.00 1723.00
    Month 3 42 3 2711.76 2304.96 0.00 1008.00 2082.00 4222.00 10315.00
    gEVAR/E Month 1 44 1 543.70 465.89 −111.00 104.00 508.50 826.00 1920.00
    Month 2 45 0 300.42 336.69 −460.00 103.00 300.00 429.00 1088.00
    Month 3 45 0 2385.11 2307.17 −460.00 819.00 1478.00 3888.00 9485.00
    Varilrix gE/Y Month 1 9 1 150.78 735.34 −812.00 −271.00 −77.00 664.00 1263.00
    Month 2 9 1 540.56 597.57 −125.00 211.00 316.00 712.00 1721.00
    Month 3 9 1 609.78 735.25 −565.00 377.00 576.00 895.00 1986.00
    gEVAR/Y Month 1 10 0 −171.70 949.81 −1498.00 −545.00 −111.00 135.00 1991.00
    Month 2 9 1 1396.11 925.12 443.00 678.00 1111.00 1980.00 3192.00
    Month 3 10 0 1717.20 1413.72 133.00 532.00 1356.50 2606.00 4739.00
    VAR/E Month 1 42 3 290.62 714.95 −689.00 5.00 161.00 401.00 3784.00
    Month 2 43 2 121.05 534.68 −2122.00 −83.00 134.00 369.00 1492.00
    Month 3 44 1 257.48 599.43 −1964.00 −17.00 196.00 504.50 1857.00
    gE/E Month 1 42 3 438.14 817.33 −695.00 −21.00 173.00 644.00 3233.00
    Month 2 43 2 71.42 575.91 −1320.00 −274.00 69.00 255.00 1678.00
    Month 3 42 3 1254.76 1389.73 −548.00 382.00 827.50 1798.00 6315.00
    gEVAR/E Month 1 44 1 586.45 695.20 −363.00 169.50 437.50 858.00 3292.00
    Month 2 45 0 420.22 582.63 −416.00 78.00 185.00 545.00 2287.00
    Month 3 45 0 1648.53 1355.42 71.00 742.00 1148.00 2418.00 5462.00
    CD4-TNFα Pool gE gE/Y Month 1 9 1 560.22 934.14 12.00 65.00 123.00 756.00 2903.00
    Month 2 9 1 791.78 1375.33 3.00 149.00 315.00 623.00 4378.00
    Month 3 9 1 1324.00 1590.20 206.00 415.00 831.00 1105.00 5212.00
    gEVAR/Y Month 1 10 0 532.30 452.83 −11.00 253.00 503.50 651.00 1572.00
    Month 2 9 1 715.00 462.65 38.00 503.00 712.00 1039.00 1314.00
    Month 3 10 0 1653.00 811.66 465.00 1195.00 1850.50 1931.00 2902.00
    VAR/E Month 1 42 3 51.69 229.81 −470.00 −57.00 41.00 115.00 1215.00
    Month 2 43 2 −86.14 688.49 −4412.00 −46.00 2.00 126.00 254.00
    Month 3 44 1 77.75 960.07 −3944.00 −80.00 1.00 94.00 4212.00
    gE/E Month 1 42 3 325.40 519.68 −165.00 0.00 161.50 419.00 2302.00
    Month 2 43 2 191.19 319.19 −246.00 0.00 119.00 225.00 1367.00
    Month 3 42 3 1815.83 1594.15 −152.00 690.00 1389.50 2762.00 7491.00
    gEVAR/E Month 1 44 1 275.16 261.28 −156.00 57.50 233.50 480.00 1045.00
    Month 2 45 0 164.93 267.03 −494.00 26.00 126.00 316.00 675.00
    Month 3 45 0 1508.64 1548.74 −433.00 508.00 875.00 2193.00 6403.00
    Varilrix gE/Y Month 1 9 1 57.67 443.72 −683.00 −219.00 47.00 528.00 634.00
    Month 2 9 1 450.11 411.03 −101.00 184.00 411.00 513.00 1364.00
    Month 3 9 1 374.89 664.84 −945.00 113.00 404.00 637.00 1536.00
    gEVAR/Y Month 1 10 0 −156.30 634.57 −1203.00 −365.00 −107.50 217.00 941.00
    Month 2 9 1 1047.56 757.92 179.00 535.00 765.00 1585.00 2566.00
    Month 3 10 0 1200.00 918.82 −123.00 626.00 1214.50 1693.00 3132.00
    VAR/E Month 1 42 3 250.64 695.21 −805.00 −33.00 138.50 281.00 3707.00
    Month 2 43 2 110.26 519.34 −1984.00 −121.00 103.00 294.00 1491.00
    Month 3 44 1 210.23 548.98 −1984.00 −10.00 167.50 423.50 1806.00
    gE/E Month 1 42 3 298.93 637.78 −566.00 −45.00 146.50 405.00 2494.00
    Month 2 43 2 29.81 538.43 −1359.00 −171.00 13.00 150.00 1845.00
    Month 3 42 3 967.05 1085.98 −609.00 239.00 707.50 1502.00 4441.00
    gEVAR/E Month 1 44 1 405.30 604.26 −432.00 90.00 304.50 554.50 2871.00
    Month 2 45 0 293.78 495.54 −347.00 −34.00 167.00 324.00 2242.00
    Month 3 45 0 1229.38 1061.80 −73.00 492.00 913.00 1565.00 4380.00
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of subjects with available results
    N miss. = number of subjects with missing results
    SD = Standard Deviation
    Min, Max = Minimum, Maximum
    Q1, Q3 = First, Third quartile
  • SUPPLEMENTARY TABLE C.3
    Intracellular Cytokine Staining (ICS): Descriptive
    Statistics on CD8 T cells at POST-PRE (Total vaccinated Cohort)
    Test Antigen Group POST N N miss. Mean SD Min Q1 Median Q3 Max
    CD8-ALL Pool gE gE/Y Month 1 9 1 24.00 136.52 −136.00 −61.00 0.00 67.00 344.00
    DOUBLES Month 2 9 1 549.89 1599.52 −67.00 −2.00 0.00 69.00 4810.00
    Month 3 9 1 0.89 83.03 −136.00 −61.00 0.00 65.00 140.00
    gEVAR/Y Month 1 10 0 −116.70 198.88 −537.00 −139.00 −34.00 0.00 63.00
    Month 2 9 1 −128.67 170.57 −413.00 −205.00 −68.00 0.00 0.00
    Month 3 10 0 26.80 117.89 −142.00 −68.00 0.00 69.00 271.00
    VAR/E Month 1 42 3 −13.38 97.87 −278.00 −65.00 0.00 0.00 210.00
    Month 2 42 3 −3.50 76.50 −222.00 −22.00 0.00 0.00 209.00
    Month 3 44 1 −10.48 107.47 −347.00 −11.00 0.00 0.00 285.00
    gE/E Month 1 42 3 10.45 95.31 −211.00 0.00 0.00 1.00 421.00
    Month 2 43 2 22.51 95.28 −220.00 0.00 0.00 70.00 367.00
    Month 3 42 3 7.29 88.24 −211.00 0.00 0.00 0.00 460.00
    gEVAR/E Month 1 42 3 26.12 69.05 −71.00 0.00 0.00 68.00 295.00
    Month 2 43 2 16.16 62.56 −147.00 0.00 0.00 67.00 201.00
    Month 3 43 2 65.00 217.39 −219.00 0.00 0.00 70.00 1134.00
    Varilrix gE/Y Month 1 9 1 88.78 274.69 −67.00 −1.00 0.00 0.00 817.00
    Month 2 9 1 484.11 1376.23 −1.00 0.00 1.00 68.00 4153.00
    Month 3 9 1 −86.78 246.23 −707.00 −68.00 0.00 0.00 135.00
    gEVAR/Y Month 1 10 0 −20.80 71.94 −141.00 −66.00 0.00 0.00 133.00
    Month 2 9 1 30.44 143.10 −213.00 −66.00 0.00 139.00 273.00
    Month 3 10 0 56.10 163.61 −213.00 0.00 35.00 140.00 414.00
    VAR/E Month 1 42 3 −31.67 340.22 −1801.00 −71.00 0.00 74.00 491.00
    Month 2 43 2 −52.51 298.58 −1664.00 −68.00 0.00 68.00 362.00
    Month 3 44 1 131.75 725.55 −611.00 −26.00 0.00 104.50 4674.00
    gE/E Month 1 42 3 59.62 265.24 −296.00 −72.00 0.00 81.00 1015.00
    Month 2 43 2 −10.51 382.79 −1736.00 −42.00 0.00 71.00 1242.00
    Month 3 42 3 28.60 190.71 −423.00 −71.00 0.00 72.00 597.00
    gEVAR/E Month 1 42 3 5.90 351.50 −1924.00 −1.00 0.00 73.00 694.00
    Month 2 43 2 15.98 365.42 −1594.00 −70.00 0.00 143.00 1213.00
    Month 3 43 2 129.19 225.91 −149.00 0.00 16.00 265.00 916.00
    CD8- Pool gE gE/Y Month 1 9 1 24.11 127.75 −67.00 −61.00 0.00 0.00 344.00
    CD40L Month 2 9 1 535.00 1604.13 −67.00 0.00 0.00 0.00 4810.00
    Month 3 9 1 −13.89 55.72 −67.00 −67.00 0.00 0.00 69.00
    gEVAR/Y Month 1 10 0 −95.80 189.16 −469.00 −139.00 0.00 0.00 63.00
    Month 2 9 1 −113.11 179.39 −413.00 −205.00 0.00 0.00 0.00
    Month 3 10 0 34.10 138.26 −210.00 0.00 0.00 69.00 339.00
    VAR/E Month 1 42 3 −4.40 43.17 −141.00 0.00 0.00 0.00 152.00
    Month 2 42 3 −7.29 37.64 −141.00 0.00 0.00 0.00 104.00
    Month 3 44 1 −0.77 37.03 −73.00 0.00 0.00 0.00 102.00
    gE/E Month 1 42 3 1.45 39.39 −75.00 0.00 0.00 0.00 76.00
    Month 2 43 2 6.33 45.80 −75.00 0.00 0.00 0.00 145.00
    Month 3 42 3 −1.93 36.10 −75.00 0.00 0.00 0.00 72.00
    gEVAR/E Month 1 42 3 10.86 48.91 −70.00 0.00 0.00 0.00 220.00
    Month 2 43 2 16.56 45.02 −70.00 0.00 0.00 65.00 145.00
    Month 3 43 2 40.72 152.63 −70.00 0.00 0.00 0.00 779.00
    Varilrix gE/Y Month 1 9 1 −24.78 56.16 −138.00 −67.00 0.00 0.00 51.00
    Month 2 9 1 30.67 102.65 −68.00 −1.00 0.00 69.00 272.00
    Month 3 9 1 −19.78 46.08 −73.00 −67.00 0.00 0.00 68.00
    gEVAR/Y Month 1 10 0 −20.00 32.21 −68.00 −66.00 0.00 0.00 0.00
    Month 2 9 1 0.78 68.53 −68.00 −66.00 0.00 0.00 141.00
    Month 3 10 0 41.60 134.83 −68.00 0.00 0.00 0.00 414.00
    VAR/E Month 1 42 3 16.17 63.26 −72.00 0.00 0.00 0.00 260.00
    Month 2 43 2 2.09 48.77 −73.00 0.00 0.00 0.00 153.00
    Month 3 44 1 2.34 43.59 −73.00 0.00 0.00 0.00 146.00
    gE/E Month 1 42 3 2.14 80.48 −149.00 0.00 0.00 0.00 362.00
    Month 2 43 2 −11.23 59.14 −218.00 0.00 0.00 0.00 152.00
    Month 3 42 3 −1.93 76.17 −226.00 0.00 0.00 0.00 217.00
    gEVAR/E Month 1 42 3 3.05 51.88 −135.00 0.00 0.00 0.00 157.00
    Month 2 43 2 −12.88 47.07 −145.00 0.00 0.00 0.00 78.00
    Month 3 43 2 −4.91 46.80 −145.00 0.00 0.00 0.00 73.00
    CD8-IFNγ Pool gE gE/Y Month 1 9 1 23.22 45.52 −61.00 0.00 4.00 66.00 67.00
    Month 2 9 1 200.56 477.92 −61.00 0.00 67.00 133.00 1463.00
    Month 3 9 1 15.89 65.31 −67.00 0.00 0.00 65.00 140.00
    gEVAR/Y Month 1 10 0 −75.50 120.41 −335.00 −142.00 −34.00 0.00 63.00
    Month 2 9 1 −68.11 59.39 −142.00 −131.00 −67.00 0.00 0.00
    Month 3 10 0 −27.00 56.93 −134.00 −68.00 0.00 0.00 67.00
    VAR/E Month 1 42 3 −15.52 75.76 −278.00 0.00 0.00 0.00 193.00
    Month 2 42 3 2.43 62.84 −139.00 0.00 0.00 0.00 192.00
    Month 3 44 1 −15.32 79.50 −347.00 0.00 0.00 0.00 75.00
    gE/E Month 1 42 3 16.93 72.52 −109.00 0.00 0.00 0.00 282.00
    Month 2 43 2 23.58 84.49 −109.00 0.00 0.00 65.00 367.00
    Month 3 42 3 18.57 70.71 −66.00 0.00 0.00 0.00 392.00
    gEVAR/E Month 1 42 3 13.55 62.27 −146.00 0.00 0.00 0.00 229.00
    Month 2 43 2 −0.47 40.58 −147.00 0.00 0.00 0.00 74.00
    Month 3 43 2 48.56 146.44 −144.00 0.00 0.00 68.00 781.00
    Varilrix gE/Y Month 1 9 1 86.67 344.40 −284.00 0.00 0.00 0.00 962.00
    Month 2 9 1 460.11 1388.68 −215.00 0.00 0.00 66.00 4155.00
    Month 3 9 1 −71.22 165.93 −425.00 0.00 0.00 0.00 68.00
    gEVAR/Y Month 1 10 0 −20.70 71.64 −139.00 −67.00 0.00 0.00 133.00
    Month 2 9 1 6.78 136.42 −282.00 −1.00 0.00 67.00 204.00
    Month 3 10 0 28.90 155.44 −282.00 0.00 0.50 146.00 273.00
    VAR/E Month 1 42 3 −23.81 304.92 −1513.00 0.00 0.00 73.00 561.00
    Month 2 43 2 −53.65 284.04 −1449.00 0.00 0.00 65.00 289.00
    Month 3 44 1 121.93 758.36 −610.00 −0.50 0.00 73.00 4889.00
    gE/E Month 1 42 3 74.10 267.93 −296.00 −2.00 0.00 71.00 1088.00
    Month 2 43 2 −4.00 372.80 −1652.00 −66.00 0.00 68.00 1170.00
    Month 3 42 3 37.74 175.85 −339.00 −3.00 0.00 74.00 670.00
    gEVAR/E Month 1 42 3 −0.81 360.67 −1999.00 0.00 0.00 73.00 694.00
    Month 2 43 2 16.63 341.39 −1452.00 −66.00 0.00 72.00 1213.00
    Month 3 43 2 119.21 197.20 −284.00 0.00 16.00 221.00 659.00
    CD8-IL2 Pool gE gE/Y Month 1 9 1 39.11 127.97 −67.00 −61.00 0.00 67.00 344.00
    Month 2 9 1 535.00 1604.48 −67.00 −61.00 0.00 67.00 4810.00
    Month 3 9 1 8.67 71.13 −67.00 −61.00 0.00 65.00 140.00
    gEVAR/Y Month 1 10 0 −102.60 186.54 −469.00 −139.00 0.00 0.00 63.00
    Month 2 9 1 −113.00 162.73 −413.00 −205.00 0.00 0.00 0.00
    Month 3 10 0 33.80 125.98 −142.00 0.00 0.00 69.00 339.00
    VAR/E Month 1 42 3 −7.79 57.52 −148.00 0.00 0.00 0.00 152.00
    Month 2 42 3 −2.90 68.64 −222.00 0.00 0.00 0.00 211.00
    Month 3 44 1 −4.02 64.96 −222.00 0.00 0.00 0.00 151.00
    gE/E Month 1 42 3 2.00 52.68 −211.00 0.00 0.00 0.00 139.00
    Month 2 43 2 13.28 64.17 −211.00 0.00 0.00 65.00 218.00
    Month 3 42 3 −4.19 59.14 −211.00 0.00 0.00 0.00 228.00
    gEVAR/E Month 1 42 3 19.67 59.09 −70.00 0.00 0.00 11.00 220.00
    Month 2 43 2 18.05 48.05 −70.00 0.00 0.00 65.00 148.00
    Month 3 43 2 40.63 153.41 −66.00 0.00 0.00 0.00 850.00
    Varilrix gE/Y Month 1 9 1 49.00 156.22 −67.00 0.00 0.00 0.00 458.00
    Month 2 9 1 125.00 298.57 −1.00 0.00 0.00 70.00 916.00
    Month 3 9 1 −9.22 73.85 −81.00 −68.00 0.00 0.00 136.00
    gEVAR/Y Month 1 10 0 −6.80 37.82 −68.00 0.00 0.00 0.00 66.00
    Month 2 9 1 23.22 76.53 −68.00 0.00 0.00 66.00 141.00
    Month 3 10 0 48.20 155.17 −68.00 0.00 0.00 0.00 480.00
    VAR/E Month 1 42 3 −23.52 167.46 −648.00 −67.00 0.00 69.00 211.00
    Month 2 43 2 −10.63 110.07 −289.00 −72.00 0.00 1.00 361.00
    Month 3 44 1 46.75 299.86 −687.00 0.00 0.00 69.00 1771.00
    gE/E Month 1 42 3 −10.98 155.68 −266.00 −110.00 0.00 0.00 539.00
    Month 2 43 2 −40.56 207.85 −1030.00 −72.00 0.00 0.00 367.00
    Month 3 42 3 13.12 137.98 −226.00 −71.00 0.00 60.00 662.00
    gEVAR/E Month 1 42 3 21.33 123.99 −425.00 −2.00 0.00 71.00 488.00
    Month 2 43 2 29.33 179.40 −301.00 −66.00 0.00 68.00 831.00
    Month 3 43 2 86.84 165.87 −136.00 0.00 0.00 199.00 709.00
    CD8-TNFα Pool gE gE/Y Month 1 9 1 −22.33 33.50 −67.00 −67.00 0.00 0.00 0.00
    Month 2 9 1 −7.44 40.26 −67.00 0.00 0.00 0.00 67.00
    Month 3 9 1 0.56 59.77 −67.00 −1.00 0.00 0.00 140.00
    gEVAR/Y Month 1 10 0 −34.00 65.20 −200.00 −67.00 0.00 0.00 0.00
    Month 2 9 1 −30.22 68.11 −200.00 0.00 0.00 0.00 1.00
    Month 3 10 0 −27.00 71.95 −200.00 −67.00 0.00 0.00 67.00
    VAR/E Month 1 42 3 −6.71 90.36 −278.00 0.00 0.00 0.00 210.00
    Month 2 42 3 −6.67 78.03 −219.00 −1.00 0.00 0.00 209.00
    Month 3 44 1 −11.98 89.66 −347.00 0.00 0.00 0.00 206.00
    gE/E Month 1 42 3 12.95 86.37 −184.00 0.00 0.00 7.00 421.00
    Month 2 43 2 10.81 69.64 −220.00 0.00 0.00 65.00 220.00
    Month 3 42 3 5.45 65.44 −140.00 0.00 0.00 0.00 305.00
    gEVAR/E Month 1 42 3 14.10 72.50 −219.00 0.00 0.00 0.00 229.00
    Month 2 43 2 6.28 57.99 −219.00 0.00 0.00 0.00 148.00
    Month 3 43 2 39.09 129.10 −219.00 0.00 0.00 68.00 639.00
    Varilrix gE/Y Month 1 9 1 76.33 232.77 −71.00 0.00 0.00 0.00 690.00
    Month 2 9 1 468.78 1436.63 −143.00 0.00 0.00 0.00 4297.00
    Month 3 9 1 −86.11 218.67 −632.00 −1.00 0.00 0.00 70.00
    gEVAR/Y Month 1 10 0 −14.10 70.26 −141.00 −66.00 0.00 0.00 133.00
    Month 2 9 1 29.89 146.91 −213.00 −66.00 0.00 69.00 273.00
    Month 3 10 0 8.60 118.21 −213.00 −66.00 0.00 72.00 214.00
    VAR/E Month 1 42 3 −40.52 354.84 −1873.00 −68.00 0.00 69.00 491.00
    Month 2 43 2 −51.70 327.59 −1961.00 0.00 0.00 6.00 361.00
    Month 3 44 1 110.00 653.00 −991.00 0.00 0.00 73.00 4087.00
    gE/E Month 1 42 3 52.86 220.80 −455.00 −4.00 0.00 71.00 869.00
    Month 2 43 2 17.14 356.23 −1493.00 −19.00 0.00 71.00 1312.00
    Month 3 42 3 15.07 172.57 −571.00 0.00 0.00 70.00 449.00
    gEVAR/E Month 1 42 3 15.48 312.96 −1711.00 0.00 0.00 134.00 694.00
    Month 2 43 2 10.81 297.77 −1440.00 −66.00 0.00 67.00 838.00
    Month 3 43 2 109.00 211.09 −148.00 0.00 0.00 205.00 904.00
    gE/Y = gE-AS1/18-30 years;
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years;
    gE/E = gE-AS1/50-70 years;
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of subjects with available results;
    N miss. = number of subjects with missing results
    SD = Standard Deviation
    Min, Max = Minimum, Maximum
    Q1, Q3 = First, Third quartile
  • TABLE C.4
    Intracellular Cytokine Staining (ICS): Inferential statistics: P-
    values from Kruskal-Wallis Tests for CD4 T cells at POST-PRE
    (Total Vaccinated Cohort)
    P_value at P_value at P_value at
    Groups Month 1- Month 2- Month 3-
    T cells compared Antigen Test PRE PRE PRE
    CD4 VAR\E and Pool gE ALL DOUBLES 0.0000 0.0004 0.0000
    gEVAR\E CD40L 0.0000 0.0002 0.0000
    IFNγ 0.0000 0.0429 0.0000
    IL2 0.0000 0.0000 0.0000
    TNFα 0.0000 0.0009 0.0000
    Varilrix ALL DOUBLES 0.0078 0.1736 0.0000
    CD40L 0.0090 0.0727 0.0000
    IFNγ 0.0261 0.0447 0.0000
    IL2 0.0067 0.0575 0.0000
    TNFα 0.0620 0.1957 0.0000
    VAR\E and Pool gE ALL DOUBLES 0.0000 0.0004 0.0000
    gE\E CD40L 0.0000 0.0001 0.0000
    IFNγ 0.0001 0.0880 0.0000
    IL2 0.0000 0.0003 0.0000
    TNFα 0.0009 0.0018 0.0000
    Varilrix ALL DOUBLES 0.5370 0.1120 0.0000
    CD40L 0.5137 0.2217 0.0000
    IFNγ 0.7205 0.2367 0.0000
    IL2 0.5791 0.3599 0.0000
    TNFα 0.8440 0.0880 0.0001
    gE\E and Pool gE ALL DOUBLES 0.3100 0.6612 0.3060
    gEVAR\E CD40L 0.3996 0.7134 0.3350
    IFNγ 0.2366 0.7134 0.6835
    IL2 0.4707 0.3629 0.4148
    TNFα 0.3923 0.7134 0.2480
    Varilrix ALL DOUBLES 0.1034 0.0049 0.1231
    CD40L 0.1262 0.0054 0.1305
    IFNγ 0.0832 0.0021 0.0910
    IL2 0.0921 0.0040 0.0831
    TNFα 0.1179 0.0035 0.1372
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
  • SUPPLEMENTARY TABLE C.4
    Intracellular Cytokine Staining (ICS): Inferential
    statistics: P-values from Kruskal-Wallis Tests for CD8 T cells at
    POST-PRE (Total Vaccinated Cohort)
    Groups P_value at P_value at P_value at
    T cells compared Antigen Test description Month 1-PRE Month 2-PRE Month 3-PRE
    CD8 VAR\E and Pool gE ALL DOUBLES 0.0575 0.2069 0.1364
    gEVAR\E CD40L 0.1647 0.0113 0.1579
    IFNγ 0.1411 0.8759 0.0360
    IL2 0.0456 0.1080 0.1442
    TNFα 0.2938 0.3356 0.0499
    Varilrix ALL DOUBLES 0.6363 0.8116 0.1785
    CD40L 0.6944 0.4151 0.9266
    IFNγ 0.5953 0.8108 0.0486
    IL2 0.6656 0.5567 0.1544
    TNFα 0.3677 0.8788 0.2679
    VAR\E and Pool gE ALL DOUBLES 0.2913 0.1159 0.9259
    gE\E CD40L 0.5885 0.2542 0.9217
    IFNγ 0.1900 0.3113 0.4158
    IL2 0.1687 0.1288 0.8127
    TNFα 0.3700 0.2008 0.8454
    Varilrix ALL DOUBLES 0.9067 0.9436 0.4197
    CD40L 0.1382 0.4574 0.7783
    IFNγ 0.7445 0.6841 0.8567
    IL2 0.1893 0.3980 0.3536
    TNFα 0.6716 0.8132 0.6206
    gE\E and Pool gE ALL DOUBLES 0.3308 0.6165 0.1380
    gEVAR\E CD40L 0.4801 0.2231 0.1503
    IFNγ 0.9259 0.2911 0.1157
    IL2 0.4306 1.0000 0.0678
    TNFα 0.9797 0.6343 0.0646
    Varilrix ALL DOUBLES 0.5447 0.7670 0.0227
    CD40L 0.2490 0.9913 0.8265
    IFNγ 0.4940 0.5395 0.0801
    IL2 0.0705 0.1827 0.0264
    TNFα 0.6200 0.7754 0.1098
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    • Lymphoproliferation Tables
  • LIST OF TABLES
    PAGE
    Table L.1 Descriptive statistics on the Stimulating Index for
    lymphoproliferation (ATP cohort for
    immunogenicity) . . .
    Table L.2 Lymphoproliferation: Geometric Mean (ATP cohort
    for immunogenicity) . . .
    Table L.3 Lymphoproliferation: Inferential statistics on
    Stimultaing Index (ATP cohort for
    immunogenicity) . . .
    Table L.4 Lymphoproliferation: Fold increase in Geometric
    Mean (GMR) (ATP cohort for immunogenicity) . . .
  • TABLE L.1
    Descriptive statistics on the Stimulating Index for
    lymphoproliferation (ATP cohort for immunogenicity)
    Stimulating N
    Concentration Antigen Group Timing N miss. Mean SD Min Q1 Median Q3 Max
    0.1 CPAU/ml VZV VAR/E Day 0 44 1 27.40 35.81 1.06 9.90 17.22 33.96 221.53
    Month 1 44 1 29.82 25.70 0.94 9.36 23.66 45.66 92.16
    Month 2 43 2 27.50 17.97 5.61 13.90 24.01 34.62 95.32
    Month 3 43 2 29.34 24.53 6.72 13.62 20.55 36.93 124.46
    gE/E Day 0 43 2 21.86 17.72 1.21 9.66 17.76 28.15 91.05
    Month 1 42 3 28.36 23.99 2.55 12.13 21.85 31.99 107.18
    Month 2 42 3 27.47 22.90 1.62 14.85 20.71 32.88 138.04
    Month 3 42 3 28.52 17.80 2.16 15.28 24.92 40.87 87.26
    gE/Y Day 0 10 0 37.50 16.31 9.36 28.85 33.88 43.11 67.30
    Month 1 9 1 42.87 28.45 5.42 24.89 38.04 44.23 102.82
    Month 2 10 0 47.78 29.73 12.35 24.79 42.91 63.27 108.21
    Month 3 10 0 47.77 25.64 8.87 25.98 44.79 74.27 82.49
    gEVAR/E Day 0 42 2 19.30 21.14 1.35 6.27 17.79 22.49 136.88
    Month 1 42 2 28.63 18.39 3.31 15.08 21.69 44.13 68.92
    Month 2 42 2 30.92 24.15 1.97 11.97 23.06 49.92 96.33
    Month 3 43 1 37.51 29.04 4.45 19.92 29.98 43.02 142.50
    gEVAR/Y Day 0 10 0 49.64 22.42 29.45 39.22 41.28 57.67 106.72
    Month 1 10 0 54.43 29.44 18.42 27.53 49.96 77.50 105.66
    Month 2 9 1 51.83 24.74 11.07 34.87 52.85 74.34 82.69
    Month 3 10 0 47.69 21.37 16.19 34.27 50.79 66.25 77.75
      1 CPAU/ml VZV VAR/E Day 0 44 1 35.73 29.28 0.81 15.47 27.32 49.16 143.45
    Month 1 44 1 43.08 28.02 1.58 22.67 34.43 58.49 122.15
    Month 2 43 2 50.16 87.00 12.27 23.16 34.68 41.08 586.25
    Month 3 43 2 36.02 23.73 8.56 17.36 28.63 46.93 116.31
    gE/E Day 0 43 2 32.54 26.56 4.59 17.91 27.88 39.18 139.71
    Month 1 42 3 35.02 25.59 1.54 19.97 28.32 37.30 110.93
    Month 2 42 3 35.73 22.52 1.46 21.91 31.20 41.19 107.68
    Month 3 42 3 37.34 19.84 8.37 20.36 32.55 52.92 85.04
    gE/Y Day 0 10 0 43.97 23.26 9.30 31.05 43.43 53.02 87.99
    Month 1 9 1 51.10 35.47 6.31 37.60 44.42 57.47 132.58
    Month 2 10 0 54.24 20.58 16.73 44.20 51.53 71.02 88.07
    Month 3 10 0 56.04 37.19 13.72 35.84 45.31 68.27 143.80
    gEVAR/E Day 0 42 2 29.13 24.91 1.20 12.54 23.70 39.25 146.46
    Month 1 42 2 39.10 23.60 3.01 22.28 33.18 52.91 108.05
    Month 2 42 2 41.11 26.67 7.67 21.90 35.00 55.75 126.34
    Month 3 43 1 46.67 33.81 3.98 24.34 35.11 64.97 151.51
    gEVAR/Y Day 0 10 0 59.60 32.75 27.66 39.90 46.26 75.47 138.10
    Month 1 10 0 71.90 45.92 21.95 24.54 61.95 117.28 145.08
    Month 2 9 1 68.71 36.16 28.77 34.89 69.01 94.82 128.29
    Month 3 10 0 67.50 34.90 18.29 36.67 62.03 92.64 118.24
     20 μg/ml gE VAR/E Day 0 44 1 2.85 3.08 0.77 1.24 1.68 2.81 14.30
    Month 1 44 1 3.53 3.87 0.57 1.34 2.03 4.31 20.96
    Month 2 43 2 4.09 5.08 0.86 1.54 2.12 4.64 30.33
    Month 3 43 2 3.66 3.01 0.60 1.53 2.48 5.72 14.05
    gE/E Day 0 43 2 3.45 5.78 0.78 1.11 1.93 2.99 37.21
    Month 1 42 3 12.69 10.72 0.76 5.41 8.88 17.63 45.95
    Month 2 42 3 11.76 11.43 0.93 4.35 8.44 14.46 51.08
    Month 3 42 3 30.34 21.83 1.97 15.69 21.16 40.12 101.46
    gE/Y Day 0 10 0 2.62 1.24 1.01 1.75 2.18 3.71 4.88
    Month 1 9 1 19.09 15.69 2.17 6.67 13.12 35.81 43.15
    Month 2 10 0 25.50 18.51 9.37 10.31 16.67 32.61 60.58
    Month 3 10 0 37.46 21.69 4.72 27.78 31.11 52.84 76.56
    gEVAR/E Day 0 42 2 3.84 7.70 0.59 1.17 1.49 3.61 49.50
    Month 1 42 2 9.78 9.70 0.94 3.82 6.44 12.74 49.37
    Month 2 42 2 9.89 8.26 0.79 3.88 8.90 13.30 43.68
    Month 3 43 1 34.03 25.88 3.01 14.92 30.69 45.24 117.38
    gEVAR/Y Day 0 10 0 5.78 5.63 1.85 2.42 3.26 7.53 20.39
    Month 1 10 0 19.80 16.75 5.89 9.80 13.77 18.38 51.54
    Month 2 9 1 24.38 14.38 8.00 9.03 22.40 38.49 44.11
    Month 3 10 0 33.17 19.70 6.72 11.15 32.50 52.45 58.00
      4 μg/ml gE VAR/E Day 0 44 1 2.19 2.64 0.67 1.14 1.37 2.30 14.80
    Month 1 44 1 3.47 3.55 0.26 1.31 1.87 4.70 17.20
    Month 2 43 2 2.86 2.94 0.62 1.10 1.52 3.55 15.40
    Month 3 43 2 3.30 2.69 0.47 1.36 2.36 4.20 11.36
    gE/E Day 0 43 2 2.74 4.00 0.29 1.04 1.37 3.24 25.55
    Month 1 42 3 10.08 12.66 0.65 2.84 4.49 14.49 67.46
    Month 2 42 3 8.07 8.23 0.87 2.88 4.02 10.16 38.39
    Month 3 42 3 28.13 21.36 1.78 14.58 20.83 36.28 104.34
    gE/Y Day 0 10 0 2.85 1.95 0.85 1.12 2.70 3.69 6.21
    Month 1 9 1 14.39 15.26 0.83 5.17 9.06 13.73 49.06
    Month 2 10 0 19.81 14.60 4.71 9.75 13.64 28.99 51.20
    Month 3 10 0 32.53 17.61 3.93 26.84 32.60 43.71 56.99
    gEVAR/E Day 0 42 2 3.30 6.69 0.66 1.11 1.56 2.64 43.49
    Month 1 42 2 7.40 9.69 0.88 2.33 4.80 8.10 58.76
    Month 2 42 2 6.94 6.77 0.91 2.25 5.37 9.28 40.34
    Month 3 43 1 30.45 25.08 4.02 9.63 24.42 43.85 110.76
    gEVAR/Y Day 0 10 0 4.15 3.07 1.31 1.91 2.85 5.65 10.99
    Month 1 10 0 15.96 10.92 3.86 10.96 13.00 15.98 40.77
    Month 2 9 1 21.57 14.61 3.08 8.91 22.20 26.82 47.30
    Month 3 10 0 30.11 19.58 3.58 8.61 30.13 51.66 54.23
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of subjects with available results
    N miss. = number of subjects with missing results
    SD = Standard Deviation
    Min, Max = Minimum, Maximum
    Q1, Q3 = First, Third quartile
  • TABLE L.2
    Lymphoproliferation: Geometric Mean of stimulation index
    (ATP cohort for immunogenicity)
    Stimulating N
    Concentration Antigen Group Timing N miss. GMT Min Max
    0.1 CPAU/ml VZV VAR/E Day 0 44 1 15.69 1.06 221.53
    Month 1 44 1 19.10 0.94 92.16
    Month 2 43 2 22.62 5.61 95.32
    Month 3 43 2 22.77 6.72 124.46
    gE/E Day 0 43 2 15.38 1.21 91.05
    Month 1 42 3 20.48 2.55 107.18
    Month 2 42 3 21.23 1.62 138.04
    Month 3 42 3 22.60 2.16 87.26
    gE/Y Day 0 10 0 33.69 9.36 67.30
    Month 1 9 1 33.79 5.42 102.82
    Month 2 10 0 39.66 12.35 108.21
    Month 3 10 0 40.08 8.87 82.49
    gEVAR/E Day 0 42 2 12.94 1.35 136.88
    Month 1 42 2 22.67 3.31 68.92
    Month 2 42 2 22.03 1.97 96.33
    Month 3 43 1 28.62 4.45 142.50
    gEVAR/Y Day 0 10 0 46.28 29.45 106.72
    Month 1 10 0 46.68 18.42 105.66
    Month 2 9 1 44.87 11.07 82.69
    Month 3 10 0 42.48 16.19 77.75
      1 CPAU/ml VZV VAR/E Day 0 44 1 22.89 0.81 143.45
    Month 1 44 1 33.48 1.58 122.15
    Month 2 43 2 34.44 12.27 586.25
    Month 3 43 2 29.76 8.56 116.31
    gE/E Day 0 43 2 24.61 4.59 139.71
    Month 1 42 3 27.63 1.54 110.93
    Month 2 42 3 29.72 1.46 107.68
    Month 3 42 3 31.84 8.37 85.04
    gE/Y Day 0 10 0 37.53 9.30 87.99
    Month 1 9 1 39.83 6.31 132.58
    Month 2 10 0 49.89 16.73 88.07
    Month 3 10 0 46.60 13.72 143.80
    gEVAR/E Day 0 42 2 20.59 1.20 146.46
    Month 1 42 2 32.04 3.01 108.05
    Month 2 42 2 33.52 7.67 126.34
    Month 3 43 1 35.94 3.98 151.51
    gEVAR/Y Day 0 10 0 53.44 27.66 138.10
    Month 1 10 0 57.76 21.95 145.08
    Month 2 9 1 60.28 28.77 128.29
    Month 3 10 0 58.44 18.29 118.24
     20 μg/ml gE VAR/E Day 0 44 1 2.05 0.77 14.30
    Month 1 44 1 2.41 0.57 20.96
    Month 2 43 2 2.75 0.86 30.33
    Month 3 43 2 2.71 0.60 14.05
    gE/E Day 0 43 2 2.15 0.78 37.21
    Month 1 42 3 8.48 0.76 45.95
    Month 2 42 3 7.76 0.93 51.08
    Month 3 42 3 23.31 1.97 101.46
    gE/Y Day 0 10 0 2.36 1.01 4.88
    Month 1 9 1 12.71 2.17 43.15
    Month 2 10 0 20.50 9.37 60.58
    Month 3 10 0 30.14 4.72 76.56
    gEVAR/E Day 0 42 2 2.08 0.59 49.50
    Month 1 42 2 6.68 0.94 49.37
    Month 2 42 2 7.09 0.79 43.68
    Month 3 43 1 25.27 3.01 117.38
    gEVAR/Y Day 0 10 0 4.29 1.85 20.39
    Month 1 10 0 15.21 5.89 51.54
    Month 2 9 1 20.06 8.00 44.11
    Month 3 10 0 26.11 6.72 58.00
      4 μg/ml gE VAR/E Day 0 44 1 1.63 0.67 14.80
    Month 1 44 1 2.37 0.26 17.20
    Month 2 43 2 2.03 0.62 15.40
    Month 3 43 2 2.48 0.47 11.36
    gE/E Day 0 43 2 1.75 0.29 25.55
    Month 1 42 3 5.74 0.65 67.46
    Month 2 42 3 5.36 0.87 38.39
    Month 3 42 3 20.95 1.78 104.34
    gE/Y Day 0 10 0 2.26 0.85 6.21
    Month 1 9 1 8.55 0.83 49.06
    Month 2 10 0 15.55 4.71 51.20
    Month 3 10 0 25.27 3.93 56.99
    gEVAR/E Day 0 42 2 1.94 0.66 43.49
    Month 1 42 2 4.64 0.88 58.76
    Month 2 42 2 4.90 0.91 40.34
    Month 3 43 1 21.47 4.02 110.76
    gEVAR/Y Day 0 10 0 3.31 1.31 10.99
    Month 1 10 0 13.14 3.86 40.77
    Month 2 9 1 16.14 3.08 47.30
    Month 3 10 0 22.09 3.58 54.23
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of subjects with available results
    N miss. = number of subjects with missing results
    GMT = Geometric Mean Titer
    LL, UL = Lower, Upper Limit of 95% confidence interval
    Min, Max = Minimum, Maximum
  • TABLE L.3
    Lymphoproliferation: Inferential statistics on Stimulating Index
    (ATP cohort for immunogenicity)
    P-value
    Stimulating Kruskal-
    Groups compared Concentration Antigen Timing Wallis
    gE\Y and 0.1 CPAU/ml VZV Day 0 0.1509
    gEVAR\Y Month 1 0.3272
    Month 2 0.6242
    Month 3 0.8206
    1 CPAU/ml VZV Day 0 0.3643
    Month 1 0.3691
    Month 2 0.5676
    Month 3 0.3643
    20 μg/ml gE Day 0 0.0963
    Month 1 0.7440
    Month 2 0.8065
    Month 3 0.7624
    4 μg/ml gE Day 0 0.2899
    Month 1 0.3691
    Month 2 0.9349
    Month 3 0.7624
    VAR\E and gE\E 0.1 CPAU/ml VZV Day 0 0.9594
    Month 1 0.9037
    Month 2 0.7317
    Month 3 0.6226
    1 CPAU/ml VZV Day 0 0.6899
    Month 1 0.1062
    Month 2 0.5041
    Month 3 0.4657
    20 μg/ml gE Day 0 0.9526
    Month 1 0.0000
    Month 2 0.0000
    Month 3 0.0000
    4 μg/ml gE Day 0 0.7342
    Month 1 0.0002
    Month 2 0.0000
    Month 3 0.0000
    gE\E and 0.1 CPAU/ml VzAg Day 0 0.3794
    gEVAR\E Month 1 0.5489
    Month 2 0.6939
    Month 3 0.1903
    1 CPAU/ml VzAg Day 0 0.5097
    Month 1 0.2412
    Month 2 0.3855
    Month 3 0.3653
    20 μg/ml gE Day 0 0.6226
    Month 1 0.1375
    Month 2 0.6164
    Month 3 0.5737
    4 μg/ml gE Day 0 0.6226
    Month 1 0.4524
    Month 2 0.8161
    Month 3 0.9160
    VAR\E and 0.1 CPAU/ml VzAg Day 0 0.5059
    gEVAR\E Month 1 0.5922
    Month 2 0.8812
    Month 3 0.0913
    1 CPAU/ml VzAg Day 0 0.2688
    Month 1 0.5803
    Month 2 0.7450
    Month 3 0.1253
    20 μg/ml gE Day 0 0.7690
    Month 1 0.0000
    Month 2 0.0000
    Month 3 0.0000
    4 μg/ml gE Day 0 0.3553
    Month 1 0.0016
    Month 2 0.0000
    Month 3 0.0000
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
  • TABLE L.4
    Lymphoproliferation: Fold increase in Geometric Mean (GMR)
    (ATP cohort for immunogenicity)
    Stimulating Ratio N
    Concentration Antigen Group POST/PRE N miss. GMR LL UL Min Max
    0.1 CPAU/ml VZV VAR/E Month 1/Month 0 43 2 1.54 1.01 2.34 0.04 27.05
    Month 2/Month 0 42 3 1.65 1.05 2.58 0.09 52.56
    Month 3/Month 0 42 3 2.04 1.39 2.99 0.29 48.92
    gE/E Month 1/Month 0 41 4 1.39 1.01 1.92 0.15 18.32
    Month 2/Month 0 41 4 1.42 0.94 2.12 0.02 20.08
    Month 3/Month 0 41 4 1.86 1.38 2.52 0.13 14.83
    gE/Y Month 1/Month 0 9 1 0.68 0.28 1.61 0.05 1.53
    Month 2/Month 0 10 0 1.01 0.73 1.40 0.44 1.72
    Month 3/Month 0 10 0 1.16 0.88 1.53 0.61 2.17
    gEVAR/E Month 1/Month 0 40 4 2.10 1.45 3.04 0.13 31.67
    Month 2/Month 0 40 4 2.06 1.36 3.11 0.06 58.19
    Month 3/Month 0 41 3 3.22 2.28 4.54 0.86 82.33
    gEVAR/Y Month 1/Month 0 10 0 0.87 0.63 1.20 0.34 1.44
    Month 2/Month 0 9 1 0.87 0.52 1.43 0.18 1.37
    Month 3/Month 0 10 0 0.64 0.37 1.11 0.12 1.06
      1 CPAU/ml VZV VAR/E Month 1/Month 0 43 2 1.73 1.17 2.56 0.06 86.17
    Month 2/Month 0 42 3 1.63 1.06 2.51 0.08 124.71
    Month 3/Month 0 42 3 1.79 1.24 2.59 0.47 70.57
    gE/E Month 1/Month 0 41 4 1.18 0.90 1.53 0.05 13.44
    Month 2/Month 0 41 4 1.16 0.82 1.64 0.01 18.94
    Month 3/Month 0 41 4 1.64 1.23 2.18 0.09 19.91
    gE/Y Month 1/Month 0 9 1 0.75 0.32 1.73 0.05 1.38
    Month 2/Month 0 10 0 1.14 0.91 1.42 0.78 1.81
    Month 3/Month 0 10 0 1.21 1.01 1.46 0.83 1.69
    gEVAR/E Month 1/Month 0 40 4 1.85 1.40 2.43 0.46 15.65
    Month 2/Month 0 40 4 1.82 1.33 2.49 0.13 48.63
    Month 3/Month 0 41 3 2.52 1.88 3.38 0.88 80.53
    gEVAR/Y Month 1/Month 0 10 0 0.93 0.75 1.17 0.48 1.33
    Month 2/Month 0 9 1 0.98 0.79 1.22 0.60 1.26
    Month 3/Month 0 10 0 0.76 0.46 1.26 0.15 1.29
     20 μg/ml gE VAR/E Month 1/Month 0 43 2 1.35 1.04 1.75 0.16 11.02
    Month 2/Month 0 42 3 1.46 1.10 1.94 0.27 20.90
    Month 3/Month 0 42 3 1.90 1.42 2.54 0.39 26.66
    gE/E Month 1/Month 0 41 4 4.26 2.98 6.07 0.22 74.67
    Month 2/Month 0 41 4 3.62 2.41 5.46 0.05 28.79
    Month 3/Month 0 41 4 13.90 9.16 21.07 0.31 205.73
    gE/Y Month 1/Month 0 9 1 3.84 1.17 12.65 0.11 12.75
    Month 2/Month 0 10 0 7.45 5.15 10.77 3.91 15.23
    Month 3/Month 0 10 0 12.50 7.41 21.10 3.14 37.77
    gEVAR/E Month 1/Month 0 40 4 3.89 2.90 5.22 0.95 28.69
    Month 2/Month 0 40 4 3.86 2.54 5.87 0.03 38.27
    Month 3/Month 0 41 3 17.92 12.65 25.38 1.38 172.56
    gEVAR/Y Month 1/Month 0 10 0 3.07 1.40 6.72 0.38 15.77
    Month 2/Month 0 9 1 4.09 2.10 7.98 1.85 15.42
    Month 3/Month 0 10 0 4.25 1.60 11.30 0.28 15.60
      4 μg/ml gE VAR/E Month 1/Month 0 43 2 1.75 1.36 2.25 0.08 8.82
    Month 2/Month 0 42 3 1.40 1.03 1.89 0.12 36.27
    Month 3/Month 0 42 3 2.17 1.60 2.95 0.51 66.05
    gE/E Month 1/Month 0 41 4 3.32 2.34 4.69 0.31 36.29
    Month 2/Month 0 41 4 3.10 2.02 4.76 0.04 25.22
    Month 3/Month 0 41 4 14.32 9.39 21.82 0.26 110.97
    gE/Y Month 1/Month 0 9 1 2.88 0.75 11.06 0.07 21.03
    Month 2/Month 0 10 0 5.91 3.32 10.52 2.49 31.74
    Month 3/Month 0 10 0 10.95 5.62 21.37 3.07 48.19
    gEVAR/E Month 1/Month 0 40 4 2.90 2.26 3.71 0.54 22.40
    Month 2/Month 0 40 4 2.96 2.08 4.21 0.10 35.98
    Month 3/Month 0 41 3 16.40 11.62 23.15 1.51 237.09
    gEVAR/Y Month 1/Month 0 10 0 3.43 1.61 7.32 0.41 16.60
    Month 2/Month 0 9 1 3.98 1.76 9.01 0.91 31.37
    Month 3/Month 0 10 0 4.65 1.72 12.60 0.30 19.48
    gE/Y = gE-AS1/18-30 years
    gEVAR/Y = gE-AS1 + Varilrix/18-30 years
    VAR/E = Varilrix/50-70 years
    gE/E = gE-AS1/50-70 years
    gEVAR/E = gE-AS1 + Varilrix/50-70 years
    N = number of subjects with available results
    N miss. = number of subjects with missing results
    GMR = Geometric Mean ratio
    LL, UL = Lower, Upper Limit of 95% confidence interval for GMR
    Min, Max = Minimum, Maximum
    • CONCLUSIONS
  • The gE AS1 vaccine and the concomitant delivery of gE AS1 with the OKA strain both provoke a good immune response in comparison to the response obtained by the OKA strain alone.

Claims (40)

1. A method of preventing herpes zoster reactivation in an individual, said method comprising sequential delivery of:
a live attenuated or whole inactivated varicella-zoster virus (VZV); and
an immunogenic composition comprising VZV gE, 3D-MPL and QS21.
2. The method of claim 1, wherein 3D-MPL is provided in liposomes.
3. The method of claim 2, wherein the liposomes comprise cholesterol.
4. The method of claim 1, wherein two or more immunizations are employed.
5. The method of claim 4, wherein the immunogenic composition is delivered first, followed by delivery of the live attenuated or whole inactivated VZV.
6. The method of claim 1, wherein the live attenuated or whole inactivated VZV is delivered first, followed by delivery of the immunogenic composition.
7. The method of claim 1, wherein the live attenuated or whole inactivated VZV and the immunogenic composition are administered in a two dose regime comprising between 1-6 months between individual immunizations.
8. The method of claim 7, wherein the immunogenic composition is administered between 1-6 months following the delivery of the live attenuated or whole inactivated VZV.
9. The method of claim 7, wherein the live attenuated or whole inactivated VZV is delivered between 1-6 months following the delivery of the immunogenic composition.
10. The method of claim 1, wherein the VZV is a live attenuated OKA strain.
11. The method according to claim 1, wherein the gE is a truncate.
12. The method according to claim 11, wherein the gE is a C-terminal truncate.
13. The method according to claim 12, wherein the gE has the amino acid sequence of SEQ ID NO: 1.
14. The method of claim 1, wherein between 25-100 μg of VZV gE are delivered.
15. The method of claim 14, wherein between 40-100 μg of VZV gE are delivered.
16. The method of claim 1, further comprising repeating the delivery of the live attenuated or whole inactivated VZV.
17. The method of claim 16, comprising repeating the delivery of the live attenuated or whole inactivated VZV two or more times.
18. The method according to claim 1, wherein the sequential delivery is administered to an individual of at least 50 years of age.
19. The method according to claim 1, wherein the sequential delivery is administered to an immunocompromised individual.
20. A method of ameliorating the severity of herpes zoster reactivation and/or post herpetic neuralgia in an individual, said method comprising sequential delivery of
a live attenuated or whole inactivated varicella-zoster virus (VZV); and
an immunogenic composition comprising VZV gE, 3D-MPL and QS21.
21. The method of claim 20, wherein 3D-MPL is provided in liposomes.
22. The method of claim 21, wherein the liposomes comprise cholesterol.
23. The method of claim 20, wherein two or more immunizations are employed.
24. The method of claim 23, wherein the immunogenic composition is delivered first, followed by delivery of the live attenuated or whole inactivated VZV.
25. The method of claim 20, wherein the live attenuated or whole inactivated VZV is delivered first, followed by delivery of the immunogenic composition.
26. The method of claim 20, wherein the live attenuated or whole inactivated VZV and the immunogenic composition are administered in a two dose regime comprising between 1-6 months between doses.
27. The method of claim 26, wherein the immunogenic composition is administered between 1-6 months following the delivery of the live attenuated or whole inactivated VZV.
28. The method of claim 26, wherein the live attenuated or whole inactivated VZV is delivered between 1-6 months following the delivery of the immunogenic composition.
29. The method of claim 20, wherein the VZV is a live attenuated OKA strain.
30. The method according to claim 20, wherein the gE is a truncate.
31. The method according to claim 30, wherein the gE is a C-terminal truncate.
32. The method according to claim 31, wherein the gE has the amino acid sequence of SEQ ID NO: 1.
33. The method of claim 20, wherein between 25-100 μg of VZV gE are delivered.
34. The method of claim 33, wherein between 40-100 μg of VZV gE are delivered.
35. The method of claim 20, further comprising repeating the delivery of the live attenuated or whole inactivated VZV.
36. The method of claim 35, comprising repeating the delivery of the live attenuated or whole inactivated VZV two or more times.
37. The method according to claim 20, wherein the sequential delivery is administered to an individual of at least 50 years of age.
38. The method according to claim 1, wherein the sequential delivery is administered to an immunocompromised individual.
39. A method of preventing herpes zoster reactivation in an individual, said method comprising concomitant delivery of
a live attenuated or whole inactivated varicella-zoster virus (VZV); and
an immunogenic composition comprising VZV gE, 3D-MPL and QS21.
40. A method of ameliorating the severity of herpes zoster and/or post herpetic neuralgia in an individual, said method comprising a concomitant delivery of
a live attenuated or whole inactivated varicella-zoster virus (VZV); and
an immunogenic composition comprising VZV gE, 3D-MPL and QS21.
US12/784,296 2005-03-03 2010-05-20 Vaccine against varicella zoster virus Abandoned US20110045059A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/784,296 US20110045059A1 (en) 2005-03-03 2010-05-20 Vaccine against varicella zoster virus
US12/986,928 US7939084B1 (en) 2005-03-03 2011-01-07 Vaccine against varicella zoster virus

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine
GB0504436.7 2005-03-03
EPPCT/EP2006/002070 2006-03-01
PCT/EP2006/002070 WO2006094756A2 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
US81717507A 2007-08-27 2007-08-27
US12/784,296 US20110045059A1 (en) 2005-03-03 2010-05-20 Vaccine against varicella zoster virus

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US11/817,175 Continuation US20080171079A1 (en) 2005-03-03 2006-03-01 Vaccine
PCT/EP2006/002070 Continuation WO2006094756A2 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
US81717507A Continuation 2005-03-03 2007-08-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/986,928 Continuation US7939084B1 (en) 2005-03-03 2011-01-07 Vaccine against varicella zoster virus

Publications (1)

Publication Number Publication Date
US20110045059A1 true US20110045059A1 (en) 2011-02-24

Family

ID=34430592

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/817,175 Abandoned US20080171079A1 (en) 2005-03-03 2006-03-01 Vaccine
US12/784,296 Abandoned US20110045059A1 (en) 2005-03-03 2010-05-20 Vaccine against varicella zoster virus
US12/986,928 Active 2029-11-21 US7939084B1 (en) 2005-03-03 2011-01-07 Vaccine against varicella zoster virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/817,175 Abandoned US20080171079A1 (en) 2005-03-03 2006-03-01 Vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/986,928 Active 2029-11-21 US7939084B1 (en) 2005-03-03 2011-01-07 Vaccine against varicella zoster virus

Country Status (35)

Country Link
US (3) US20080171079A1 (en)
EP (4) EP2281831B1 (en)
JP (2) JP5420842B2 (en)
KR (2) KR20140006115A (en)
CN (2) CN103028113B (en)
AR (2) AR052498A1 (en)
AU (1) AU2006222225B2 (en)
BR (1) BRPI0607840B1 (en)
CA (2) CA2600905C (en)
CY (5) CY1116108T1 (en)
DK (4) DK1858917T3 (en)
EA (1) EA011884B1 (en)
ES (4) ES2532803T3 (en)
GB (1) GB0504436D0 (en)
HK (1) HK1111427A1 (en)
HR (4) HRP20150142T1 (en)
HU (4) HUE038468T2 (en)
IL (1) IL185442A (en)
LT (4) LT2281831T (en)
LU (1) LUC00087I2 (en)
MA (1) MA29714B1 (en)
MX (2) MX346865B (en)
MY (1) MY148464A (en)
NL (1) NL300951I2 (en)
NO (1) NO341841B1 (en)
NZ (1) NZ561075A (en)
PE (2) PE20100658A1 (en)
PL (4) PL2301955T3 (en)
PT (4) PT2301955T (en)
SI (4) SI2281831T1 (en)
TR (2) TR201809393T4 (en)
TW (1) TWI403517B (en)
UA (1) UA94900C2 (en)
WO (1) WO2006094756A2 (en)
ZA (1) ZA200707144B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962439B2 (en) 2013-10-03 2018-05-08 Nitto Denko Corporation Injectable vaccine composition

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
WO2009012486A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella zoster virus-virus like particles (vlps) and antigens
FR2952825B1 (en) 2009-11-24 2012-05-25 Goaster Jacqueline Le USE OF A VZV / HSV3 VIRUS VACCINE FOR TREATING HERPETIC INFECTIONS WITH HSV1 VIRUS AND / OR HSV2 VIRUS
BR112013000244A2 (en) 2010-07-06 2016-05-17 Novartis Ag lipid liposomes having advantageous pka for administration of rna
SI2591114T1 (en) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Immunisation of large mammals with low doses of rna
LT3243526T (en) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
UA112970C2 (en) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. INITIATED WINDOW ISLAND VIRUS, METHOD OF ITS RECEIVING AND APPLICATION
SI3970742T1 (en) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6499420B2 (en) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 Vaccines and infection protection kits
BE1022523B1 (en) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa VACCINATION
EP3233118A1 (en) * 2014-12-18 2017-10-25 GlaxoSmithKline Biologicals S.A. Vaccination
SG11201803360UA (en) * 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
RS63381B1 (en) 2015-10-22 2022-08-31 Modernatx Inc Respiratory virus vaccines
EP4001290A1 (en) 2015-11-06 2022-05-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN110167587A (en) 2016-11-11 2019-08-23 摩登纳特斯有限公司 Influenza vaccines
US10874734B2 (en) 2016-11-25 2020-12-29 Mogam Institute For Biomedical Research Varicella zoster virus vaccine
WO2018097642A1 (en) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 Varicella zoster virus vaccine
CN107022559A (en) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 A kind of preparation method of varicellazoster virus glycoprotein E extracellular region protein
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR102034234B1 (en) * 2016-12-26 2019-10-18 재단법인 목암생명과학연구소 Herpes zoster vaccine composition
CN108727503A (en) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV recombinates gE- flagellum plain fusion proteins and its preparation method and application
EP3615039A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. Triterpene saponin analogues
KR20190137827A (en) * 2017-04-25 2019-12-11 아쥬반스 테크놀로지스 인코포레이티드 Triterpene Saponin Analogues
EP3615061A1 (en) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
EP3697802A4 (en) 2017-10-16 2021-11-24 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CN108315344A (en) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 VZV glycoprotein E genes expression vector and its restructuring yeast strains and application
KR102337922B1 (en) 2018-04-19 2021-12-09 가천대학교 산학협력단 Pharmaceutical composition for inhibiting varicella-zoster virus comprising compounds isolated from Elaeocarpus sylvestris extract as an active ingradient
KR20190121956A (en) 2018-04-19 2019-10-29 가천대학교 산학협력단 Pharmaceutical composition for inhibiting varicella-zoster virus comprising compounds isolated from Elaeocarpus sylvestris extract as an active ingradient
BR112020023642A2 (en) * 2018-05-23 2021-02-17 Mogam Institute For Biomedical Research variant of varicella zoster virus antigen and use of it
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CN108992667A (en) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 A kind of shingles zoster vaccine and preparation method thereof, application
CN113164586B (en) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 Immune composition and preparation method and application thereof
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CN109602901B (en) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 Herpes zoster virus vaccine and preparation method and application thereof
EP3980044A1 (en) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponin purification
CN112142828B (en) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 gE gene and vector for expressing the gene
KR20210110242A (en) * 2020-02-28 2021-09-07 (주)셀트리온 Fusion Protein of Varicella Zoster Virus and Immunogenic Composition Comprising the Same
KR102270048B1 (en) * 2020-07-10 2021-06-28 주식회사 녹십자 Method for production of surface protein antigen of varicella zoster virus
CA3188708A1 (en) 2020-08-07 2022-02-10 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
EP4212173A1 (en) * 2020-09-11 2023-07-19 Eubiologics Co., Ltd. Vaccine composition for chickenpox or varicella zoster and method of using same
RU2750818C1 (en) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Viral strain for obtaining attenuated live culture vaccine for prevention and treatment of herpes zoster for adult population
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116350770A (en) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 Herpes zoster vaccine preparation and preparation method thereof
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985615A (en) * 1974-03-12 1976-10-12 Research Foundation For Microbial Diseases Of Osaka University Process for preparing live varicella vaccines
EP0405867A1 (en) * 1989-06-27 1991-01-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
US5750110A (en) * 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
US6214354B1 (en) * 1992-07-17 2001-04-10 Merck & Co., Inc. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
JP4028593B2 (en) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 3-O deacylated monophosphoryl lipid A-containing vaccine composition
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0817847B2 (en) * 1995-03-23 2009-09-09 Immunex Corporation Il-17 receptor
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
KR0177323B1 (en) * 1996-02-16 1999-04-01 성재갑 Human diploid lung cells useful for virus vaccine production and method for preparing chickenpox vaccine using the same
IL132126A0 (en) 1997-04-01 2001-03-19 Ribi Immunochem Research Inc Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
MXPA03003408A (en) * 2000-10-18 2005-06-30 Glaxosmithkline Biolog Sa Vaccines.
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985615A (en) * 1974-03-12 1976-10-12 Research Foundation For Microbial Diseases Of Osaka University Process for preparing live varicella vaccines
EP0405867A1 (en) * 1989-06-27 1991-01-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
US5750110A (en) * 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
US6214354B1 (en) * 1992-07-17 2001-04-10 Merck & Co., Inc. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Atkinson WL, et. al. CDC: MMWR: Recommendations and Reports. "General Recommendations on Immunization." Feb. 8, 2002/51(RR02);1-36. *
Grose C, Faga B. VZV envelope glycoprotein E. Accession #: AAG32558.1. Direct submission: EMBL/GenBank/DDBJ Database. Sub. 10/23/2000 *
Jacquet A, Haumont M, Massaer M, Garcia L, Mazzu P, Daminet V, Grégoire D, Jacobs P, Bollen A. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine. 2002 Feb 22;20(11-12):1593-602. *
Litwin V, Jackson W, Grose C. Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J Virol. 1992 Jun;66(6):3643-51. *
Shiver JW, et. al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002 Jan 17;415(6869):331-5. *
Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 2004 Feb;25(2):98-104. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962439B2 (en) 2013-10-03 2018-05-08 Nitto Denko Corporation Injectable vaccine composition

Also Published As

Publication number Publication date
CY1118629T1 (en) 2017-07-12
DK2281830T3 (en) 2017-03-20
HK1111427A1 (en) 2008-08-08
EP2301955A2 (en) 2011-03-30
KR20070110413A (en) 2007-11-16
CN103028113A (en) 2013-04-10
LT2281830T (en) 2017-02-10
KR101357204B1 (en) 2014-02-06
CA2882255A1 (en) 2006-09-14
SI1858917T1 (en) 2015-03-31
CA2882255C (en) 2018-03-27
ES2618037T3 (en) 2017-06-20
LUC00087I2 (en) 2018-11-26
WO2006094756A3 (en) 2007-02-15
NO341841B1 (en) 2018-02-05
EP1858917B8 (en) 2015-05-06
EA011884B1 (en) 2009-06-30
TWI403517B (en) 2013-08-01
PE20100658A1 (en) 2010-10-23
HUE038467T2 (en) 2018-10-29
NO20074392L (en) 2007-11-27
JP5420842B2 (en) 2014-02-19
PL1858917T3 (en) 2015-05-29
NL300951I2 (en) 2020-08-31
AR107285A2 (en) 2018-04-18
BRPI0607840B1 (en) 2021-06-29
DK2281831T3 (en) 2018-06-14
EP2281830A3 (en) 2012-01-25
CY2018025I1 (en) 2018-12-12
CY1120347T1 (en) 2018-12-12
MA29714B1 (en) 2008-09-01
CY2018025I2 (en) 2018-12-12
ES2675054T3 (en) 2018-07-06
PT2301955T (en) 2018-06-18
NZ561075A (en) 2009-06-26
HUS1800038I1 (en) 2018-10-29
EP2281831A3 (en) 2011-11-16
LTC2281831I2 (en) 2020-08-25
EP2281831A2 (en) 2011-02-09
EP1858917B1 (en) 2014-12-24
BRPI0607840A2 (en) 2009-06-13
US20110104260A1 (en) 2011-05-05
CN101189254A (en) 2008-05-28
IL185442A (en) 2013-07-31
CA2600905C (en) 2015-05-05
DK1858917T3 (en) 2015-02-02
MY148464A (en) 2013-04-30
SI2301955T1 (en) 2018-07-31
CY1121211T1 (en) 2020-05-29
GB0504436D0 (en) 2005-04-06
JP5840167B2 (en) 2016-01-06
AU2006222225A1 (en) 2006-09-14
PT2281831T (en) 2018-06-15
TW200643028A (en) 2006-12-16
SI2281831T1 (en) 2018-07-31
PT2281830T (en) 2017-02-24
HRP20170081T1 (en) 2017-03-24
PL2301955T3 (en) 2018-08-31
NL300951I1 (en) 2018-09-26
LT2281831T (en) 2018-07-10
LT2301955T (en) 2018-07-10
US20080171079A1 (en) 2008-07-17
JP2008531637A (en) 2008-08-14
PE20061287A1 (en) 2006-12-07
CN101189254B (en) 2013-05-22
MX346865B (en) 2017-04-04
EA200701632A1 (en) 2008-02-28
HUE038468T2 (en) 2018-10-29
MX2007010626A (en) 2007-10-16
ES2532803T3 (en) 2015-03-31
HRP20180988T1 (en) 2018-08-10
EP2281830B1 (en) 2016-12-21
TR201809397T4 (en) 2018-07-23
UA94900C2 (en) 2011-06-25
ES2675055T3 (en) 2018-07-06
LTPA2018012I1 (en) 2018-11-12
HUE032544T2 (en) 2017-10-30
EP2281830A2 (en) 2011-02-09
ZA200707144B (en) 2009-11-25
CN103028113B (en) 2015-05-20
PL2281830T3 (en) 2017-06-30
KR20140006115A (en) 2014-01-15
AU2006222225B2 (en) 2012-08-16
PL2281831T3 (en) 2018-08-31
CY1116108T1 (en) 2017-02-08
PT1858917E (en) 2015-02-24
DK2301955T3 (en) 2018-06-14
HRP20180989T1 (en) 2018-08-10
EP2281831B1 (en) 2018-04-18
WO2006094756A2 (en) 2006-09-14
CA2600905A1 (en) 2006-09-14
JP2013144710A (en) 2013-07-25
US7939084B1 (en) 2011-05-10
EP1858917A2 (en) 2007-11-28
EP2301955B1 (en) 2018-04-18
HRP20150142T1 (en) 2015-05-22
EP2301955A3 (en) 2011-11-16
AR052498A1 (en) 2007-03-21
IL185442A0 (en) 2008-01-06
TR201809393T4 (en) 2018-07-23
SI2281830T1 (en) 2017-03-31

Similar Documents

Publication Publication Date Title
US7939084B1 (en) Vaccine against varicella zoster virus
AU2012213948B2 (en) Vaccine
US20080152671A1 (en) Novel vaccination

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION